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ABSTRACT 
Oral squamous cell carcinoma is the sixth commonest cancer in the world. Most 
patients who develop oral cancer are elderly males who are heavy users of tobacco and 
alcohol although the incidence is increasing in younger individuals and in those who 
neither smoke nor drink. 
Approximately 80% of human cancers result from exposure to xenobiotics. Over 
the millennia Man has evolved complex families of detoxification enzymes to metabolise 
and eliminate these harmful compounds. Many of the genes that code for these enzymes 
are polymorphic, sometimes encoding enzymes with abnormal activity profiles. Numerous 
diseases have been shown to be more frequent in individuals with abnormal detoxification 
enzyme activity 
This study investigated the association between polymorphisms in cytochrome 
P450 and glutathione S-transferase genes and disease susceptibility in 106 patients with 
histologically proven squamous cell carcinoma of the oral cavity. 
The CYP2D6 PM phenotype was associated with a significantly increased risk of 
oral cancer (p = 0.0012). The CYP2D6 PM and HET phenotypes appear to be markers for 
a putative tumour suppressor gene at or close to 22q12. The EM phenotype is a risk factor 
in individuals who are heavy drinkers and smokers, possibly due to phase 1 activation of 4- 
(methylnitrosamino)- 1 -(3 pyridyl)- 1 -butanone. 
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1.1 Historical Perspective 
Evidence for the occurrence of oral cancer in ancient civilisations is currently 
limited to the examination of a very few skeletal remains and papyri. The oldest cranial 
remains that show the stigmata of malignant disease during life date back some 5000 years 
(Wells, 1963). A skull dating from about 3,500 - 3,000 B.C. excavated from the Tepee 
Hissar site in Iran in 193 1 by staff of the University of Pennsylvania shows evidence of 
massive destruction of the maxilla, zygoma and palate on the left extending into the floor 
of the orbit. Krogman (1940), suggested that the destruction is the result of extensive 
inflammation secondary to sinus infection. However, Wells (1963), proposed that the 
appearances are strongly suggestive of carcinoma. Certainly, the appearances of the skull 
as detailed in Figure 1 of Krogman’s paper (Krogman,1940), are consistent with 
widespread bone destruction from an uncontrolled primary carcinoma of the maxillary 
antrum. 
rd-  th An ancient Egyptian skull dating from the 3 5 dynasty (2686 - 2494 B.C), 
(Mellersh, 1995) and presently housed in the Duckworth Laboratory, University of 
Cambridge has approximately 26 osteolytic lesions involving either the inner or the outer 
tables of many of the cranial bones. The same skull also shows evidence of extensive 
destruction of the posterior hard palate, posterior antral wall, alveolus and pterygoid plates 
on the left side. There is thus strong circumstantial evidence that the skull lesions 
represent secondary deposits from a primary nasopharyngeal carcinoma (Wells, 1963; 
Nunn, 1996). 
Very few, if any, written accounts of oral carcinoma in the ancient world have 
survived. Although there are extensive references to the diagnosis and treatment of 
traumatic head and neck injuries in the ancient Egyptian medical papyri, in particular the 
Edwin Smith surgical papyrus, none make any specific mention of tumours of this area 
(Christ, 1979). Some authors (Martin, 1940), have interpreted references in the Ebers 
Papyrus (c 1500 B.C.) to “eating ulcer” of the gums and “illness of the tongue” to be 
descriptions of oral cancer, but others are more cautious (Christ, 1979; Nunn, 1996). While 
the paucity of data concerning oral cancer in antiquity may simply reflect the destruction 
and loss of informative remains and texts over the intervening millennia, it is likely that 
there was a lower incidence of cancer in ancient populations in comparison to modem ones 
due to a combination of limited life expectancy and reduced exposure to carcinogens 
(Christ, 1979; Nunn, 1996). 
Hippocrates’ (460 - 370 B.C.) is almost certainly referring to lingual carcinomas in 
his Prorrheticon in which he describes chronic ulcers on the edge of the tongue 
(Martin, 1940). In the same volume he exhorts his readers not to treat those who have 
internal cancer “since if treated they die quickly; but if not treated, they last a long time”, 
and confines his advice on the treatment of tongue cancer to the elimination of any 
associated sharp teeth (Christ, 1979). The first account of surgical treatment for oral cancer 
is ascribed to Avicenna (A.D. 980 -1037) who reputedly excised carcinomas of the lip but 
allowed them to heal by secondary intention rather than attempting wound closure or 
reconstruction (Christ, 1979). He was doubtless describing a lingual carcinoma in his 
Canon of Medicine when he refers to “apostema dura (hard sore) of the tongue 
(Martin, 1940). Marchetti, Professor of Surgery in Padua, who some authors refer to as the 
grandfather of head and neck surgery, is credited with the first surgical excision of a 
lingual carcinoma in 1664 using cautery (Martin, 1940; Absolon et al., 1962). However, it 
was not until Hams introduced the V-shaped incision and primary closure technique in 
1835 that simultaneous resection and reconstruction for oral cancer became popular 
(Absolon et al., 1962). New surgical procedures designed to manage larger primary 
tumours and even nodal metastases rapidly developed. In 1836 Roux described the first 
combined lip split and midline mandibulotomy and in 1875 Baron Von Langenbeck was 
the first to excise enlarged regional lymph nodes in the submandibular triangle in addition 
to a primary floor of mouth carcinoma (Absolon et al., 1962). A seminal work describing 
the lymphatic drainage of buccal carcinoma and emphasising the necessity for radical 
removal of both the primary tumour and the regional lymph nodes was published by Polya 
and von Navratil in 1902 (Polya and von Navratil, 1902; McGregor, 1987). The importance 
of removing the regional lymph nodes in cases of oral cancer was also emphasised by 
Butlin (1 845 - 19 12), who advocated dissection of the contents of the anterior triangle of 
the neck at the same time as excision of the primary tumour (Butlin,1909; Martin,1940; 
Absolon et al., 1962; Uttley and McGurk, 1996). Butlin’s pioneering work culminated in 
the introduction of the block or radical neck dissection by Crile in 1906. In his classic 
paper (Crile,1906), he described the results of 132 neck dissections and differentiated the 
radical block neck dissection from the block neck dissection. The former included the 
excision of the internal jugular vein and was performed for palpable nodal disease. The 
latter spared the internal jugular vein and was reserved for clinically negative necks. 
Current surgical techniques for the management of the regional lymph nodes have changed 
little since Crile’s description. 
The discovery of X-rays by Roentgen in 1895 was shortly followed by their 
application in the treatment of oral cancer. In 1903 Engman reported a case of lingual 
cancer treated by fractionated X-rays in which the local tumour was healed within a month 
and the patient was alive and well a year later (Martin, 1940). Brachytherapy for oral 
cancer was first introduced by Stevenson in 1914 who used needles containing either 
radium or radon and implanted them into tongue carcinomas apparently with good results 
(Martin, 1940). The early teletherapy (external beam) sources were low energy (up to 
300kv) orthovoltage X-ray machines. The resulting X-rays were of low penetrance 
resulting in excessive skin damage. They were also preferentially absorbed by bone 
resulting in a high incidence of osteoradionecrosis (Henk and Langdon, 1985). Recent 
advances in radiotherapy techniques have been improved radiation sources including 
telecobalt machines, linear accelerators and iridium wires and improved treatment 
scheduling such as fractionation, hyperfractionation and afterloading. All of which have 
resulted in improved local control rates and reduced side effects such as skin damage and 
osteoradionecrosis. 
The major surgical advances in oral cancer management over the last few decades 
have by and large been in the areas of reconstruction and rehabilitation. The first 
significant advance was the development of split skin grafts by Esser in 19 17 (Esser, 19 17), 
which resulted in improved healing of intraoral wounds following resection. However, 
despite their advantages, it soon became apparent that split skin grafts did not provide 
adequate bulk to reconstruct large defects and that they resulted in excessive contracture 
and deformity, especially when applied to the floor of the mouth and tongue (Christ, 1979). 
Numerous local and regional random and axial pattern flaps were rapidly devised in an 
attempt to overcome these limitations. The forehead flap, a local axial pattern flap based on 
the superficial temporal artery became the mainstay of intraoral reconstruction for many 
years (Edgerton, 195 1; McGregor, 1963; Christ 1979). Although providing adequate and 
reliable soft tissue, the forehead flap was limited by its relatively short transfer distance 
and by the significant cosmetic donor site defect. Many of these problems were overcome 
by the deltopectoral flap popularised by Bakamjian in 1963 (Bakamjian, 1963). Large 
amout of skin could be transferred over considerable distances and the donor site, 
although requiring skin grafting was on the chest and hidden by clothing. Flap reliability 
and length was found to be increased if the flap was delayed prior to transfer. Delay 
converted an essentially random flap into an axial one. The deltopectoral flap remained 
the workhorse flap for reconstructing head and neck defects for many years. However, 
while capable of providing good quality skin cover it was unable to provide the bulk of 
tissue required to reconstruct major defects in the floor of the mouth or of the tongue. This 
problem was overcome by the pectoralis major myocutaneous flap popularised by Ariyan 
(Ariyan,1979). However, its major limitation, like all pedicled flaps is that transfer 
distances and hence the defects that can be reconstructed are limited by the maximum 
length of pedicle available. It was not until the development and perfection of 
microvascular free tissue transfer techniques that it became possible to reliably reconstruct 
defects at sites remote from the donor site. In 1974, surgeons in Japan and USA 
simultaneously and independently reported on the successful reconstruction of head and 
neck defects using free groin flaps (Harashina et al., 1974; Panje et al., 1974). Perhaps the 
most important publication in the English literature in this area came in 1982 when 
Professor Muhlbauer reported his experiences while visiting burns units in the Peoples 
Republic of China in 1980 (Muhlbauer et al., 1982). Surgeons there were harvesting 
fasciocutaneous flaps from the flexor surface of the forearm and anastamosing the radial 
artery and cephalic veins to suitable recipient vessels in order to reconstruct bum defects. 
The radial forearm flap or “Chinese flap” as it is often known was developed in 1978 at the 
Shenyang Military Hospital by Dr Yang Goufan, Dr Chen Baoqui and Dr Gao Yuzhi 
(Soutar et al., 1983). The potential for this flap to reconstruct head and neck defects, 
particularly intraoral defects was instantly appreciated. The development and 
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popularisation of this flap is arguably the most important advance in reconstructive 
techniques to have emerged in recent times. The radial forearm flap has become the 
mainstay of intraoral reconstruction. Over the last decade numerous other free flaps have 
been developed enabling the surgeon to reconstruct both hard and soft tissue defects either 
singly or simultaneously. This explosion in reliable reconstructive techniques has resulted 
in vastly improved local control rates and improved quality of life for patients with oral 
cancer. 
Oral cancer has claimed the lives of several eminent and world famous people 
including two presidents of the United States and Sigmund Freud. General Ulysses S 
Grant (1822-1885) was diagnosed as having a right tonsillar carcinoma with cervical node 
metastases in October 1844 from which he died 9 months later having received essentially 
no treatment (Renehan and Lowry,1995). S Grover Cleveland (1 837-1908), developed a 
lesion originally diagnosed as a squamous cell carcinoma of the left hard palate in May 
1893 (Morreels Jr, 1967). Following a hemimaxillectomy performed on board a friend’s 
yacht in July 1893 and a few minor interventions to fit and replace Obturators over the 
subsequent years Cleveland enjoyed a long disease free interval and died in June 1908 
(Morreels Jr, 1967; Renehan and Lowry, 1995). Indeed, the long survival called into 
question the accuracy of the original pathology report. After numerous possibilities were 
proffered and refuted a consensus was reached in 1980 that the original lesion had been a 
verrucous carcinoma (Renehan and Lowry, 1995). Freud first sought help for ulceration of 
the right hard palate in 1923, although he had been aware of a problem since 1917 
(Davenport,l993). This was initially treated by right partial maxillectomy in April 1923 
but the tumour recurred due to incomplete excision. Subsequent right hemimaxillectomy 
and obturation 5 months later followed by numerous changes of Obturator gave Freud 16 
7 
years of reasonable health before he finally succumbed to his disease (Davenport, 1993). It 
is noteworthy that both President Grant and Sigmund Freud were heavy cigar smokers and 
chose to ignore their tumours before seeking treatment (Davenport, 1993; Renehan and 
Lowry, 1995) 
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1.2 Overview of Oral Cancer 
Oral cancer is the sixth most common cancer in the world and is largely 
preventable (Parkin et al., 1988; Raubenheimer et al., 1989). It accounts for approximately 
4% of all cancers and 2% of all cancer deaths world-wide (Boring et al., 1993). It is the 
third commonest malignant neoplasm in developing countries and the eighth commonest in 
industrialised Western societies (Parkin et al., 1988). In India it is the commonest 
malignant neoplasm, accounting for 20-30% of all cancers (Nair et al., 1990). In excess of 
1900 patients every year in the United Kingdom develop oral cancer and every year 900 
patients die from this disease (Johnson and Warnakulasuriya, 1991). In the United States 
the annual new registration and death rates are 42,000 and 12,000 respectively (Boring et 
al., 1993). With a death:registration ratio of 0.45 oral cancer is a disease of high lethality, 
comparable to that for carcinoma of the cervix (0.48) and greater than that for malignant 
melanoma (0.38) (Johnson and Warnakulasuriya,1993). 
More than 80% of oral cancers are squamous cell carcinomas arising from the oral 
mucosa with the tongue being the commonest site (Johnson et al., 1993; Smith,1995). 
While over 70% of all oral cancers arise in the so called “sump” area formed by the floor 
of the mouth, ventral and lateral surfaces of the tongue and mandibular alveolus, this area 
comprises only 30% of the surface area of the mouth. A possible explanation for this is the 
increased exposure of these non-keratinised and permeable tissues to putative xenobiotics 
and carcinogens pooling and collecting in the “sump” (Jovanovic et al., 1993; Cawson et 
al., 1996). A recent study by Thomson (1997) has also demonstrated that cells in the basal 
layer of human floor of mouth and ventral tongue epithelium have higher labelling indices 
than those in other oral mucosal sites as assessed by double labelling techniques using 
tritiated thymidine and bromodeoxyuridine followed by autoradiography and 
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immunocytochemistry respectively. This suggests that floor of mouth and ventral tongue 
epithelium has a higher innate proliferative capacity, which may render it more susceptible 
to malignant transformation. 
The anatomical sites covered by the term “oral” include the lips and all intra-oral 
sites corresponding to the International Classification of Diseases ninth revision (ICD9) 
(WHO,1977) codes 140 (lip), 141 (tongue), 143 (gum), 144 (floor of mouth) and 145 
(other non-specific sites), but exclude sites 142 (major salivary glands), 146 (oropharynx), 
147 (nasopharynx), 148 (hypopharynx) and 149 (ill defined oral/oropharynx) (Johnson et 
al., 1993). This definition of “oral” will be used throughout unless stated otherwise. 
Oral cancer predominantly affects those in their sixties and seventies and is more 
common in males than females. In the series reported by Langdon et al. (1977), the mean 
age of presentation was 63.5 years for males and 60.6 years for females with a male: 
female ratio of 1.3: 1. However, there is compelling evidence for an increasing incidence of 
oral cancer in younger subjects (Binnie et al., 1972; Worrall,1995; Johnson et al., 1996). 
World wide, the major risk factors for developing oral cancer are heavy tobacco 
and alcohol consumption but a significant minority of patients with oral cancer are non- 
smokers and teetotal (Lemon et al., 1964; Henk and Langdon,1985; Ehlinger et al., 1993). 
Factors such as nutritional deficiencies, exposure to xenobiotic compounds, local trauma, 
viral, bacterial and fungal infections, immunological deficiencies and various potentially 
malignant lesions and conditions are also thought to be important (Johnson and 
Warnakulasuriya, 1993). The marked variation in geographical and racial incidence 
together with the multiplicity of known and putative risk factors for oral cancer are highly 
suggestive that the disease is the result of a complex interplay between genetic 
susceptibility and exposure to environmental carcinogenic agents. 
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The last 40 years has seen tremendous advances in the surgical and non-surgical 
management of oral cancer. In particular, the advent and widespread adoption of 
microvascular reconstructive techniques allowing the opportunity for enhanced functional 
rehabilitation following major ablative surgery and the development of mega voltage 
radiotherapy machines resulting in enhanced tumour cell killing with reduced normal host 
cell damage has revolutionised patient management. However, despite improvements in 
the ability to control disease locally, the cure rate for oral cancer has improved little during 
this period. The overall 5 year survival rate remains depressingly low at around 35% even 
though oral cancer is a curable disease if patients are treated sufficiently early (Stell et al., 
1982; Ogden et al., 1996). In a study of 194 patients over a 16 year period, Henk and 
Langdon (1985), reported an uncorrected overall 5 year survival rate of 32.8%. In the 
same series of patients the uncorrected 5 year survival rate was 42.1% for women but only 
22.9% for men (Henk and Langdon,l985). The enhanced survival in women may be 
related to their tendency to present earlier for treatment and with smaller tumours than men 
(Worrall and Corrigan, 1995). These depressing statistics suggest that alternatives to 
surgery and radiotherapy will need to be found if long term patient survival from oral 
cancer is ever going to be improved. 
In many cases, invasive oral cancer is preceded by a potentially malignant lesion or 
condition. Potentially malignant lesions are those in which the oral mucosa locally has 
undergone sufficient cytological change as to render it more likely than normal tissue to 
become malignant. The majority, if not all potentially malignant conditions are systemic 
disorders that result in atrophy of the oral mucosa resulting in increased penetrance of 
carcinogens (Johnson et al., 1993). At the present time it is not possible to differentiate the 
lesions that will ultimately progress to invasive carcinoma and as such warrant early 
1 1  
aggressive treatment from those that will regress and can safely be left alone. Likewise, it 
is not possible to accurately predict an individual patient’s prognosis. Some patients with 
small localised tumours at the primary site at presentation develop early nodal and 
systemic metastases with a resultant poor outcome while others may have a large tumour at 
presentation which remains localised to the primary site and has a good outcome. The 
inability to predict the behaviour of these lesions results in some patients being under 
treated with a consequent risk of a sub-optimal outcome, while others may be over treated 
and suffer unnecessary morbidity. Greater understanding of the individual patient’s 
genetic susceptibility to oral cancer should enable a more scientific management strategy 
to be developed resulting in improved quality of life and survival to say nothing of the 
potential for screening, early detection and possibly even prevention. 
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1.3 Epidemiology 
Incidence 
There is a marked geographic variation in the incidence of oral cancer both 
between and within countries (Blot et al., 1994) (Figure 1). 
In Europe the male incidence varies between 16.9: 100,000 in Malta to 6.9: 100,000 
in the northern UK and 2.5: 100,000 in the southern UK. The mean UK annual incidence 
rate for both sexes is approximately 4.5: 100,000. These variations can be almost entirely 
explained by the increased incidence of lip cancer in Malta compared to the southern UK 
consequent upon an increased exposure to actinic radiation. Similar variations are seen in 
America between Newfoundland (29.9: 100,000) and British Colombia (8.2: 100,000) again 
resulting from increased exposure to actinic radiation. Evidence for the protective role of 
racial cutaneous pigmentation exists in that the non-Maori population of New-Zealand has 
an incidence of oral cancer 5 times greater than that of the Maori population. In Asia the 
incidence varies between Bombay (19.6: 100,000) and Japan (2.1: 100,000). In this 
situation however, the variation is thought to be due to the widespread habit of Betel nut 
chewing practised by certain sections of the Indian population (Waterhouse et.al., 1976; 
Henk and Langdon, 1985). 
Although confined to a small and well defined anatomical area, the sites that 
together comprise the term “oral” as defined previously, show very different patterns of 
tumour incidence, behaviour and prognosis. It is thus misleading to equate incidence and 
survival figures pertaining to oral cancer as a whole (or worse still, “head and neck 
cancer”) with those for the individual sites within the oral cavity (Table 1). 
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The site specific oral cancer data also show wide geographical variation (Table 2). 
For example, the Bas-Rhin region in France has the highest recorded incidence of oral 
cancer in the world. This is thought to be due to the combined effects of alcoholic liver 
disease and the large quantity of home-brewed spirits containing toxic distillation by- 
products produced and consumed in this region (Binnie et al., 1972; Henk and 
Langdon,l985). However, Bombay, which has the second highest incidence of oral cancer 
in the world, has a greater incidence of lingual carcinoma than does Bas-Rhin. 
Regardless of geographical or anatomical site, oral cancer affects men more 
frequently than it affects women. The overall mean age at first presentation is in the range 
of 60-65 years, with men presenting approximately 5 years earlier than women (62.6 and 
67.2 years respectively) (Henk and Langdon,l985; Shah et al., 1990; Worrall and 
Corrigan, 1995). 
Since the turn of the century there has been a steady decline in the incidence of oral 
cancer. However, several authors have reported an increasing incidence in some oral 
cancers in both men and women (Hindle and Nally, 199 1 ; Zakrzewska, 1994; Worrall, 1995; 
Hindle et al., 1996). Analysis of all new oral cancer registrations in England & Wales over 
the last 20 years confirms this increasing incidence and also shows a trend towards first 
presentation in a younger age group (Table 3). It should be noted that these are raw data 
and are not standardised either for age, sex or population. Furthermore, while the 
percentage changes in incidence may be large the actual number of cases involved is small. 
Conclusions drawn from this data could thus be misleading. Nevertheless, it is instructive 
to note the changing pattern of disease over this time period. 
There were 173 1 new oral cancer registrations in 1989 compared to 1570 in 197 1, 
an increase of 10.3%. Comparing the periods 1971-75 with 1985-89 there was a slight fall 
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in new registrations from 8313 to 81 14 (2.4%). The male: female ratio has fallen from 
2.1 : 1 in 1971 to 1.8: 1 in 1989. Regardless of whether the data were compared between the 
single years 1971-1989 or the two 5 year periods 1971-75 & 1985-89 the overall trends for 
each oral cancer site were the same. 
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The incidence of carcinoma of the lip has declined in all age groups and in both 
sexes since 197 1. A similar decline in alveolar carcinoma is seen in all male age groups 
but has increased in women under 45 years by over 30%. Carcinoma of the tongue and 
floor of mouth has increased markedly in males and females. This increase has been in a 
younger population than traditionally felt to be at risk. Floor of mouth cancer has seen the 
largest overall increase in both women (33%) and men (25%). Lingual and floor of mouth 
carcinoma has increased in men under 45 years of age (80.4%) and (85.7%) respectively 
(Figures 2 and 3). 
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Hindle and Nally (1991), have drawn attention to the increasing incidence of oral 
cancer particularly in women. They suggested that this may be due to a rise in alcohol 
consumption in men and to a rise in both tobacco and alcohol consumption in women. 
More recently, Hindle et al., (1996) have reported on the epidemiological trends in 
oral cancer in the UK from 1901 to 1990. This large study demonstrated that there have 
been significant increases in oral cancer incidence and mortality in younger males and a 
smaller increase in younger females over the last 30 years confirming the results of the 
previously cited smaller studies. Male mortality from oral cancer in the 35-64 year old age 
group rose from a century low of 1.67:100,000 in 1966-1970 to 2.91: 100,000 in 1986- 
1990. Incidence rates in this group have increased from 3.61:100,000 in 1962-1966 to 
5.52: 100,00 in 1982-1986. During the same time periods incidence and mortality rates for 
males aged over 65 have fallen. A similar trend was noted in young females with mortality 
rising from 0.73:100,000 in 1971-1975 to 0.93:100,000 in 1986-1990 and incidence rising 
from 1.85:100,000 in 1962-1966 to 2.19:100,000 in 1982-1986 in the 35-64 year old age 
group. Again, the incidence and mortality rates for females aged over 65 years fell during 
these time periods. The increases in mortality and incidence are associated with the cohorts 
of patients born after 19 11-1912. The authors suggest that the pronounced rise in alcohol 
consumption in the UK over the last 40 years may be responsible for the increases (Hindle 
et al., 1996). 
However, while tobacco usage is the most important cause of oral cancer, and there 
is an important synergism (multiplicative) with excessive alcohol consumption (La 
Vecchia et al., 1997), a significant minority of patients with oral cancer do not have these 
risk factors. Ehlinger et al., (1993), noted that 32.6% (78% of women) of their patients 
with oral cancer had a negative history for alcohol and tobacco consumption. There is no 
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doubt that many patients seen in oral cancer clinics are life time teetotallers and non- 
smokers. 
Aetiology 
It has been estimated that up to 80% of all human malignancies result from 
exposure to and mutational damage from environmental carcinogens (Doll and Peto,1981). 
There is no reason to suppose that this is not equally applicable to the aetiology of oral 
cancer. It is likely that certain individuals are at increased risk of developing oral cancer 
not only because of increased exposure to mutagenic environmental agents consequent on 
their lifestyle, but also because of a reduced ability to deal adequately with these agents 
due to inherited genetic defects, notably in the loci coding for phase 1 and phase 2 
detoxification enzymes. 
The risk factors involved in the aetiology of cancer of the lip are to a large extent 
different to those involved in intra oral carcinoma. The vast majority of labial carcinomas 
involve the lower lip. The vermilion border and labial mucosa are exposed to carcinogens 
acting on both the oral cavity and the extraoral facial skin. Actinic radiation is the pre- 
eminent risk factor for labial carcinoma. The geographic variations in oral cancer 
incidence rates described previously can be explained almost entirely by variations in the 
amount of average daily sunshine to which the local population is exposed, and the degree 
of racial pigmentation of that population. Dark skinned races have considerably lower 
rates of lip cancer compared to fair skinned races living at the same latitude indicating the 
protective role of melanin (Anderson, 197 1 ; Lindquist and Teppo, 1978). 
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Pipe smoking, in particular clay pipes has long been associated with lip cancer 
(Levin et al., 1950). The combined effects of heat from the non-insulated pipe stem and 
the carcinogens in the tobacco are both felt to be causally involved. The high incidence of 
labial cancer in certain regions of Czechoslovakia is thought to be due to the combined 
carcinogenic effects of sunlight, spiced food and the smoking of short stemmed pipes 
(Henk and Langdon,1985). The fall in labial cancer incidence rates in UK males may be 
due to a reduction in pipe smoking (especially clay pipes) and a reduction in outside 
working (Hindle and Nally, 199 1 ; Johnson and Warnakulasuriya, 1993). It is likely that 
reduced exposure to actinic damage is also responsible for the fall in labial cancer in 
women, albeit from a much lower incidence base than in men. 
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Tobacco 
Globally, tobacco consumption in all its various forms (smoking, chewing & snuff 
dipping etc.) is the commonest aetiological risk factor for the subsequent development of 
oral cancer (Elwood et al., 1984; IARC, 1985; Blott et al., 1988). In developing countries 
the use of tobacco and /or the areca nut produces chronic, potentially malignant lesions 
(leucoplakia, erythroplalua & submucous fibrosis) from which the majority of oral cancers 
arise (Daftary et al., 1992). Conversely, in the developed Western countries, potentially 
malignant lesions or conditions are identifiable in only a minority of cases and the majority 
of oral cancers arise de novo from clinically normal oral mucosa (Table 4). These cancers 
are more aggressive and have a poorer prognosis than cancers arising within pre-existing 
potentially malignant lesions, most notably from within areas of tobacco induced 
leucoplakia. (Henk and Langdon, 1985; Johnson et al., 1993). 
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In the Western world cigarette smoking is responsible for the vast majority of all 
tobacco related oral cancers. In Southern Asia, particularly the Indian sub-continent, both 
tobacco smoking and chewing habits are major aetiological factors. Bidi smoking and pan 
chewing are the commonest forms of tobacco usage in India. The Bidi is a cheap home 
made smoking stick comprising coarse tobacco wrapped in a temburni leaf. Pan is a small 
packet or quid containing areca nut, lime and usually tobacco wrapped in a betel leaf 
(Gupta,1984). It has been estimated that some 200 million people chew betel quid making 
this the single most important known aetiological risk factor for the development of oral 
cancer world wide (Johnson and Warnakulasuriya, 1993). 
The risk of developing oral cancer is directly related to the intensity of tobacco 
usage (Graham et al., 1977; La Vecchia et al., 1997) with heavy smokers (over 20 
cigarettes or 5 cigars per day) having a six fold increased risk of developing the disease 
compared to non-smokers (Cawson et al., 1996). Quitting smoking, especially for 10 years 
or more reduces the odds ratio for developing oral cancer almost to unity (Franceschi et al., 
1990). For those who both chew betel quid and smoke cigarettes the risk of developing oral 
cancer is 12 times greater than exists for non-chewers and non-smokers (WHO,1984). 
Further evidence for the carcinogenic nature of tobacco derives from the fact that 
when tobacco is absent from the betel quid the incidence of oral leucoplakia is low 
(Johnson et al., 1993). Addition of tobacco to the betel quid increases the relative risk of 
developing oral cancer by a factor of three (Warnakulasuriya and Johnson, 199 1). The 
probable cause of this differential effect is that when chewed, the carcinogens in the 
tobacco such as polycyclic aromatic hydrocarbons (PAH), N-nitrosamines and epoxides 
are held directly in contact with the oral mucosa. 
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Oral cancer is rare in non-smokers. In a study of 47,866 Californian Seventh Day 
Adventists (a relatively non-smoking religious sect) between 195 8 and 1963 only 1 male 
and 2 females died of oral or oropharyngeal cancer (Lemon et al., 1964). Oral and 
oropharyngeal cancer deaths accounted for 0.4% and 0.5% of all male and female deaths 
respectively in this group. The solitary male was among a small sub-group of sect 
members who had smoked for up to 20 years. During the same time period 1,855 males 
and 595 females from the same geographical area in California who were not Seventh Day 
Adventists died from oral cancer. Representing 3.5% and 1.3% of all deaths in males and 
females respectively in this group. 
Alcohol 
The consumption of alcoholic beverages in excess is another major aetiological 
factor in the genesis of oral cancer. This is likely to be due to a local carcinogenic effect 
on the oral mucosa as excess alcohol intake is not associated with an increased incidence 
of carcinoma of the intrinsic larynx (Elwood et al., 1984). In the mouth, alcohol may act as 
a solvent enhancing the transfer of carcinogens across the normally intact mucosal barrier 
(La Vecchia et al., 1997). There are often confounding variables between smoking and 
alcohol because many heavy smokers are also heavy drinkers (Cawson et al., 1996). In a 
recent study of 116 patients with oral squamous cell carcinoma 80% of men and 50% of 
women were smokers with 45% of each sex smoking over 20 cigarettes per day. In the 
same study 74% of men and 53% of women drank alcohol with 33% of men consuming 
over 40 units per week. Seven of the ten patients in the study who drank over 40 units per 
week also smoked over 20 cigarettes per day (Worrall and Corrigan, 1995). However, 
several studies have demonstrated that the consumption of alcohol is a risk factor for oral 
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cancer independent of tobacco smoking (Blott et al., 1988; Elwood et al., 1984). As with 
tobacco consumption there is a direct relationship between the amount of alcohol 
consumed and the development of oral cancer. There is evidence suggesting that it may 
not be the ethanol itself in the alcoholic beverage that is responsible for the carcinogenic 
effect, rather it may be due to contaminants or to by-products of ethanol metabolism such 
as acetaldehyde (MacSween, 1982; Ng et al, 1993). In addition to its primary aetiological 
role in oral cancer, alcohol acts synergistically with tobacco in an additive or multiplicative 
fashion (Elwood et al., 1984). The relative risk for the development of oral cancer in both 
heavy drinkers and heavy smokers has been shown to be as high as 24 (McCoy and 
Wynder, 1979). In a study of 29 1 Italian patients with oral and oropharyngeal cancers 
Franceschi et al (1990), demonstrated that heavy drinkers and heavy smokers had an 80 
fold greater odds ratio for cancer than light drinkers and smokers. 
Potentially malignant lesions 
Leucoplakia and erythroplakia are frequently referred to as premalignant or 
precancerous lesions. The implication being, that once present, there is an inevitable 
progression from a white or red patch through various stages of epithelial dysplasia and 
cellular atypia to invasive carcinoma. However, not all leucoplakias and erythroplakias 
will progress to invasive carcinoma. Some will remain static while others may regress 
completely (van der Waal et al., 1997). It is thus more accurate to use the term potentially 
malignant lesions when referring to leucoplakia and erythroplakia (Johnson et al., 1993). 
Leucoplakia, defined as a white patch that cannot be characterised as, or associated 
with, any other disease or any physical or chemical agent except the use of tobacco, is the 
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commonest potentially malignant oral lesion (Axell et al., 1984). The smoking and/or the 
chewing of tobacco are widely accepted to be the major aetiological factors for the 
development of oral leucoplakia (Pindborg, 1980). Although the majority of leucoplakias 
world wide are induced by tobacco and local trauma, the factors involved in the causation 
of many of these lesions remains unknown. And while most leucoplakias simply reflect 
benign hyperkeratosis of the oral mucosa (Silverman Jr et al., 1984), globally some 70% of 
all oral cancers arise from such lesions (Johnson et al., 1993). 
The true rate of malignant transformation is difficult to quantify with various 
studies quoting a range of between O. 13 - 6% (Tradati et al., 1997). Although the World 
Health Organisation consensus range is between 3 and 6% (WHO,1978; Johnson et al., 
1993), the actual rate may be significantly greater than this and may be a high as 15% 
(Tradati et al., 1997) The nodular or speckled variety of leucoplakia caries a greater risk 
of malignant transformation than the commoner, homogenous type although homogenous 
leucoplakia in the floor of the mouth known as sublingual keratosis, is more prone to 
malignant change. In a study of 257 patients with oral leucoplakia followed up for an 
average period of 7.2 years, 45 (17.5%) subsequently developed oral squamous cell 
carcinomas. Although 73% of patients smoked at the time of diagnosis there was a higher 
rate of malignant transformation of leucoplakias in non-smokers (1 8%) than smokers 
(15%) (Silverman Jr et al., 1984). Banoczy and Csiba (1976), reporting on 500 
leucoplakias found an overall malignant transformation rate of 9.6%. The transformation 
rate increased to 13.2% (9/68) in leucoplakias showing histological features of dysplasia. 
Of the 9 cancers, 8 arose in patients whose leucoplakia was managed conservatively and 
not surgically excised. These authors also noted increased malignant transformation rates 
for lingual leucoplakias. 
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Oral leucoplakia is positively associated with bidi smoking, betel quid chewing and 
the use of smokeless tobacco such as snuff dipping (Johnson et al., 1993). Gupta (1984), 
surveyed over 12,000 tobacco users in Kerala, India to assess their tobacco habits and 
identify any associated oral lesions. Nearly 10,500 subjects either chewed betel quids or 
smoked bidis and the remainder both chewed and smoked. A highly significant dose- 
response relationship was demonstrated which was stronger for smoking than chewing. 
Leucoplakia was found in 20.7: 1000 of all subjects, ranging from 11.3: 1000 in those who 
smoked or chewed between 1 and 5 bidis or betel quids respectively per day, to 33.7:1000 
for those who smoked or chewed 16 or more bidis or betel quids respectively per day. 
There is evidence that the leucoplalua associated with bidi smoking has a greater potential 
for malignant transformation than that associated with betel quid chewing (Mehta et al., 
1981). The stronger correlation between bidi smoking and leucoplalua, and the poorer 
prognosis for bidi associated leucoplakias may be due to the composition of the bidi smoke 
which has a significantly higher concentration of carcinogenic agents compared to 
traditional Western type cigarette smoke (Hoffman et al., 1974). 
As with the risk of developing oral cancer, the presence or absence of tobacco 
from the betel quid is important for the subsequent development of leucoplakia. The 
presence of tobacco in the betel quid increases the relative risk of developing leucoplakia 3 
fold (Warnakulasuriya and Johnson,1991). 
When considering the role of tobacco smoking in leucoplakia and oral cancer it is 
important to appreciate the differences between commercially produced cigarettes and the 
items smoked in developing countries. Despite the extensive evidence implicating 
cigarette smoking in the genesis of oral cancer, Western style tobacco smoke is a relatively 
weak carcinogen and it probably has a relatively limited influence on the incidence of oral 
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cancer globally (Henk and Langdon,l985). In contrast, tobacco smoking habits in the 
developing countries where the bidi or similar home made smoking sticks are employed 
are strongly associated with oral leucoplakia and cancer. The increased risks are due not 
only to the enhanced carcinogenic potential of the bidi smoke in comparison to Western 
cigarettes, but also to the vast numbers of people world wide who engage in these smoking 
habits. 
Moreover, in Western countries, while tobacco smoking and chewing are potent 
causes of leucoplakia non-users of tobacco with idiopathic leucoplakia are at increased 
risk of developing oral cancer. This risk increases if there is histological evidence of 
epithelial dysplasia and/or the leucoplakia is on the tongue. Clearly, these high risk 
leucoplakias warrant aggressive treatment by surgical excision. 
Since its original description in 19 1 1 as a lesion occurring on the glans penis in 
elderly syphilitic men when it was termed erythroplasia, erythroplakia has become widely 
recognised as the other clinically significant potentially malignant oral lesion 
(Raubenheimer and De Villiers, 1989; Johnson et al., 1993). It is defined as any lesion of 
the oral mucosa presenting as a bright red velvety plaque which cannot be characterised 
clinically or pathologically as any other lesion (Henk and Langdon,l985). Like 
leucoplakia the diagnosis is clinical and by exclusion. Areas of leucoplakia and 
erythroplakia may coexist, and the speckled areas in speckled leucoplakia are often 
separate areas of erythroplakia (Cawson et ul., 1996). Erythroplakia is much rarer than 
leucoplakia but it caries a significantly greater risk of malignant transformation. The 
malignant transformation rate of erythroplakia is approximately 17 times that of 
leucoplakia and the majority if not all are areas of either severe epithelial dysplasia, 
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carcinoma in situ or invasive carcinoma (Shafer and Waldron, 1975). Of extreme clinical 
importance is the fact that erythroplakia is clinically indistinguishable from many innocent 
inflammatory conditions and that very small innocuous areas of erythroplakia may escape 
detection yet be the site of an invasive carcinoma (Shafer et al., 1974; Raubenheimer and 
De Villiers, 1989). 
Diet and nutrition 
Dietary factors have long been implicated in the aetiology of colorectal carcinoma. 
There is a strong correlation between the intake of meat, particularly red meat and the 
incidence of colorectal carcinoma (Hill, 1997). The cooking process results in the 
formation of N-heterocyclic compounds from sugars, amino acids and creatinine contained 
in red meat via the Maillard reaction (O'Brien, 1997). Heterocyclic amines derived from 
precursor N-heterocyclic compounds are activated by the cytochrome P450 (CYP) 
CYP 1A2 enzyme and subsequently undergo Phase 2 esterification by N-acetyl transferases 
(NAT) and Glutathione S-transferases (GST) resulting in the production of genotoxic 
species that have been demonstrated to be mutagenic in animals (Gooderham, 1997). 
Interestingly, the food carcinogen 2-amino- 1 -methyl-6-phenylimidazo [4,5-b] Pyridine 
(PhIP), which is the predominant heterocyclic amine present in the human diet, is capable 
of detoxification by animals but not by humans who almost exclusively activate PhIP via 
CYP1A2 (Gooderham, 1997). 
Nutritional factors, in particular dietary deficiencies have been associated with an 
increased risk of developing oral cancer. The Patterson-Kelly syndrome was first 
described by Donald Rose Patterson and Adam Brown Kelly in 1919, and subsequently by 
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Henry Stanley Plummer and Porter Paisley Vinson in 192 1, hence its alternative eponym 
of the Plummer-Vinson syndrome (Harding Rains and Ritchie, 1984; Schusterman et al., 
1991). This syndrome consisting of iron deficiency anaemia, sideropaenic dysphagia and 
post-cricoid carcinoma is a well recognised disease entity, particularly in Scandinavian 
women (Larsson et al., 1975). Various dietary micro-nutrients such as vitamins and trace 
elements have recently been shown to be protective against oral cancer. Frequent 
consumption of fresh fruit and vegetables is associated with a reduced risk (0.5-0.7) of 
developing oral and oropharyngeal cancer (La Vecchia et al., 1993). More specifically, the 
antioxidant nutrients ß-Carotene and vitamin E have been shown to produce regression of 
oral leucoplakia, while diets low in carotenoid intake result in an increased cancer risk 
(Garewal and Schantz, 1995). Evidence is emerging that prolonged and heavy 
consumption of foods rich in nitrites and nitrosamines such as preserved meats and fish 
significantly increases lifetime risk for the development of oral cancer (Johnson et al., 
1996). Approximately 15% of oral and oropharyngeal cancers can be attributed to dietary 
deficiencies or imbalances (La Vecchia et al., 1997). 
Published in August1980, the Black Report highlighted the association between 
social (occupational) class and health in the UK (Working Group on Inequalities in Health, 
1980). The report showed that low socio-economic status is positively associated with 
increased morbidity and mortality. For example, in England and Wales in 197 1 the death 
rate for adult men in social class 5 was almost two and a half times that of adult men in 
social class 1 (9.88/1000 and 3.98 /1000 respectively). Furthermore, an almost linear 
relationship was demonstrated between lower social class and rising standardised mortality 
ratio in adult males dying from malignant neoplasms (Working Group on Inequalities in 
Health, 1980, page 40). 
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Lower socio-economic status is also positively linked with a higher incidence of 
oral cancer (Table 5 ) .  The excess oral cancer incidence seen in socially and financially 
disadvantaged patient groups is also likely to explain the time-honoured association 
between poor oral hygiene with a neglected dentition and an increased incidence of oral 
cancer (Graham et al., 1960). Part, but not all of the increased oral cancer risk seen with 
diets low in fresh fruit and vegetables is likely to be due to the association between poor 
diet and low socio-economic status. 
The traditional argument that it is the chronic trauma from broken teeth which leads 
to the development of an oral cancer is probably spurious. Rather, it is likely that 
numerous factors such as increased tobacco and alcohol consumption, poor nutritional 
status and crowded living conditions with increased exposure to environmental 
carcinogens and infectious agents all combine to produce the excess of oral cancers seen in 
this group. 
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Infections 
Conflicting evidence exists for the role of various infectious agents in the aetiology 
of oral cancer. For many years syphilis has been felt to be an important cause of oral 
cancer, particularly lingual and labial carcinoma (Henk and Langdon, 1985). During the 
1920’s patients with lingual carcinoma were up to 5 times more likely to have syphilis than 
other hospitalised patients (Fry,1929). It is possible that in the past the carcinogenic effects 
were due as much to the arsenic used in therapy as the disease itself (Smith,1973; Shafer 
et al., 1974). It has been reported that the incidence of syphilis in the UK population is 
falling rapidly and that this reduction may account for a significant proportion of the fall in 
labial carcinoma currently occurring in the UK (Binnie et al., 1983; Henk and 
Langdon,l985). While screening for current or previous syphilis infection was a routine 
component of the clinical assessment of patients presenting with oral cancer until fairly 
recently, many units have abandoned this procedure because of the perceived fall in 
disease prevalence. In one series of 197 patients with oral cancer only 3 (1.5%) had 
positive syphilis serology (Henk and Langdon et al., 1977). However, one recent study 
found that 5 of 63 patients (8%) with carcinoma of the tongue tested positive for syphilis 
antibodies, indicating that the disease may be more prevalent than was thought to be the 
case and that routine screening for syphilis is probably warranted in this group of patients 
(Dickenson et al., 1995). 
Considering the high frequency of oral viral infections within the population it is 
not surprising that an aetiological role for viruses in oral carcinoma has been sought. 
Especially as there is compelling evidence linking specific viruses with squamous cell 
carcinoma of tissues outwith the oral cavity such as the uterine cervix (zur Hausen,1980). 
Of the many viruses that are potential candidates for oral carcinogenesis there is little or no 
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evidence at the present time for either the retroviruses, adenoviruses or the Epstein-Barr 
virus being involved either directly or indirectly (Cox et al., 199 1). Although Herpes 
simplex viruses (HSV) and the Human papillomaviruses (HPV) and antibodies to them are 
found in patients with and without oral cancer, and electron microscopy has failed to 
demonstrate viral particles within tumour cells (Chen and Hardwick, 1977), there is 
mounting data implicating these viruses in the aetiology of some oral cancers (Johnson and 
Warnakulasuriya, 1993). 
HPV 16 can induce malignant transformation in human squamous epithelial cells 
(Munger et al., 1989) and HPV infection is known to block p53 function following its 
degradation by the HPV-16 associated E6 protein (Johnson et al., 1993). HPV-E7 protein 
binds to the retinoblastoma gene product and sequesters it thus enhancing its transforming 
activity (Johnson et al., 1996). HPV may also integrate into or close to proto-oncogenes 
such as c-myc and ras and by upregulating them stimulate mitosis (Johnson et al., 1996). 
Mutations at the loci coding for both retinoblastoma and p53 protein have been reported in 
a wide range of head and neck cancers, in particular tonsil carcinomas indicating a possible 
oncogenic role for HPV (Field, 1992). In the largest reported molecular epidemiological 
study of HPV infection in human oral squamous cell carcinoma, Balaram et al., (1999, 
amplified tumour DNA using the polymerase chain reaction (PCR) and HPV specific 
primers and found viral DNA sequences in 74% of the lesions. Forty one percent of the 
HPV positive cases demonstrated infection by multiple HPV strains. The majority of their 
patients were also betel nut chewers and they propose that carcinogens derived from the 
betel quid act synergistically with HPV to cause neoplastic transformation. 
There is thus increasing although at times conflicting evidence for a role for HPV 
infection in oral carcinogenesis. Although HPV 16 and 18 are the most frequent types 
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involved other less well investigated strains may also be important (La Vecchia et al., 
1997). 
Patients with oral cancer have raised titres of antibodies against HSV when 
compared to non-smoking controls but similar titres to smoking controls suggesting that 
cigarette smoking may predispose to mucosal HSV infection (Shillitoe et al., 1982). 
Cigarette smoking is known to suppress natural killer (NK) cell activity which is necessary 
for normal host defences against HSV infection (Ferson et al., 1979; Lopez et al., 1985). 
Strong evidence for an association between HSV infection and oral cancer comes from the 
finding of RNA complementary to HSV-DNA in oral squamous cell carcinoma tissue but 
not in normal mucosa taken from the same patients (Eglin et al., 1983). Moreover, 
immunisation against HSV prevents the co-carcinogenic activity of HSV and Dimethyl 
Benzanthracene in the hamster cheek pouch model (Park et al., 1990). 
While it is tempting to speculate that HSV and HPV may be responsible for some 
oral cancers the evidence for their involvement in oral carcinogenesis remains essentially 
circumstantial. Given the ubiquitous nature of HSV and HPV infection within the 
population and the relatively low incidence of oral cancer, if they do have an oncogenic 
role it must be small. There is still the distinct possibility that tumour cells provide a 
convenient environment for viral infection and that the viruses are little more than innocent 
passengers (Scully et al., 1985). 
Candida albicans, a normal oral commensal is not infrequently isolated from oral 
carcinomas which has lead many to speculate that it may have a role in oral carcinogenesis 
(Langdon and Henk, 1995). Candida1 hyphae are intracellular parasites (Cawson and 
Rajasingham, 1972) which have been shown to induce epithelial hyperplasia in vitro 
(Cawson’1973). O’Grady and Reade (1992) produced tongue and palate carcinomas in 
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experimental rats infected with C. Albicans following prior application of 4-nitroquinoline- 
1-oxide (4NQO). The oral mucosa in rats treated with 4NQO but not infected with C. 
Albicans did not develop carcinomas. The authors concluded that C. Albicans might 
participate in causing neoplastic transformation in humans. 
Possible carcinogenic mechanisms include the elaboration of genotoxic metabolites 
(Krogh et al., 1987) and /or the transfection of invaded epithelial cells by ras fungal 
oncogenes (Johnson and Warnakulasuriya, 1993). There is evidence that C. Albicans may 
be involved in the genesis of some potentially malignant lesions. The speckled 
leucoplakias are frequently infected with candida, and as previously discussed the 
incidence of malignant change is significantly greater in the speckled, non-homogenous 
leucoplakias than it is in the homogenous ones. Treatment with antimycotics often results 
in partial or complete resolution of these lesions with leucoplakias previously classified as 
severely dysplastic reverting to mild dysplasia. 
Interestingly, although vaginal infection with C. Albicans is common, particularly 
in pregnancy where over 20% of women harbour the fungus (Llewellyn-Jones, 1986) there 
is little published literature on the association between carcinoma of the uterine cervix and 
C. Albicans infection. An Internet Medline search ( 1966- 1987) of the terms “carcinoma of 
the cervix” and ”Candida Albicans” produced 34,098 references of which only 2 discussed 
the association between infection and carcinoma or its’ treatment. It would appear that the 
incidence of infection with C. Albicans is no higher in patients with cervical carcinoma 
than the normal female population unless treated by radiotherapy when carriage rates 
increase (Richter et al., 1977; Talwar et al., 1992). 
As with HSV and HPV infections, it is likely that in the majority of cases the 
presence of candida in oral carcinomas simply reflects secondary infection by 
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opportunistic organisms. While antibodies to C. Albicans are present at high levels in 
patients with oral carcinoma, the titres are not significantly different to those detected in 
normal patients or those with non-malignant oral diseases (Winters et al., 1984). The lack 
of evidence for an association between C. Albicans and carcinoma of the uterine cervix, a 
site with a high fungal carriage rate further suggests that it is unlikely to be of significance 
in oral carcinoma. Most authors are in agreement that if C. Albicans is involved in oral 
carcinogenesis it accounts for relatively few cases (Cawson et al., 1996). 
Xenobiotics and detoxification enzymes 
All living organisms are continuously exposed to exogenous and endogenous toxic 
chemicals. While it is tempting to blame modem industrialised manufacturing processes 
and motor vehicle pollution for producing these compounds, many xenobiotics occur 
naturally in plants and have been present in the environment since life began (Hayes and 
Pulford, 1995). Flavinoids, glucosinolates and saponins present in various plants are rodent 
carcinogens and mould aflatoxin is one of the most potent carcinogenic agents known. 
Humans may consume 1.5 g of these naturally occurring plant pesticides each day. 
Furthermore, many toxic compounds arise as a result of endogenous metabolism. Cell 
membrane lipid peroxidation occurs following attack by reactive oxygen species (ROS) 
such as the superoxide radical, hydrogen peroxide and the hydroxyl ion derived from 
various metabolic reactions including aerobic respiration and inflammation (Hayes and 
Pulford, 1995). 
To protect themselves from somatic and genetic damage consequent on exposure to 
both exogenous xenobiotics and endogenous electrophiles, higher organisms have evolved 
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complex and complementary enzyme systems capable of detoxifying and eliminating these 
harmful compounds. Over the millennia there has been an evolutionary pressure, or 
molecular drive for organisms to continuously adapt their set of detoxification enzymes in 
order to metabolise ever changing plant phytotoxins (Ingelman-Sundberg and Johansson, 
1995). In the process, several enzyme systems, including the CYP, GST and NAT have 
evolved to protect cells from chemical damage (Smith et al., 1995). While these enzymes 
are able to metabolise xenobiotics and thus eliminate potentially harmful ingested 
exogenous compounds, many also play a major role in cellular homeostasis by detoxifying 
and eliminating endogenously produced chemicals. Detoxification enzyme activity is 
frequently increased following exposure to a wide variety of substrates indicating a 
pleiotropic adaptive response to chemical stress. In particular, GST is induced by 
environmental pollutants, phytochemicals, and raised intracellular (Hayes and 
Pulford, 1995). 
Oral cancer is thought to be the end result of a multi-phase process in which 
carcinogen induced genetic changes produce unrestrained cellular growth (Bongers et al., 
1995). The first step in this process involves the covalent binding of exogenous xenobiotic 
compounds to cellular DNA (Harris,1991). The polycyclic aromatic hydrocarbon 9,10- 
dimethyl- 1,2-benzanthracene (DMBA) reliably induces malignant transformation when 
applied to hamster cheek pouches (MacDonald, 1978; MacDonald and Pospisil, 198 1) and 
industrial exposure to wood dust and organic chemicals are risk factors for oro-pharyngeal 
and laryngeal cancer (Johnson and Warnakulasuriya, 1993). However, it is the carcinogens 
present in tobacco products that are the major xenobiotics involved in oral carcinogenesis. 
Human drug metabolism is classically considered as occurring in 2 distinct phases 
(Figure 4). In phase 1 metabolism, both endogenous and exogenous electrophillic 
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compounds are converted to reactive intermediary species, most commonly by CYP mono- 
oxygenases via the insertion of an atom of molecular oxygen (Smith et al., 1995). The 
activated metabolites of phase 1 metabolism have an increased affinity for the phase 2 
enzymes such as GST and NAT which ultimately results in enhanced excretion of the 
original compound from the body. However, certain compounds, notably many 
carcinogens are activated by CYP phase 1 metabolism and are converted to mutagenic 
electrophiles (e.g. epoxides) (Smith et al., 1995). Following phase 1 metabolism, the 
activated intermediaries are rendered more hydrophilic by conjugation with glutathione 
(GSH), glucuronic acid or other polar groups via the phase 2 enzymes GST, UDP- 
glucuronyl transferase and NAT and ultimately excreted (Smith et al., 1995). Variations in 
the activity of either the phase 1 or phase 2 enzymes could thus be expected to influence 
disease susceptibility by causing elevated levels of reactive and mutagenic metabolites 
either due to increased synthesis or reduced elimination or a combination of both. Thus, the 
carcinogens present in tobacco smoke for example, may lead to malignant transformation 
of oral epithelial cells if those cells are either unable to eliminate the carcinogens, or they 
convert them to more reactive and mutagenic compounds. 

40 
cytochrome P450 2D6 (CYP2D6) phase 1 detoxification enzyme normally responsible for 
metabolising Debrisoquine. Since then it has been unequivocally established that many 
detoxification enzyme proteins are the products of genes that are polymorphic and are thus 
subject to variable expression and activity (Smith et al., 1995). 
CYP 
The cytochrome P450s are a superfamily of hemoproteins which display a 
characteristic 450 nm absorption spectrum in the reduced CO-bound state (Crespi et al., 
199 1 ; Ingleman-Sundberg, 1995). They are divided into 12 families on the basis of their 
sequence homologies, those CYPs with greater than 40% similarity are largely grouped 
into the same family while those with over 55% homology are placed in the same 
subfamily. The CYPs are responsible for the phase 1 metabolism of a wide range of drugs, 
plant toxins, xenobiotics and endogenous compounds including steroids, fatty acids and 
cholesterol. Despite the fact that over 350 different CYPs have been cloned, it appears that 
only about 6 are important for human drug metabolism or homeostasis (Ingleman- 
Sundberg, 1995). 
The CYP1A gene family located at 15q22-ter has 2 functional genes, CYP1A1 and 
CYP1A2. CYP 1 A 1 , which is predominantly an extrahepatic enzyme metabolises 
polycyclic aromatic hydrocarbons such as 3-methylcholanthrene and benzo(a)pyrene while 
CYP1A2, which is liver specific metabolises nitrosamines and arylamines (Smith et al., 
1995). Currently, 3 CYP1A1 polymorphisms have been described; a T-C transition in the 
3’ non-coding region, an A-G point mutation in exon 7 resulting in an isoleucine to valine 
substitution and an AT-GC transition in the 3’ non-coding region (Smith et al., 1995). 
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CYP1A1 expression is induced by tobacco smoke derived PAH's in the lungs of over 80% 
of smokers and in Japanese but not Caucasian populations CYP1A1 polymorphisms are 
associated with an increased risk of lung cancer (Smith et al., 1995; Nebert et al., 1996). 
The CYP2D6 (debrisoquine hydroxylase) enzyme is involved in the metabolism of 
over 40 drugs and xenobiotics including antidepressants, neuroleptics, serotonin-specific 
compounds, ß-blockers, anti-arrhythmics and opiates (Marzo and Balant, 1996; Nebert et 
al., 1996). It also metabolises and activates the carcinogenic tobacco smoke-derived 
nitrosamine, 4-(methylnitrosamino)- 1 -(3 pyridyl)- 1 -butanone (NNK) producing agents 
capable of both methylating and pyridyloxobutylating DNA (Crespi et al., 1991). NNK is 
the only procarcinogen reported that is activated by CYP2D6 (Crespi et al. , 1991). 
Variation in CYP2D6 enzyme activity is based on an autosomal recessively 
inherited polymorphism at its gene locus on human chromosome 22q13.1 (Gough et al., 
1993; Ingleman-Sundberg and Johansson, 1995). 
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There are over 53 allelic variants of CYP2D6 but only 3 are common (Marez et al., 
1997): 
CYP2D6A results from a base pair deletion in exon 5 producing a frame shift 
mutation 
CYP2D6B is due to a G-to-A transition at the intron 3 / exon 4 boundary which 
shifts the position of the 3’ splice site resulting in defective splicing prior to 
mRNA synthesis 
CYP2D6D which is due to an entire gene deletion. 
Of these CYP2D6B is the commonest polymorphism accounting for over 70% of all 
PM genotypes (Gough et al., 1990; Heim and Meyer,1990; Smith et al., 1995; Lear et al., 
1996; Nebert et al., 1996). 
Polymorphism appears to have resulted from homologous unequal cross-over of a 
2.8 kb repeat region which flanks the active CYP2D6 gene (Steen et al., 1995). Inheritance 
of 2 functioning alleles produces the wild type or extensive metabolizer (EM) genotype 
(80-90% of the population) while a polymorphism resulting in no CYP2D6 enzyme 
activity results in the poor metabolizer (PM) genotype. A small, poorly categorised EM 
subgroup termed ultrarapid metabolizers (up to 5% of the population) (Steen et al., 1995; 
Nebert et al., 1996) possess enhanced CYP2D6 enzyme activity as a result of gene 
amplification (Steen et al., 1995). PM frequency varies in different ethnic populations. 
Between 5% and 7% of Caucasians but only 1% of the Chinese population have the 
CYP2D6 PM genotype (Johansson et al., 1991). 
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GST 
The glutathione S-transferases (GST) are a supergene family of phase 2 
detoxification enzymes that play a central role in the metabolism of reactive Substrates, 
many of which are the products of previous CYP phase 1 reactions (Smith et al., 1995; 
Strange and Fryer, 1997). The GST are intracellular cytosolic or membrane bound 
enzymes capable of catalysing a wide range of reactions with both endogenous and 
exogenous Substrates. Typically, they catalyse the conjugation of the sulphur atom of 
glutathione to the electrophilic centres of compounds such as arene oxides and organic 
halides (Bongers et al., 1995; Strange and Fryer, 1997). Numerous carcinogenic 
compounds contain electrophillic centres including aflatoxin benzo[a]pyrene, 7,12 and 
dimethylbenz[a]anthracene (Hayes and Pulford, 1995). 
The GST act co-operatively with numerous anti-oxidant agents including the C and 
E vitamins and the carotenoids playing a pivotal role in protecting cells from damage 
mediated by oxidative stress (Bongers et al., 1995). GST mediated GSH-electrophile 
conjugates are less reactive, less hydrophobic, less likely to partition into membrane lipids 
and have a shorter half life than their parent compounds. However, the major biological 
value for GSH conjugation probably lies in its ability to produce compounds that can be 
exported from the cell by specific ATP-dependent GSH-conjugate efflux pumps called GS- 
X pumps (Hayes and Pulford,1995). Because the GST are also involved in the 
detoxification of many cancer chemotherapeutic agents including cisplatin and alkylating 
agents, enhanced GST activity may result in reduced tumour cell killing by these agents 
resulting in the emergence of drug-resistant tumours (Sarkar et al., 1997). 
The dimeric cytosolic GST are divided into 6 classes alpha, mu, pi, theta, sigma 
and zeta on the basis of their sequence homology with members of the same class showing 
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a minimum of 65% aminoacid homology (Smith et al., 1995; Board et al., 1997). While 
most work has focused on the activities of the cytosolic GST and their role in 
detoxification reactions and free radical scavenging, it is known that the membrane bound 
enzymes play a major role in protecting cell membranes from peroxidation damage 
(Bongers et al., 1995; Smith et al., 1995; Strange and Fryer, 1997) (Table 6). 
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The first GST demonstrated to be polymorphic was the GSTM1 locus (Board, 
1981). This locus consists of 3 possible alleles: GSTM1 *O, GSTM1 *A and GSTM1 *B. The 
GSTM1 *0 is deleted, hence GSTM1 *0 homozygotes (GSTM1 null), express no GSTM1 
protein. GSTM1 *A and GSTM1 *B differ by just one base in exon 7 (Strange and 
Fryer,1997). There is evidence that GSTM1 *A and GSTM1 *B confer differing 
susceptibilities to diseases such as bladder cancer, Crohn’s disease and multiple cutaneous 
basal cell carcinomas. GSTM1 A/B but not GSTM1 A or GSTM1 B appear protective 
against these diseases. Considering that the in vitro catalytic activities of the enzyme 
products of these 2 alleles are identical some other phenomenon must also be involved 
(Inskip et al., 1995). 
Similarly, the GSTM3 locus comprises 2 alleles, GSTM3 *A and GSTM3 *B which 
differ due to the deletion of 3 base pairs in intron 6 of GSTM3 *B. It has been suggested 
that GSTM3 *B but not GSTM3 *A is inducible, due to the presence in the former of the 5’- 
AAGATA-3’ recognition site for the YY1 transcription factor (Inskip et al., 1995). The 
intron 6 deletion being the only difference between the 2 alleles must thus influence the 
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YY1 recognition motif (Inskip et al., 1995 ; Strange and Fryer,1997). It also appears that 
there is linkage disequilibrium between GSTM3*B and GSTM1 *A, with subjects of 
haplotype GSTM1 *A/GSTM3 *B expected to express a disproportionate amount of GSTM3 
(Inskip et al., 1995). It is thus important to recognise that the effects of GSTM1 
polymorphisms will be affected by Co-inherited GSTM3 polymorphisms. Disease 
susceptibility hypotheses centred around single mutated alleles are likely to be too 
simplistic (Yengi et al., 1996). 
Enzymes of the GST-a class are theoretically well placed to be involved in 
carcinogenesis as they display high activity against cumene hydroperoxide and 4- 
hydroxynonenal (Strange and Fryer, 1997). However, while there appears to be strong 
phenotypical evidence for the existence of polymorphisms in these enzymes to date, 
restriction fragment polymorphisms have only been reported in GSTA2 (Chen and 
Board, 1987; Strange and Fryer,1997). 
Polymorphism has recently been identified at the locus (Ali-Osman et al., 
1995). Subjects with the GSTPZ AA genotype have an A to G transition in exon 5 resulting 
in an Ile (ATC) to Val (GTC) base change on both alleles at position 104 (Zimniak et 
al.,1994; Matthias et al., 1998a). Introduction of valine into the GSTP1 enzyme protein 
close to its binding site increases affinity and activity for electrophillic substrates (Zimniak 
et al., 1994). 
GSTPl is the most widespread of the human GST enzymes and is present in 
particularly high concentrations in cells of the gastrointestinal tract, lung, erythrocytes, 
platelets and foetal liver (Bongers et al., 1995). GST-pi is highly inducible being found in 
elevated concentrations in experimentally induced malignant and premalignant human 
lesions (Zhang et al., 1994; Bongers et al., 1995). The GSTP1 enzyme is also able to 
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metabolise cigarette smoke derived carcinogens like benzo[a]pyrene diol epoxide and 
acrolein (Hayes and Pulford, 1995; Strange and Fryer, 1997). 
The enzyme protein products of the GSTT1 locus are responsible, amongst other 
things, for the metabolism of monohalomethanes, ethylene oxide and epoxides, all putative 
carcinogens present in cigarette smoke (Ketterer et al., 1993, Strange and Fryer, 1997). 
Board’s group in Australia has recently reported the identification of 2 previously 
undescribed GST’s, GSTZ and GSTT2. GSTZ is a dimeric enzyme composed of 2 24.2 kD 
subunits present in both plants and animals (Board et al., 1997). The gene coding for the 
newly discovered theta class GSTT2 is polymorphic and located on chromosome 22 close 
to the CYP2D6 locus (Strange RC, personal communication). The association between 
both GSTZ and GSTT2 and carcinogenesis is currently unclear. 
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1.4 Detoxification Enzyme Polymorphisms and Disease 
Numerous examples in the plant and animal kingdoms testify to an organism’s 
increased susceptibility to disease consequent upon altered expression at loci coding for 
detoxification enzymes. The GT112 strain of maize is GST null and lacks the ability to 
detoxify S-chlorotriazines rendering it very sensitive to herbicides containing this 
compound and differences in the expression of GSTA in the rat and the mouse are thought 
to be responsible for the selective toxicity of aflatoxin in the former and the resistance 
in the latter (Hayes and Pulford, 1995). 
In addition to the slow metabolism of Debrisoquine consequent on the CYP2D6 PM 
genotype discussed previously, numerous other detoxification enzyme polymorphisms 
have been shown to confer altered disease susceptibility in humans. Patients with the 
CYP2D6 PM genotype possess a 2-3 fold increased risk of developing Parkinson’s disease 
(Smith et al., 1992) and both astrocytoma and meningioma have been reported to be more 
frequent in patients who are CYP2D6 PM or GSTT1 null (Elexpuru-Camiruaga et al., 
1995). Squamous cell carcinoma of the uterine cervix is positively associated with 
cigarette smoking and the CYP2D6 EM phenotype is significantly higher in women with 
high grade cervical intraepithelial neoplasia (CIN), particularly in those who smoke than it 
is in controls (Warwick et al., 1994b). Smokers who are CYP2D6 EM are at increased 
risk of developing lung cancer possibly as a result of activation of a tobacco smoke derived 
carcinogen, while those with the PM and HET genotypes appear to be protected (Caporaso 
et al., 1990; Crespi et al., 1991). There is also some evidence that CYP2D6 
polymorphisms may also be associated with cancer of the urinary bladder, another 
malignancy positively linked to cigarette smoking (Chineegwundoh and Kaisarv, 1996). 
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In a study of 108 patients with non-small cell lung tumours Ryberg ed al., (1994), 
demonstrated that 32% of patients had a somatically acquired mutation at one or both p53 
loci and that 91% of heavy smokers with GC transversion mutations were GSTM1 null. 
Similarly, in a study of ovarian cancers, Sarhanis et al., (1996) demonstrated that 87% of 
tumours that reacted positively for p53 immunostaining were also GSTM1 null. These data 
suggest that GSTM1 plays a central role in the detoxification of the products of oxidative 
stress consequent on the exposure of cells to certain xenobiotics and that it protects p53 
against carcinogen-DNA adduct damage via carcinogens such as benzo( a)pyrene (Strange 
and Fryer, 1997). 
The first evidence for an association between GSTM1 null and lung cancer was 
provided by Seidegard et al., (1986), who demonstrated a 1.6 fold increase in the 
frequency of this genotype in patients with lung cancer. Subsequent studies have 
frequently produced conflicting data perhaps reflecting the weak influence any single 
genotype has on this disease process. Meta analyses suggest that the GSTM1 null genotype 
confers a small increased risk for lung cancer (Strange and Fryer, 1997). While theses 
findings are consistent with the known biological activity of GSTM1 against PAH 
epoxides present in cigarette smoke it has also been shown that susceptibility to lung 
cancer in GSTM1 null individuals may be modified by dietary factors, particularly the 
serum levels of vitamin C and E (Hayes and Pulford, 1995). 
Both the GSTM1 null and GSTT1 null genotypes have been shown to be associated 
with an increased risk of ulcerative colitis, Crohn’s disease and cancer of the colon 
(Deakin et al., 1996; Strange and Fryer, 1997). 
High grade cervical intraepithelial neoplasia (CIN) has been shown to be more 
common in women who smoke and who are either, GSTM1 null, GSTT1 null or CYP2D6 
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EM(extensive metaboliser) than in controls (Warwick et al., 1994b). However, although 
women who are CYP2D6 EM and smoke are at higher risk than controls of developing 
high grade CIN they have been shown to be less likely to progress to invasive carcinoma. 
Perhaps because of enhanced detoxification of an as yet unidentified chemical required for 
disease progression (Warwick et al., 1994a). 
Yengi et al, (1996), have shown that GSTM3 is expressed in the basal layer of the 
epidermis and that the GSTM3 AA genotype is associated with an increased risk for the 
development of multiple cutaneous basal cell carcinomas in patients who also have skin 
type 1 or who are GSTM1 null or CYP1A1 ml ml. They hypothesise that GSTM3, like 
GSTM1 plays an important role in free radical scavenging following ultra-violet (UV) light 
induced oxidative stress in the epidermis. 
Polymorphism at the GSTM3 locus has been shown to influence susceptibility to 
laryngeal carcinoma but not pharyngeal carcinoma (Matthias et al., 1998b). The same 
study demonstrated that the GSTM3 subunit was strongly expressed in the laryngeal cilia 
while being undetectable in the anatomically close pharyngeal mucosa. 
There is also evidence in support of the hypothesis that oral cancer risk is enhanced 
by certain detoxification enzyme polymorphisms. GSTM1 null and GSTT1 null genotype 
frequencies have been found to be significantly more common in patients with either oral 
cavity, pharyngeal or laryngeal cancer (Trima et al., 1995) (Table 7). Hung et al. (1997) 
reported that male Taiwanese patients with the combined GSTM1 null and/or GSTT1 null 
genotype had an increased oral cancer risk compared to those who were non-null for both 
GSTM1 and GSTT1 (OR = 4.6,95% CI = 0.9 - 23.7). However, in contrast to Trima et al. 
(1995) they were unable to demonstrate a significant association between oral cancer risk 
and the individual GSTM1 or GSTT1 genotypes (Hung et al.,1997). 
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Induction of squamous cell carcinoma in hamster cheek pouches by the application 
of DMBA has been shown to result in the production of positive cells (Zhang et al., 
1994). Significantly lower (p=0.003) levels of the high activity GSTP1 AA genotype have 
recently been reported in patients with pharyngeal but not laryngeal cancer compared to 
controls and the GSTP1 enzyme subunit has been shown to be expressed widely 
throughout the mucosa lining the pharynx and larynx (Matthias et al., 1998a). These data 
suggest that GSTP1 influences susceptibility to squamous cell carcinoma of the upper 
aerodigestive tract and that subjects with the GSTP1 AA genotype are better able to 
detoxify environmental carcinogens and hence are at lower risk of developing pharyngeal 
cancer. 
Immunocytochemical staining of both normal and progressively more dysplastic 
oral mucosa leading up to invasive squamous cell carcinoma has demonstrated that GSTP1 
expression mirrors the degree of tissue abnormality present (Table 8). Plasma GSTPl 
levels also reflected the extent of the primary disease with higher levels being found in 
higher stage disease (Table 9). 
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Table 8 
Staining intensity 
HIstological diagnosis + ++ +++ +++ 
Mild dysplasia 40% 60% O O 
Moderate dysplasia 10% 40% 50% O 
Severe dysplasia & CIS O O 80% 20% 
Epithelial hyperplasia 60% 40% O O 
Normal oral epithelium 60% 60% O O 
. . __ 
SCC O O 10% 90% 
GSTP1 staining intensity and oral mucosal lesions. 
+ = weakly positive, ++ = moderately positive, +++ = strongly positive, ++++ = very 
strongly positive. 
(Adapted from Zhang et al., 1994). 
Table 9 
GSTP 1 
(ng/ml) (ng/ml) positive 
Histological diagnosis Mean Range % N 
SCC - Stage 1 33.2 17-63 50 12 
SCC - Stage 2 33.4 10-60 64.3 14 
SCC - Stage 3 45.1 13-87 70.6 17 
SCC - Stage 4 47.2 2 1-98 77.8 18 
Recurrence 43.0 20-78 76.9 13 
Normal controls 17.8 5-30 O 78 
Benign tumour 19.5 8-2 8 O 12 
GSTP1 levels in patients with oral SCC, benign tumours and normal controls. 
Positive levels were taken as >30.4 ng/ml (mean + 2SD of normal control levels) 
(Adapted from Hirata et al., 1992). 
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Sarkar et al. (1997) have demonstrated that GSTP1 expression is significantly 
higher in recurrent oral carcinomas than in primary oral tumours again suggesting a 
possible clinical role for GSTP1 in prognosis prediction. However, the same authors also 
demonstrated that GSTPl expression in normal oral mucosa is comparable to that seen in 
tumour tissue taken from the same patients suggesting that elevated GSTP1 expression 
may be a function of increased carcinogen exposure (in this case betel nut) rather than a 
marker for oral cancerper se (Sarkar et al., 1997). 
There is thus mounting evidence to suggest that allelic variation at the loci 
responsible for the production of many of the phase 1 and phase 2 enzymes described 
above significantly influences individual susceptibility to certain cancers, particularly those 
known to be tobacco related. 
However, while molecular epidemiological techniques have been employed to 
construct phylogenetic trees that suggest that these detoxification enzymes evolved in 
order to metabolise environmental toxins (Johansson et al., 199 1; Ingleman- 
Sundberg, 1995) one must be wary of misinterpreting these findings. Surely these enzyme 
systems are not in existence solely to detoxify the by-products of human excesses! 
Moreover, as cancer overwhelmingly affects subjects already well into, if not past their 
fertile years, it is hard to reconcile how an evolutionary selection advantage is conferred on 
individuals who inherit enzymes that reduce their cancer risk. A more plausible 
explanation is that the detoxification enzymes exist because they are vital to normal 
cellular growth and homeostasis. The fact that they may also detoxify xenobiotics is an 
added bonus. 
Although individual phase 1 or phase 2 enzyme polymorphisms may well influence 
disease susceptibility, it is more likely that inheritance of a combination of specific 
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polymorphisms at phase 1 and phase 2 enzyme loci is qualitatively a more important risk 
factor. Moreover, these multiple polymorphisms probably also need to act in concert with 
exposure to environmental or endogenous carcinogens such as tobacco smoke or alcohol. 
Such a cascade would be compatible with the current hypothesis that cancer is the end 
result of a multi-stage process involving loss of normal function, DNA damage and 
accumulation of adverse genetic and epigenetic events ultimately resulting in unrestrained 
growth and invasive carcinoma (Ryberg et al., 1994; Sidransky, 1995). 
In the final analysis the raison detre for the presence of the detoxification enzyme 
system may be unimportant. If the identification of certain allelic variations identifies 
individuals at high risk for the development of certain cancers and facilitates better 
prognosis estimation, treatment and survival we can use them to improve the management 
of our patients. 
Given that abnormal detoxification profiles of xenobiotics and their metabolites are 
associated with increased malignant potential, by what mechanism do these reactive 
intermediaries exert their mutagenic effects? There is mounting evidence indicating an 
association between detoxification enzyme polymorphisms and mutations and 
amplifications of oncogenes and tumour suppressor genes. 
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1.5 Cancer Genetics 
Cancer is a genetic disease, and carcinogenesis is now held to be a multi-stage 
process involving the progressive accumulation of genetic alterations in previously normal 
cells ultimately resulting in malignant transformation (Field, 1 992; Sidransky, 1995; 
Califano et al., 1996, Sidransky and Hollstein, 1996). Approximately 6-10 separate genetic 
events are required to transform a normal cell into a malignant one (Sidransky, 1995). 
Cancer cells are distinguished from their normal counterparts by virtue of their 
immortality, transformation and in many cases their ability to metastasise (Lewin, 1994). 
These properties, which constitute the malignant phenotype, arise from aberrant cellular 
growth control and interaction processes (Partridge, 1995). Moreover, while the cellular 
composition of normal mucosa is polyclonal, being derived from numerous and diverse 
stem cells, carcinomas are monoclonal, indicating an origin from a single neoplastic cell 
that has undergone clonal expansion (Fearon and Vogelstein, 1990; Califano et al., 1996). 
There are 2 main classes of cancer genes; the oncogenes and the tumour suppressor 
genes although cancer results from the complex interplay of may environmental and 
genetic factors and is thus a polygenic disease (Field, 1992; Lewin, 1994; Partridge, 1995). 
Oncogenes are identified by genetic alterations that result in a gain of function, whereas 
tumour suppressor genes are identified by mutations that result in loss of function 
(Lewin, 1994). 
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Oncogenes 
The term oncogene is potentially misleading because it implies that it is always 
associated with malignancy, whereas oncogenes are DNA sequences found in normal cells, 
where they play a vital role in regulating growth and differentiation. It is only when they 
become altered either qualitatively or quantitatively that they develop oncogenic potential 
(Field, 1992). They are perhaps better referred to as proto-oncogenes (Lewin, 1994). 
Activation of proto-oncogenes can result from mutation following exposure to chemical 
carcinogens irradiation or viruses (Field, 1992; Partridge, 1995). 
There are 2 broad categories of oncogenes; cellular oncogenes (c-onc) and viral 
oncogenes (v-onc). As described above, c-onc 's or proto-oncogenes are specific DNA 
sequences that code for proteins whose function is to regulate cell growth and 
differentiation. The v-onc genes are sequestered in the form of RNA following a retroviral 
infection of a mammalian cell. Following reverse transcription of viral DNA, the viral 
genome is incorporated into the host DNA which may be close to a proto-oncogene. 
During viral replication part of the host DNA may become incorporated into the viral 
genome. If this host DNA contains a proto-oncogene sequence the retrovirus will now 
have the capacity to transform subsequently infected host cells as it now carries a viral 
oncogene. 
The ability of viral oncogenes genes to transform normal cells together with the 
very close sequence homology between v-onc 's and their corresponding c-onc suggests 
that they act by mimicking normal cellular growth systems but without the usual tight 
control and restraint that is characteristic of normal cell differentiation. The proto- 
oncogene protein products are known to be involved with several aspects of cell growth 
control, in particular the regulation of DNA transcription following activation of a trans- 
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membrane cytosolic receptor (Lewin, 1994; Partridge, 1995). They include; growth factors, 
growth factor receptors, signal transduction cascade proteins and transcription factors 
acting in a cascaded sequence: 
Growth factor 
Growth factor receptor (tyrosine kinase) 
Kinase cascade (serine/threonine kinases) 
Normal and malignant epithelial cells secrete transforming growth factor alpha 
(TGF-a) and related ligands, a small polypeptide proto-oncogene product which stimulates 
cell growth by binding to a family of cell surface epidermal growth factor receptors (EGF). 
These cells also secrete TGF-ß which has a growth inhibitory effect on normal epithelial 
cells. However, TGF-ß is normally secreted in an inactive form and activation of TGF-ß, 
perhaps via protease digestion or acidification plays a crucial regulatory role in the control 
of cell proliferation (Partridge, 1995). Cell surface EGF receptor expression in oral 
squamous cell carcinomas is related to its state of differentiation and inversely proportional 
to the level of TGF-a secreted suggesting that binding of TGF-a to the EGF receptor is 
responsible for stimulating cell proliferation. Furthermore, growth and proliferation of 
many head and neck squamous cell carcinoma cell lines is not restrained by TGF-ß, 
possibly due to failure of TGF-ß activation, EGF receptor down regulation or subsequent 
failure of activation of the post-receptor kinase cascade (Figure 5) (Partridge, 1995). 
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It is self evident that there must be some difference between a proto-oncogene and 
its associated v-onc and “activated’ c-onc otherwise life could not exist. It appears that 
differences in both structure and amount are responsible for the transforming potential of 
the v-onc genes and activated oncogenes. 
There are 3 active genes in the oncogenes derived from the c-ras family: N-ras, H- 
ras and K-Ras. Each codes for a 21 kD protein (p21) on the inner cell membrane that binds 
guanosine triphosphate (GTP) in its active state. The v-ras and c-ras sequences differ by 
only a single amino acid, most commonly at positions 12 or 6 1. Glycine is normally found 
at position 12, if mutation results in its replacement by any amino acid other than proline 
an activated oncogene results. The mutated rus gene produces a permanently active p21 
protein resulting in uncontrolled activation of the kinase cascade (Lewin, 1994; 
Partridge, 1995). Rus mutations have been demonstrated in approximately half of all 
colorectal carcinomas and large adenomas but in fewer than 10% of small adenomas 
(Fearon and Vogelstein,1990; Field,l992). These data suggest that rus mutations are 
important in the early stages of colonic carcinogenesis (Field, 1992). Although H-ras 
mutations are uncommon in oral carcinomas in the western World they have been 
demonstrated in over one third of such lesions occurring in India (Field,1992). 
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As discussed previously, betel nut chewing is a major aetiological factor for oral 
squamous cell carcinoma in India and it is possible that carcinogens in the betel quid could 
be responsible for the H-ras mutations. Not all active oncogenes or v-onc 's have differing 
sequence homologies from their c-onc counterparts. The myc gene is a nuclear proto- 
oncogene coding for the 62 kD p62 protein involved in DNA and cell replication. If a 
retrovirus inserts close to the c-myc locus it can cause increased expression of p62 because 
virus controlled c-myc transcription is more efficient than normal transcription due to the 
enhanced promotion afforded by the long terminal repeat (LTR) sequences of the 
retrovirus. The c-myc locus may also be involved in a reciprocal translocation with the 
immunoglobulin heavy chain (IgH) locus on chromosome 14 which also results in 
increased expression and elevated levels of p62. If colonies of immature B lymphocytes 
are subjected to p62 hyper-expression because of a failure to turn off c-myc they are unable 
to differentiate into mature cells resulting in the formation of a lymphoma (Lewin,1994). 
Bcl-2 and c-myc, both play an important role in cell apoptosis and are detectable at an early 
stage in the change from normal to dysplastic mucosa. Bcl-2 appears to be able to protect 
cells from programmed cell death, while c-myc activation is frequently associated with 
malignant transformation (Scott et al., 1996). Like H-ras, members of the c-myc gene 
family have not been shown to be important in head and neck cancer in the western World 
but have been shown to be amplified in over one third of Indian head and neck cancers 
(Field, 1992). 
Two other nuclear proto-oncogenes, which like c-myc code for DNA binding 
proteins, are c-fos and c-jun. The fos and jun oncogene proteins form a heterodimer which 
is a component of the AP-1 transcription factor (Partridge, 1995). We can now construct a 
61 
flow schematic detailing the interactions between proto-oncogenes which helps to explain 
their action following mutation of their normal cellular homologues (Figure 6). 
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Tumour suppressor genes 
Unlike the oncogenes which introduce a gain of function leading to uncontrolled 
cellular growth and proliferation, abnormalities of the tumour suppressor genes are 
oncogenic because they result in loss of normal function (Partridge,l995). While 
oncogenes can be visualised as “dominant” genes inasmuch as only one proto-oncogene 
allele needs to be mutated for it to become an oncogene, tumour suppressor genes are 
“recessive” because both normal alleles need to be defective for tumorigenesis to occur. 
The loci coding for the production of the retinoblastoma (Rb) and p53 proteins are 
currently the best characterised tumour suppressor genes (Lewin, 1995). 
Rb 
The Rb gene is located at 13q14. If both Rb alleles are inactive the affected 
individual will inevitably develop a retinoblastoma. Affected individuals may have the 
inherited form of retinoblastoma in which one Rb allele caries a germ line mutation and a 
subsequent somatic mutation in the retinal cells results in loss of both alleles. 
Alternatively, in the sporadic form of retinoblastoma both inherited Rb alleles are normal 
but somatic mutation of the retinal cells results in loss of both alleles. 
Rb is a nuclear phosphoprotein that in its dephosphorylated form sequesters the 
E2F transcription factor and inhibits cell proliferation by blocking the cell cycle in the 
phase. Phosphorylated Rb releases the cell cycle block allowing the cell to enter the S 
phase of mitosis. It is hypothesised that allelic loss at both Rb loci removes one of the cell 
cycle control blocks permitting unimpeded cell proliferation (Sidransky and Hollstein, 
1996). 
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Transcription of the cyclin D1 (CCND1) gene, located on chromosome 1 1q13 
which codes for the proto-oncogene cyclin D1, is induced and positively regulated by 
various growth factors (Betticher et al., 1995; Lewin, 1995). The activated cyclin 
dependent kinase CDK4 complexes with cyclin D1 and inactivates the Rb protein by 
phosphorylation in the process releasing the previously Rb bound E2F transcription factor. 
Free E2F then activates several genes required for cell division. By competitively binding 
to CDK4, the p16 protein inhibits CDK4-cyclin D1 complex formation and induces 
accelerated turnover of unbound cyclin D1 during S phase (Betticher, 1996). Alternate 
binding and release of cyclin D1 to CDK4 thus controls the cell cycle and associated 
transcription events. Cyclin D1 thus appears to be a growth factor sensor and initiator of 
the cell cycle and drives it through the first restriction (START) point acting via the down 
regulation of the Rb protein (Figures 7a and 7b) (Betticher et al., 1995; Betticher, 1996; 
Betticher et al., 1996). 
Cyclin D1 is potentially oncogenic in that its overexpression will result in induced 
cell proliferation (Betticher et al., 1995). The 1 1q13 locus containing the CCND1 gene is 
one of the most commonly amplified loci in human carcinomas and cyclin D1 over 
expression in head and neck cancer is associated with local invasion early regional lymph 
node metastasis and poor prognosis (Michalides et al., 1995; Bellacosa et al., 1996; 
Betticher et al., 1996). However, cyclin D1 is likely to be one of many factors responsible 
for normal cell cycle regulation as it has been shown that in cyclin D1 “knocked out” mice 
cell proliferation continues virtually unchanged (Betticher, 1996). 
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Defective control of the formation of CDK4-Cyclin D 1 complexes is another 
potential cause for abnormal cell proliferation. The ink4 gene codes for the production of 
p16 the critical inhibitor of CDK4-Cyclin D1 complexes and is located on chromosome 
9p21 (Serrano et al., 1993). The 9p21-22 locus is the most commonly deleted region (66%) 
in head and neck cancer (Sidransky, 1995). 
P53 
This tumour suppressor gene is defective in approximately half of all malignant 
neoplasms (Sidransky and Hollstein, 1996). 
The p53 gene is located on human chromosome 17 and codes for a 53 kD nuclear 
phosphoprotein which was first discovered in SV40-transformed cells (Lewin, 1994; 
Partridge, 1995). Mutation of the p53 gene is the most common genetic event implicated in 
human carcinogenesis (Iggo et al., 1990; Ryberg et al., 1994; Shintani et al., 1995). Wild 
type p53 protein is present in minute concentrations in normal cells and is virtually 
undetectable. Mutation at the p53 locus results in the production of an abnormal protein, 
which unlike wild type p53 is unable to bind to the T-antigen of SV40. Furthermore, the 
mutated protein is stable and hence detectable by immunocytochemistry (Lane and 
Benchimol, 1990; Lewin, 1994; Partridge, 1995 ). In the Li-Fraumeni syndrome, a rare form 
of inherited cancer, both p53 alleles are mutated resulting in a non-functioning protein 
(Lewin, 1994). The T-antigen present in SV40 infected cells is required for viral 
replication and entry into S phase (Partridge, 1995). The fact that wild type p53 binds to 
SV40 T-antigen interfering with its ability to promote viral replication is indicative that the 
function of p53 may be to control the cell cycle by binding to a cellular homologue of 
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SV40 T-antigen (Lewin, 1994). Wild type p53 is known to bind to sequence sgecific 
double-stranded DNA, whereas all the mutated p53 proteins isolated to date have lost this 
DNA binding capacity (Lane, 1992; Wieczorek et al., 1966). DNA binding is regulated by 
the allosteric structure of a basic region in the p53 protein located within the carboxy- 
terminal 30 amino acids (Yao et al., 1966). The mutations involve a single amino acid 
substitution at an arginine target either in regions directly responsible for DNA binding 
(class 1) or areas that stabilise the DNA binding domain (class 2) (Wieczorek et al., 1966). 
Mutant p53 is capable of binding with members of the cytoplasmic heat shock proteins 
(hsp 70) accounting for the high levels of extra-nuclear mutant p53, while wild type p53 is 
confined to the nucleus (Iggo et al., 1990). As well as its DNA binding function, wild type 
p53 also functions as a potent transcription activator (Lane,1992). Mutant p53 is known to 
act as a dominant-negative, which, by forming inactive hetero-oligomers with wild type 
p53 overwhelms the normal protein (Lane, 1992; Lewin, 1994). This effect means that even 
heterozygotes with only one mutant p53 allele may have significantly reduced wild type 
p53 function (Iggo et al., 1990). A similar oligomerization function probably accounts for 
the binding and subsequent inactivation of p53 by HPV 16 E6 protein (Field, 1992; 
Lewin,1994) which may be one of the methods by which HPV 16 induces malignant 
transformation in infected cells. Both point mutations and hetero-oligomer formation 
abolish normal p53 function. 
Of fundamental importance to the understanding of the role of p53 in cellular 
homeostasis was the finding that DNA damage mediated by chemical carcinogens or ultra 
violet irradiation results in the accumulation of cellular p53 as a result of post-translational 
stabilisation (Maltzman and Czyzyk, 1984). Wild type p53 suppresses the replication of 
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genetically damaged cells by both arresting and promoting exit from the cell cycle 
(Sidransky and Hollstein, 1996). 
There are 2 checkpoints in the cell cycle at which arrest can occur. The G1/S 
checkpoint controlled by the p53-dependent induction of p2 1, an inhibitor of the cyclin E- 
cdk2 complex, and the G2/M checkpoint which is regulated via p34 kinase (Yao et al., 
1966). Normally, following DNA damage such as strand breakage, p53 accumulates and 
arrests the cell cycle at the G1/S checkpoint thereby allowing time for DNA repair and/or 
apoptosis if repair fails (Sidransky and Hollstein,1996). Conversely, if p53 is mutated, or 
inactivated consequent on binding of viral proteins or xenobiotic attack etc, G1 cell cycle 
arrest is not possible. Cells with mutated p53 pass through the G1/S checkpoint and 
accumulate at the G2/M checkpoint (Ya0 et al., 1966). DNA damage and mutations are 
allowed to occur resulting in rapid selection out of malignant clones (Lane,1992). 
Not only does mutated p53 result in increased cell cycling and proliferation but it 
also confers resistance to tumour cell killing by irradiation or cytotoxic drugs because of 
the reduced vulnerability to apoptosis. This situation is reflected in the observation that 
tumours demonstrating a high incidence of p53 mutations such as lung and colon cancers 
respond poorly to anti-cancer chemotherapy and irradiation. Conversely, tumours 
displaying low rates of p53 mutations such as testicular cancer and Wilms’ tumour are 
successfully treated by these modalities (Yao et al., 1966). 
Between 75% and 85% of lung cancers demonstrate damage at one or both p53 
alleles (Partridge, 1995), many of which are G-T transversions, a process known to be 
inducible by exposure to benzo(a)pyrene present in cigarette smoke (Iggo et al., 1990). 
However, p53 mutations were not found in carcinoid tumours, which have a different 
aetiology and behaviour (Iggo et al., 1990). 
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Scott et al. (1996), found that p53 mutation occurred in 46% of colorectal 
carcinomas, but was never detected in normal large bowel mucosa (Scott et al., 1996). 
They also reported that p53 overexpression was a late event in the carcinogenesis process 
of colorectal tumours, only being found in highly dysplastic adenomas and invasive 
carcinomas. 
Overexpression of p53 has also been demonstrated in oral squamous cell 
carcinomas (Gusterson et al., 1991; Partridge,1995). Shintani et al., .( 1999, demonstrated 
p53 overexpression in 40.2% of oral squamous cell carcinomas, whereas there was no 
detectable p53 in 10 biopsies of normal oral mucosa (p<0.05). Interestingly, p53 was also 
overexpressed in 34.8% of biopsies taken from the macroscopically normal epithelium 
adjacent to invasive squamous cell carcinomas and in 18.7% of oral leucoplakias (Shintani 
et al., 1995). Similarly, nuclear p53 overexpression has been reported in tobacco snuff- 
induced non-malignant oral lesions but not in normal mucosa taken from patients who did 
not use snuff (Wedenberg et al., 1996). Increased p53 expression was also strongly 
associated with increased Ki-67 nuclear staining. The Ki-67 antibody reacts strongly with 
2 nuclear proteins that are present throughout the cell cycle except and the intensity of 
Ki-67 staining has been shown to be positively correlated with cell proliferation 
(Wedenberg et al., 1996). 
Not only have p53 mutations been demonstrated in a large number of head and 
neck cancers, but also in a high proportion of microscopically normal mucosal biopsies 
taken from these patients (Ogden, 1996). This finding has important therapeutic 
implications because it indicates that histologically clear tumour excision margins may still 
contain cells that are destined to become malignant. Brennan et al. (1995b) demonstrated 
that in 25 cases of head and neck squamous cell carcinoma with histologically clear 
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resection margins 52% were positive for a p53 mutation in at least one margin. Thirty 
eight percent of the cases with p53 positive resection margins developed a local recurrence 
compared to 0% of the p53 negative cases. Moreover, 21% of histologically clear cervical 
lymph nodes were shown to contain the same p53 mutations as the primary tumour 
(Brennan et al., 1995b). These data, together with the observation that polysomies of 
chromosomes 7 and 17 are present in both head and neck squamous cell carcinomas and in 
macroscopically normal oral mucosa adjacent to the primary tumour but significantly less 
frequently (p<0.001) in normal controls (Choi and Chung,1996), lends support to the 
“Field Cancerization” theory (Slaughter et al., 1953). 
The relative contributions of hereditary and environmental events ultimately 
resulting in these “normal” mucosal p53 mutations are presently unclear although recent 
work by Brennan et al. (1995a) suggests that different p53 mutations are involved. In a 
study involving 129 patients with head and neck squamous cell carcinoma 57% of patients 
who both smoked cigarettes and drank alcohol had a p53 mutation compared to only 17% 
of patients who neither smoke nor drank. Furthermore, all of the p53 mutations in the non- 
drinking non-smoking group occurred at sites containing cytidine phosphate guanosine 
dinucleotides (CpG) compared to only 23% in the drinking and smoking group (Brennan et 
al., 1995a). Defects at CpG sites are endogenous mutations resulting from deamination 
and methylation (Sidransky, 1995). 
E-cadherin, a putative tumour suppressor gene located at 16q22 plays a central role 
in cell-cell adhesion. Down regulation of E-cadherin is associated with tumour invasion 
and metastasis and 16q22 translocations have been reported in head and neck squamous 
cell carcinomas (Field, 1992). E-cadherin expression has also been reported to be reduced 
in poorly differentiated carcinomas (Johnson et al., 1996). 
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Allelic loss and tumorigenesis 
In 1990 Fearon and Vogelstein proposed a model for colorectal tumorigenesis 
based on sequential and progressive genetic alterations involving oncogenes and tumour 
suppressor genes (Figure 8a). They hypothesised that 4 or 5 mutations are required for the 
formation of a malignant tumour and that although genetic alterations often occur in a 
defined sequence, it is the accumulation of genetic changes that is important, rather than 
the exact order in which they occur (Fearon and Vogelstein, 1990) 
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Several chromosomal loci, known to code for proto-oncogenes and tumour 
suppressor genes, are commonly lost (loss of heterozygosity, LOH) in malignant head and 
neck tumours (Table 10). 
Chromosomes 3p and 9p are subject to frequent LOH in head and neck cancers 
marking them as sites for putative tumour suppresser genes (El-Naggar et al., 1995; Field 
et al.,1995). LOH at 3p has been demonstrated in 53% of potentially malignant lesions 
(Emilion et al.,1996) and in 71% of oral squamous cell carcinomas (Partridge et al.,1996). 
In a study of 48 primary oral squamous cell carcinomas, Partridge et al. (1 996) 
demonstrated a significant association between the number of regions on 3p demonstrating 
allelic loss and disease-free survival in early stage disease. They suggested that 
determination of LOH at 3p may be useful in individual prognostic prediction and 
treatment planning. 
Following a recent study of LOH in 87 mucosal lesions of the head and neck 
ranging from benign hyperplasia to early invasive carcinoma, Califano et al. (1 996), 
hypothesised a genetic progression model analogous to Fearon and Vogelstein’s colorectal 
carcinoma model. The highest LOH frequency in benign hyperplastic tissue was at the 
9p2 1 locus marking this as one of the earliest detectable events in head and neck 
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carcinogenesis. Furthermore, over 30% of histopathologically benign lesions demonstrated 
some genetic alterations. It thus seems likely that apparently normal mucosa and adjacent 
areas of epithelial dysplasia, carcinoma in situ or invasive carcinoma are all derived from a 
single clone of cells (Califano et al., 1996). This observation provides a plausible 
explanation for the phenomena of locally recurrent and persistent disease and for the field 
cancerisation theory (Slaughter et al., 1953). Later genetic events include mutations at the 
3p, 17p, 13q and 1 1q13 loci (Sidransky, 1995, Califano et al., 1996 ). One may thus 
envisage a composite molecular damage and genetic progression flow diagram 
superimposed on the traditional histopathological model of carcinogenesis (Figure 8b). 
Support for the role of genetic polymorphisms and mutations in oral carcinogenesis 
is provided by recent work that demonstrated a significantly increased risk for developing 
head and neck cancer if a first degree relative had squamous cell carcinoma of the head and 
neck (Foulkes et al., 1996). This extensive retrospective study investigated the incidence 
of squamous cell carcinoma of the head and neck in 1429 first degree relatives of 242 
patients with head and neck cancer and 934 first degree relatives of the spouses of 156 
patients with head and neck cancer who formed the control group. The relative risk for 
developing head and neck cancer if a first degree relative had also had the disease was 
3.79. Interestingly, there was no significant excess risk demonstrable if a first degree 
relative had contracted cancer at sites outwith the head and neck. Twenty patients in the 
series (8%), had multiple primary tumours of the head and neck, the adjusted relative risk 
for their first degree relatives developing head and neck cancer was 7.89 compared to 3.53 
in the 222 patients who had a single head and neck primary tumour (p = 0.009). Mention 
has already been made of the increasing number of younger patients developing oral 
cancer. It might be expected that these younger patients would be more likely to have a 
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positive family history of head and neck cancer but the study found no evidence to support 
this view (Foulkes et al., 1996). 
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1.6 The Polymerase Chain Reaction 
Following the pioneering work of Watson and Crick in 1953 (Lewin, 1994), it is 
known that the structure of DNA comprises a double helix of 2 parallel strands built from 
repeating units of the 4 deoxynucleotides deoxyadenylate (A), deoxythymidylate (T), 
deoxyguanylate (G) and deoxycytidylate (C) shaped somewhat like a ladder. It was also 
appreciated that the deoxynucleotides were arranged such that the deoxyribose-phosphate 
units formed the “sides” of the ladder, while the purine and pyrimidine bases are linked viu 
hydrogen bonds to form the “rungs”. Because of the 3 dimensional structure of their 
binding sites, A will only bond with T and C will only bond with G. As a result of the 
complementary base pairing arrangement the 2 single DNA strands are better described as 
being antiparallel (Figure 9a). 
Following the discovery of DNA polymerase by Arthur Kornberg in 1955 and 
restriction endonucleases in the 1970’s, Frederick Sanger developed a DNA sequencing 
technique which produced short fragments of previously added oligonucleotide primers 
that had been extended following the addition of nucleotide triphosphates and dideoxy 
nucleotide triphosphates catalysed by DNA polymerase. While revolutionary for its time, 
dideoxy sequencing (the Sanger technique), was laborious and time consuming as only one 
short fragment DNA copy could be produced from each single stranded DNA template. 
Unsatisfactory as it was, dideoxy sequencing was still faster than DNA cloning in plasmids 
which was the other standard technique used for human DNA analysis at the time 
(Mullis, 1990; Grainger and Madden, 1993). A new technique was required which could 
produce large amounts of DNA rapidly and reliably. 
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In April 1983, Kary Mullis, a biochemist with the Cetus Corporation, had an idea 
that was to earn him a Nobel Prize in 1993 and revolutionise the study of molecular 
genetics (Mullis, 1990; Grainger and Madden,1993). Mullis’ stroke of genius was to add 2 
primers comprising nucleotide sequences that allowed them to bind to either side of a 
targeted base pair. One primer would bracket the target base on one DNA strand while the 
other primer would bracket the target base on the opposite and complementary DNA strand 
(Mullis, 1990). As DNA polymerase will only catalyse the addition of a deoxynucleotide 
triphosphate (A, C, T or G) to the 3’ end of an oligonucleotide primer bound to a 
complementary single strand DNA template, primer extension proceeds in opposite 
directions across the targeted base pair. This results in an exponential production of DNA 
(Erlich et al., 1991) and has become known as the polymerase chain reaction (PCR). There 
are 3 discrete sequences that together constitute 1 PCR cycle (Sigg et al., 1991; Grainger 
and Madden, 1993): 
Double stranded target DNA (dsDNA) is denatured by heating to 94-98°C 
producing 2 single stranded DNA (ssDNA) templates 
The reaction mixture is cooled to 40-60°C allowing oligonucleotide primers each 
approximately 20-30 bases long and which are present in excess to anneal to the 
target flanking regions on the ssDNA templates 
After raising the reaction temperature to about 72’ C, DNA polymerase catalyses 
primer extension from the 3’ end by the sequential addition of deoxynucleotide 
triphosphates (dntp’s) complementary to the ssDNA template sequence. 
Extension continues along the length of each ssDNA template in a 3’-5’ 
direction until 2 complete copies of the original dsDNA is completed. 
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The first cycle is now completed and the whole sequence can be repeated ad 
infinitum, although usually 20-30 cycles is sufficient to produce enough dsDNA for 
investigation (Figure 9b). 
The performance of all 3 sequences in order completes 1 PCR cycle and the 
number of DNA copies that can be made equals 2 n = the number of PCR cycles 
completed (Wright and Wynford-Thomas, 1990). If 20 cycles are completed, theoretically 
over DNA copies will be produced (Mullis, 1990; Erlich et al., 1991) However, in 
practice about 25 cycles are required to produce copies because the DNA yield is not 
100% in every cycle (Sigg et al., 1991). 
Since publication of the first clinical application of PCR by Saiki et al, in 1985 who 
reported its use in the prenatal diagnosis of sickle cell anaemia following PCR 
amplification of a ß-globin Dde 1 restriction fragment, numerous improvements and 
amendments to the original technique have been reported. 
The DNA polymerase originally used by Mullis was derived from Escherichia culi 
(E. coli). Although the enzyme worked well, it was inactivated by the high temperatures 
required to produce strand separation of the dsDNA prior to primer binding. This meant 
that fresh DNA polymerase had to be added after the denaturation phase of every PCR 
cycle which greatly increased overall reaction time and the manual input required (Erlich 
et al., 199 1). Furthermore, although the E. coli DNA polymerase was capable of 
amplifying a DNA fragment by some 200,000 times, because of poor specifícity, only 
about 1% of the final PCR product contained the sequence of interest. The poor yield 
required the addition of a further post-PCR step to isolate the targeted sequence. Part of 
the reason for the poor yield was that at the relatively low reaction temperatures required to 
ensure E. coli DNA polymerase activity, there was a high percentage of non-specific 
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pimer binding. At low annealing temperatures primers will bind to non-targeted template 
sequences which are subsequently amplified thus reducing the purity of the PCR product 
(Erlich et al., 1991; Grainger and Madden, 1993). 
Again it was the scientists at the Cetus Corporation who made a breakthrough. 
They isolated the DNA polymerase from the bacteria Thermus aquaticus (Taq), whose 
natural habitat is the hot springs and geysers of Yellowstone National Park. The optimal 
temperature for the Taq polymerase is 72°C, although its activity is virtually unaffected 
even at the 94°C required for dsDNA strand separation (Erlich et al., 1991; Sigg, 1991). It 
was now unnecessary to manually add fresh polymerase to each PCR cycle and the whole 
reaction became fully automated. Furthermore, specificity was increased dramatically, 
both because of the inherent properties of the Taq polymerase and also because non- 
specific primer binding was virtually eliminated at the higher reaction temperatures 
achievable consequent on using Taq. The increased purity of the final PCR products 
meant that they could be easily detected using simple electrophoretic techniques and 
visualised as ethidium bromide stained bands under UV light, thus removing the need for 
the post PCR product isolation step (Erlich et al., 1991; Grainger and Madden,1993). 
Further recent improvements to the PCR technique and equipment include but are 
not restricted to (Erlich et al., 1991; Grainger and Madden, 1993): 
Performing the PCR in thin walled capillary tubes which allows rapid 
temperature cycling and enables a single cycle to be completed in 20 s instead of 
about 5 minutes when using traditional plastic reaction vessels 
The development and use of 2 new extreme thermophillic DNA polymerases 
Thermococcus litoralis (VENT polymeruse) and Pyrococcus furiosus which are 
more specific than Taq polymeruses 
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Hot starting, requiring the addition of an essential reaction reagent only after the 
reaction temperature has exceeded 70°C which minimises non-target 
amplification and primer-dimer formation. 
There are many other enhancements too numerous to detail, and every laboratory, if 
not every experienced PCR scientist will have there own tips, tweaks and techniques to 
improve specificity and final PCR product yield. 
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1.7 Immunohistochemistry 
Immunohistochemistry is a technique used to identify specific target cells or 
cellular components by means of an antigen-antibody reaction. The 3 dimensional structure 
of an antibodies’ variable domain allows it to specifically bind to a complementary area or 
epitope on the antigen viu hydrogen bonds, electrostatic forces and van der Waals’ forces. 
The antibodies used for immunohistochemical studies may be obtained either from 
animal sera following immunisation with the target antigen or from cell cultures of target 
antigen specific antibody secreting plasma cells. As animal immunisation results in the 
production of several antibodies, each of which is specific to a particular antigen epitope 
antibodies derived from this source are polyclonal and are likely to cross-react with non- 
target antigens in tissue sections (Robinson et al., 1990). Specificity is increased and cross- 
reactivity decreased by the use of monoclonal antibodies derived from cell cultures. 
Kohler and Milstein (1975)’ demonstrated that mouse myeloma cells could be fused with 
mouse spleen cells using the Sendai virus. When the spleen cells were harvested from a 
mouse that had previously been immunised with sheep red blood cells the resulting hybrid 
myeloma-spleen cells produced anti-sheep red blood cell antibody. By cloning the hybrid 
cells they were able to produce large quantities of antigen-specific monoclonal antibody. 
Commercial production of monoclonal antibodies involves careful screening to identify 
antibody producing hybrids without cross-reactivity and subsequently continuously 
culturing them in ascitic fluid (Robinson et al., 1990). 
If the antibody is labelled or tagged in some way then the site of an antigen- 
antibody reaction can be visualised in a tissue section following incubation with a specific 
chromogen. The label can either be conjugated onto the primary antibody that reacts 
directly with the target antigen (direct method) or else it can be conjugated to a secondary 
84 
antibody that displays specificity for the globulin fraction of a primary intermediary or 
bridging antibody (indirect method) (DeLellis et al., 1979) (Figure 10). 
Many substances including enzymes, colloidal metals, fluorescents and 
radioisotopes can be conjugated to antibodies and used as tracers or labels. Of the available 
labels, enzymes are the most frequently used and horseradish Peroxidase is the commonest 
enzyme (DeLellis et al., 1979; Robinson et al., 1990). Peroxidase is utilised in the 
peroxidase-anti-Peroxidase system. In this indirect method, 2 anti-Peroxidase antibodies 
and 3 Peroxidase molecules combine to form a labelled tertiary antibody used to locate a 
target antigen via a bridging secondary antibody that can combine to both the primary and 
tertiary antibodies (Figure 10c). 
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Use of the unlabelled antibody enzyme complex methods, in particular the 
peroxidase-anti-peroxidase technique enables the identification and classification of 
undifferentiated neoplasms with greater accuracy than either the indirect peroxidase 
method or radioimmunoassay (DeLellis et al., 1979). Nonetheless, in certain situations 
immunoperoxidase techniques can give false negative results because the 
immunohistochemical reagents used may be too large to penetrate the formalin-fixed target 
cells in sufficient concentrations to produce a visible reaction. The use of agents such as 
Trypsin to pre-treat sections can often "unmask" previously inaccessible intracellular 
antigens and reduce the false negative detection rate (Curran and Gregory, 1978). Antigen 
unmasking can also be achieved in many tissues following exposure to microwave 
irradiation (Kirkpatrick and Marshall, 1992). 
Increasing the number of tracer labels that can potentially bind to a single target 
antigen also increases immunohistochemical sensitivity and specificity. The Avidin-Biotin 
complex (ABC) (Hsu et al., 1981) method utilises the exceptional affinity of the 67 kdal 
egg white protein avidin for the low molecular weight vitamin H (biotin). Each avidin 
molecule can bind 4 biotin molecules and up to 150 biotin molecules can be attached to a 
single molecule of antibody resulting in a high tracer:antibody ratio and increased reaction 
sensitivity (Robinson et al., 1990). In the ABC reaction (Figure 10d) biotin-labelled 
peroxidase molecules containing free avidin binding sites are brought into contact with the 
target antigen via a secondary anti-avidin antibody and avidin (Hsu et al., 1981; Robinson 
et al., 1990). Unfortunately, avidin will also bind to any lectin-like proteins present in 
tissue sections resulting in an increased false positive rate because of non-specific binding. 
This disadvantage can be largely overcome by substituting avidin for Streptavidin, a 60 
kdal protein isolated from the broth of Strptomyces avidinii (Robinson et al., 1990). 
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The use of immunohistochemical techniques like the ABC reaction in conjunction 
with “unmasking” procedures such as enzyme digestion and microwaving permits the 
identification and localisation of low concentrations of target antigen facilitating both 
clinical diagnosis and research. 
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1.8 Prognostic Indicators 
A fundamental requirement for successful cancer management is the ability to 
accurately predict the likely future course of disease for every individual patient. Only 
when a patients’ prognosis has been ascertained can an individualised, logically based 
treatment plan be formulated. Numerous classification systems have been developed in an 
attempt to provide such prognostic data. Unfortunately, no single system currently 
available is sufficiently discriminating to enable it to reliably and reproducibly predict an 
individual patients prognosis. These deficiencies can, and do present patient management 
dilemmas. Recognition of the limitations of current classification systems was a major 
impetus for this study. 
Clinical classification and staging 
Tumours may be classified according to anatomical site and size, velocity of 
growth, histological grade or a combination of all these parameters (Langdon and 
Henk,1995). Both the TNM (Tumour, Node, Metastases) and the AJCC (American Joint 
Committee on Cancer) classifications are based on the anatomical size and site of the 
primary tumour and cervical lymph node metastases and the presence or absence of 
systemic metastases. Based on work first published in 1944 (Denoix,1944), the TNM 
classification (Union Internationale Contre le Cancer,1987) is now in it’s fourth major 
revision (Table 11) and exactly corresponds to the AJCC third edition (American Joint 
Committee for Cancer Staging and End Results Reporting, 1992). 
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Following assessment of the primary tumour, regional lymph nodes and distant 
sites, the patient is assigned the appropriate TNM score. In order for the TNM 
classification system to be of help in assessing prognosis it must group together 
combinations of T, N and M into homogenous groups which can be shown to have similar 
survival rates (Langdon and Henk,1995). Numerous studies have shown that in the 
majority of cases large tumours with evidence of metastatic spread have a poorer prognosis 
than tumours that remain localised to the primary site, and that the presence of cervical 
lymph node metastases is an adverse prognostic indicator (Hibbert et al., 1983; 
Davis,1985; Zatterstrom et al., 1991). The derived TNM stage groupings reflect these 
clinical and epidemiological findings such that provided the study group is of sufficient 
size stage 1 tumours have a better prognosis than stage 4 tumours (Rich and Radden,1984), 
(Tables 12 and 13). 
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The most important conclusions to be drawn from tables 12 and 13 is that the 
presence of regional lymph node metastases (N1 or above) significantly reduces 5 year 
survival rates. 
Although the TNM and AJCC systems are widely accepted internationally as the 
two standard cancer classification systems (Phillips, 1989), they suffer from several major 
deficiencies. Despite there being strong evidence that both histological and cytological 
features of a tumour influence its likely future behaviour, with well differentiated tumours 
having a better outcome than poorly differentiated tumours (Cawson et al., 1996), neither 
TNM or AJCC systems take any account of the histopathological grading (Langdon and 
Henk, 1995). In an attempt to amalgamate histopathological data with clinical findings 
Rapidis et al., (1976), devised a new grading system which added site (S) and Pathology 
categories to the existing TNM system resulting in the STNMP system. Several studies 
have found the STNMP system to be capable of more accurate prognostic prediction than 
the standard TNM system. Many patients previously classified by TNM into stages 2 ,3  or 
4 being are effectively “upstaged” by STNMP to stages 1,2 or 3 (Evans et al., 1982; 
Langdon and Henk, 1995), (Table14). However, in a study of 124 Australian patients 
with oral squamous cell carcinoma, Rich and Radden (1984), were unable to demonstrate 
any prognostic superiority for the STNMP system. 
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A major European collaborative study involving 102 1 German, Austrian and Swiss 
patients with carcinoma of the lips, oral cavity and oropharynx utilising both clinical and 
pathological determinants identified the following 7 factors that were prognostically 
relevant for individual patients (Platz et al., 1983): 
Patient age 
Tumour site 
Tumour size 
Tumour infiltration 
Tumour differentiation 
Regional lymph node status 
Systemic metastasis status. 
By assigning scores to the above items the authors have constructed a database that 
can be used to predict the likely prognosis of individual patients depending on the 
treatment modality employed. The final DOSAK database (Deutsch-Osterreichisch- 
Schweizerischer Arbeitskreis) uses 6 of the 7 determinants (tumour differentiation was 
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omitted following further multivariate analysis) and consists of 192 unique treatment 
dependent prognostic indices 
The most significant criticism of the TNM, AJCC, STNMP and DOSAK systems is 
that they are heavily reliant on subjective clinical examination of the neck in order to 
assess the presence or absence of regional lymph node metastases. This deficiency is of 
paramount importance because of the significant adverse effect that regional lymph node 
metastases confer on survival rates and because clinical examination of cervical lymph 
nodes, even when supplemented with CT imaging has been shown to be error prone 
(Woolgar et al., 1994). The 5 year survival rate of patients with oral cancer who have 
metastases in the regional lymph nodes is approximately 20% (Teichgraeber and 
Clairmont, 1984). Yet two recent studies have demonstrated that clinical examination of 
the neck for cervical lymphadenopathy has a false negative rate of between 27% and 34%, 
and a false positive rate of between 31% and 40% (Shah et al., 1990; Woolgar et al., 
1994). Preoperative CT imaging often fails to improve the accuracy of nodal staging 
because in many cases occult nodal metastases are microscopic and only detectable by 
thorough post-resection histological examination (Woolgar et al., 1994). Any preoperative 
assessment techque  that can substantially improve on the clinical and radiological 
assessment of the cervical lymph nodes will potentially be a major prognostic and hence 
therapeutic advance. 
Histopathological grading 
The degree of cellular atypia present in a squamous cell carcinoma can be used to 
grade its degree of differentiation. In other words, by how much it resembles normal oral 
mucosa. Tumours may be classified as well differentiated, moderately differentiated, 
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poorly differentiated or anaplastic according to their histological appearance (Holm et al., 
1982). The cells in well differentiated tumours are readily recognisable as epithelial cells 
many of which produce keratin indicating a high degree of normal functioning whereas 
poorly differentiated tumours display marked cellular pleomorphism and no keratin 
formation (Lighthelm et al., 1989). 
There is a strong association between the histological grade of a tumour and its 
subsequent behaviour, the 5-year survival being proportional to the degree of tumour 
differentiation. In their series of 194 patients with oral squamous cell carcinoma Langdon 
et al., (1977) found the 5-year survival to vary between 11.8% for poorly differentiated 
tumours to 40.3% for well differentiated tumours. Unfortunately, any histopathological 
grading system relies on the biopsy being representative of the tumour as a whole, many of 
which display marked heterogeneity of structure, and is ultimately dependent on the 
subjective opinion of the pathologist examining the specimen (Zatterstrom et al., 1991; 
Cawson et al., 1996). The best prognostic information is obtained if only the cells at the 
invading margin are graded (Bryne, 1991). Furthermore, some authors have failed to find 
an association between tumour grade and subsequent behaviour, particularly the 
development of lymph node metastases (Nason et al., 1990). 
Attempts have been made to reduce the subjectivity of histopathological grading 
systems while improving prognostic prediction by introducing quantitative and objective 
scoring criteria. In a retrospective study of biopsies taken from 66 patients with oral 
squamous cell carcinoma Nason et al. (1990) demonstrated that following a 
semiquantitative assessment of 8 parameters relating to the tumour cell population and the 
tumour-host relationship (cytoplasmic differentiation, nuclear pleomorphism, mitotic 
count, mode of invasion, inflammatory cell reaction, desmoplasia, vascular/lymphatic 
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invasion and level of invasion) patients assigned a high malignancy score (>16) were 
significantly (p < 0.001) more likely to develop cervical lymph node metastases than those 
with a low malignancy score (<14). 
Tumour thickness and tumour cell nuclear DNA content have also been shown to 
be related to prognosis. Patients with buccal squamous cell carcinomas less than 6mm 
thick have a significantly better survival rate (p < 0.001) than those with tumours thicker 
than 6mm regardless of TNM stage (Urist et al., 1987). Nondiploid tumours have a poorer 
prognosis than diploid tumours (Zatterstrom et al., 199 1). 
Immunocytochemical detection of ornithine decarboxylase (ODC), the rate-limiting 
enzyme in polyamine synthesis has been shown to be a good prognostic indicator of future 
tumour behaviour. ODC levels are elevated in potentially malignant and malignant oral 
lesions and ODC positivity is associated with cervical lymph node metastasis and poor 
outcome (Williams et al. 1995). 
Tumour markers 
The concept of a serological test for cancer is an appealing one because it would 
enable early detection of previously undiagnosed tumours. Markers such as oncofetal 
protein and human chorionic gonadotrophin have a role to play in detecting and monitoring 
tumours at inaccessible sites. However, the oral cavity is readily examined and easy to 
biopsy and so in theory at least there should be little need for such laboratory tests. 
Nonetheless, a reliable laboratory serological test would prove invaluable for detecting 
recurrences and perhaps for estimating tumour burden and hence prognosis (Johnson et al., 
1996). At the present time no such test exists. 
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Tumour necrosis factor alpha (TNF-a), a pleiotropic cytokine has been shown to be 
intimately associated with several local and systemic effects seen in patients with cancer. 
Examples include cachexia and neoplastic bone destruction (Parks et al., 1994). There is 
experimental evidence to suggest that the cachexia is secondary to the 
hypertriglyceridemia consequent on inactivation of endogenous lipoprotein lipase (LPL) 
resulting from increased serum levels of TNF-a, a known inhibitor of LPL (Nakajima et 
al., 1995). TNF-a levels have been shown to be significantly higher (p<0.001) in patients 
with head and neck cancer than in controls (Gallo et al., 1992) and animal studies have 
shown that TNF-a levels are elevated in experimentally produced oral carcinomas but are 
undetectable in normal control animals (Nakajima et al., 1995). In one study serum TNF-  
a levels were found to be 100 fold higher in head and neck cancer patients than in controls 
Moreover, the TNF-a levels fell dramatically after treatment (Soylu et al., 1994). Serum 
TNF-a levels may thus prove to be useful diagnostic and prognostic markers for oral 
squamous cell carcinoma. 
TNF-a induces the synthesis of matrix metalloproteinases, which together with 
cathepsins and plasminogen activators form the main classes of proteases produced by 
tumour cells enabling them to lyse extracellular matrix components facilitating invasion 
and metastasis (Verspaget, 1998). Several of these proteases have been shown to be 
prognostic markers for solid tumours of the breast, stomach, colorectum, cervix kidney and 
lung (Duffy, 1996;Verspaget, 1998). Nielsen et al. (1998) have shown that high serum 
concentrations of plasminogen activator inhibitor- 1 are associated with shorter survival in 
patients with colorectal cancer. This finding is surprising as logically it could be expected 
that the inhibitor would counteract the lytic activity of the protease and should thus be 
associated with a better outcome. However, it would appear that in most cancers 
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plasminogen activator inhibitor- 1 regulates focal extracellular matrix breakdown, cellular 
adhesion and migration via clearance of activator-inhibitor complexes and adhesion 
molecule binding thus modulating the proteolytic process (Verspaget, 1998). 
Pi class GST is the most ubiquitous of the human GST enzymes and is present in 
particularly high concentrations in cells of the gastrointestinal tract, lung, erythrocytes, 
platelets and foetal liver (Bongers et al., 1995). High levels of GST have recently been 
reported in serum samples of patients with oral cancer. Hirata et al. (1992), found a highly 
significant difference in plasma GST levels (p<0.00 1) between patients with oral cancer 
and those with benign oral diseases or normal healthy control patients. Of great clinical 
interest is the fact that GST levels fell to and remained below the cut off level (30.4ng/ml) 
in patients with no evidence of recurrent disease. However, GST levels either failed to fall 
or fell and rose rapidly above the cut off levei in those with recurrent or persistent disease. 
Elevated plasma GST levels were found in the majority of patients with recurrent disease 
well in advance of clinically detectable tumour. Assay of plasma levels is thus a 
useful marker for patients with oral cancer for monitoring tumour burden and postoperative 
recurrence (Hirata et al., 1992). 
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1.9 Management of Oral Cancer 
Treatment 
As with all other medical and surgical specialities, the advances in the diagnosis 
and management of oral cancer is advancing at such a rapid rate that it is impossible for 
any one clinician or speciality to be able to manage oral cancer patients in isolation. 
Modern management demands that patients are seen and managed in a multi-disciplinary 
“joint clinic” consisting of surgeons, oncologists and paramedical support staff (Rapidis et 
al., 1980). Indeed, current UK Department of Health guidelines on the setting up and 
running of cancer centres demand that such facilities not only exist but are held at least 
weekly (Calman, 1995). 
The fundamental question to be answered when formulating a treatment plan for a 
patient with oral cancer is whether he or she is potentially curable and thus whether 
treatment is aimed at being curative or palliative. It is axiomatic that each patient is an 
individual and thus needs to be offered a tailor-made treatment plan, a treatment plan that 
is deemed suitable for a relatively young, fit and healthy person may be totally 
inappropriate for an elderly, infirm and medically compromised patient. While these 
points are obvious, it is all too easy to loose sight of them if one adopts a “cure at all costs” 
approach to management. Thus, while modern surgical and reconstructive techniques give 
the surgeon the ability to resect and reconstruct virtually any oral cancer, many of them 
should not be so treated. The advice of the Arabian physician Avicenna (A.D. 980-1037) 
(Martin, 1940), “The cure of a disease must never be worse than the disease itself‘ is 
particularly relevant here (Langdon and Henk, 1995). 
Before embarking on a curative resection the surgeon must satisfy him or herself of 
the following points. That there is a good chance of achieving a cure, that all of the tumour 
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can be removed together with a surrounding margin of normal tissue, that function can be 
restored to as near normal as possible and that the final cosmetic result will be acceptable 
to the patient (Langdon and Henk, 1995; Cawson et al., 1996). If these conditions can not 
be satisfied, all other things being equal the patient is better served with a palliative 
management strategy. However, no matter whether the management intention is cure or 
palliation it is vital that all known risk factors including alcohol, tobacco and local trauma 
are removed (La Vecchia et al., 1997; Tradati et al., 1997). 
The size and extent of the primary tumour together with the status of the cervical 
lymph nodes, i.e. the stage of the tumour, to a large extent dictates the therapeutic strategy 
that must be employed in each case. For T1 and early T2 squamous cell carcinomas 
confined to the lining mucosa, surgery and radiotherapy offer an equal chance of cure. The 
actual therapeutic modality employed will thus often depend on local expertise and patient 
preferences (Cawson et al., 1996). Larger tumours are seldom eradicated by radiotherapy 
alone and usually require primary surgery and postoperative radiotherapy. Thus most 
clinicians employ postoperative radiotherapy if the primary tumour microscopic resection 
margins are less than 5mm, if there has been extracapsular spread of disease in one or more 
cervical lymph nodes or if more than 2 lymph nodes are involved. 
In some cases small T1 tumours may be excised and then either allowed to heal by 
secondary intention or be closed primarily. Small tumours of the tongue and lip fall into 
these categories. Hemimaxillectomy cavities and orbital exenteration defects can often be 
reliably reconstructed using a temporalis muscle axial pattern local flap (Bradley and 
Brockbank, 198 1). Larger tumours require larger, more mutilating resections and leave 
larger defects requiring subsequent reconstruction. The distant pedicled flaps such as the 
pectoralis major myocutaneous flap (Ariyan, 1979) are extremely useful where large soft 
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tissue bulk is required such as following subtotal glossectomy and radical neck dissection. 
However, in many situations, particularly for floor of mouth and smaller tongue cancers, 
the radial forearm flap provides excellent quality thin, pliable skin which improves 
postoperative tongue and floor of mouth function (Soutar et al., 1983). 
Radiotherapy is ineffective at killing tumour cells within bone. If there is evidence 
of bone invasion the involved bone must be resected, followed by reconstruction in the 
majority of cases (Langdon and Henk,1995). When bone, particularly large sections of 
mandible need to be excised and reconstructed, the choice lies between using alloplastic 
materials such as titanium reconstruction plates or bone. Reconstruction plates have the 
advantage of simplicity and reduced operative time which can be an important 
consideration, particularly in enfeebled patients, but bone remains the “Gold Standard’ for 
reconstructing mandibular defects, particularly in young people (Schusterman et al., 
1991). Bone can be transferred as a non-vascularised graft in either block, or cortico- 
cancellous “mush” form held in trays and covered with a pectoralis major flap (Phillips et 
al., 1991; Langdon and Henk,1995), or as a microvascular free bone graft, with or without 
overlying soft tissues (Soutar et al., 1983). Microvascular bone flaps have significant 
advantages over free bone grafts with respect to graft survival, particularly in previously 
irradiated tissues (Schusterman et al., 1991). Numerous donor sites are available for 
harvesting and transfer, but the radius (Soutar et al., 1983), and fibula (Lyberg and 
Olstad, 199 1 ; Serra et al., 199 1) either as bone only, or as osteo-fasciocutaneous flaps are 
ideal sources. Use of these flaps enables the surgeon to perform a one stage mandibular 
and soft tissue reconstruction and facilitates the subsequent placement of osseointegrated 
implants allowing the patient to wear implant retained dentures and a return to near normal 
masticatory functioning. 
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Recently, exciting advances in the field of distraction osteogenesis and bone 
transport have made the dream of growing and moving segments of a patients’ own 
mandible to reconstruct a post-surgical defect without the need to resort to grafts and flaps 
a reality (McCarthy et al., 1992). Over the next few years, modifications and 
enhancements to equipment and techniques are set to make distraction osteogenesis the 
reconstruction revolution of the latter half of the decade, in the same way that the radial 
forearm flap has revolutionised reconstruction in the first half. 
If there is clinical and/or imaging evidence of cervical node metastasis the majority 
of patients should receive a neck dissection, especially where surgery is to be employed to 
treat the primary site. There is still controversy however over how best to treat the NO neck 
in patients with oral cancer. The adverse prognostic significance of cervical node 
metastases has already been mentioned, as has the high false positive and false negative 
rate of clinical neck examination. The debate centres on whether one should perform an 
elective, prophylactic neck dissection in these cases, or adopt a “wait and see” policy, only 
treating the neck if and when nodal metastases declare themselves. Unfortunately, there 
can be no all encompassing solution to this dilemma. While nodal metastases reduce 5 
year survival rates by 50%, no prospective controlled trial has shown a survival advantage 
for elective treatment, and neck dissection is not without morbidity (Langdon and 
Henk,1995). Not uncommonly, NO patients will receive an elective functional neck 
dissection in order to facilitate access to the blood vessels in the neck if a microvascular 
free flap is being used to reconstruct the primary site. 
With the N+ neck the consensus is that some form of neck dissection needs to be 
performed (if it has been decided to treat the patient surgically rather than with 
radiotherapy). There is however, continuing debate on what type of neck dissection should 
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be carried out. The classical radical neck dissection (Crile,l906), to this day remains the 
benchmark operation for cervical node clearance in that all levels in both triangles are 
cleared of lymph nodes. Unfortunately, postoperative morbidity is not inconsequential 
with this operation which results in shoulder weakness consequent on transection of the 
spinal accessory nerve and an obvious cosmetic deformity. In a retrospective review of 
1,234 patient with oral squamous cell carcinoma over a 21 year period Shah et al, (1990), 
demonstrated that in selected cases, the performance of an appropriate modified neck 
dissection would have resulted in only 4% of patients being left with occult nodal disease. 
However, until data from a prospective randomised trial is available most surgeons will 
still opt for a classical radical neck dissection in all N+ necks, and an appropriate modified 
neck dissection or expectant management in patients with NO necks (Langdon and 
Henk,1995). What is required is the ability to predict which patients who present with NO 
necks will develop nodal metastases and do badly. Unfortunately, to date there is no 
routine clinical or laboratory investigation that can provide this data. Hopefully, 
continuing refinement of the histopathological, cytological and molecular biological assays 
discussed previously will help to answer these questions. 
In the UK, chemotherapy is principally used for attempted palliation in end stage 
large, inoperable tumours. Early studies demonstrated that few if any patients were cured 
by chemotherapy, especially when it was used as monotherapy (Jones and Gore,l995). For 
although tumour response rates are often high, this does not translate into improved long 
term survival and previous metanalyses have failed to show any benefit from adjuvant 
chemotherapy regimes (Munro, 1995). However, a recent metanalysis of 5 1 published 
trials did show a survival advantage if chemotherapy was used as a single agent 
synchronously with radiotherapy (Munro, 1995). 
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The UKHAN 1 trial, which started recruiting head and neck cancer patients in 1990 
randomises patients into 1 of 4 treatment arms: 
Radiotherapy alone 
Radiotherapy + simultaneous Chemotherapy 
Radiotherapy + subsequent Chemotherapy 
Radiotherapy + simultaneous & subsequent Chemotherapy. 
The aims of this trial are to assess the effectiveness of outpatient single agent 
chemotherapy, in this case Methotrexate, combined with radiotherapy in the treatment of 
head and neck cancer. Patient accrual is not expected to be complete until 1999. Since the 
start of UKHAN 1 studies like those reported by Munro (1995), have drawn attention to 
the possible survival advantage of synchronous Cisplatin and radiotherapy in the 
management of head and neck cancer and a further UKHAN trial is being considered to 
assess this new data. We must await the outcome of these important trials before passing 
final judgement on the role of chemotherapy in the management of oral cancer (UKHAN 1 
Newsletter, Autumn 1996). 
Two recent studies have shown that in the UK approximately half of all patients 
with oral cancer who are treated by Oral & Maxillofacial Surgeons receive multimodality 
treatment consisting of preoperative surgery and postoperative radiotherapy and 
approximately one third are treated by surgery alone (Webster and Worrall,1995; Worrall 
and Corrigan, 1995) (Table 15). 
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The future 
As discussed previously, oral cancer is a genetic disease and current treatment 
modalities have been singularly unsuccessful in extending 5 year survival rates. Surgery, 
and to a lesser extent radiotherapy and chemotherapy are fairly crude instruments with 
which to attack a disease that operates at the molecular level. It is hoped that in the future, 
development and refinement of emerging molecular biological and gene therapy 
techniques may produce a range of effective, non-mutilating and non-invasive therapeutic 
options. There is already evidence that such techniques may be feasible. 
The herpes simplex virus thymidine kinase (HSV tk) gene will sensitise transduced 
cells to the drug ganciclovir (GCV [9-( 1,3-dihydroxy-2propoxyrnethyl) guanine]). GCV is 
a purine analogue which is phosphorylated by the protein product of HSV tk to 
monophosphate GCV. Monophosphate GCV can be phosphorylated by normal human 
thymidine kinase into triphosphate GCV which is cytotoxic (Goebel et al., 1996). In an in 
vitro experiment using head and neck squamous cell carcinoma cell lines (Hep-2, FaDu 
105 
and SCC-4) infected with an adenovirus containing the HSV tk gene (Ad.RSV tk) dramatic 
tumour cell killing ensued following the subsequent administration of GCV. Moreover, 
substantial cytotoxic effects were observed using therapeutic concentrations of GCV 
(Goebel et al., 1996). 
Recent work has shown that unrestrained cellular proliferation and resistance to 
apoptosis consequent on loss of G1/S cell cycle control can be prevented. Enhanced 
irradiation induced apoptosis in p53 deficient mice has been demonstrated following 
caffeine induced activation of the p34 kinase controlling the G2/M check point (Yao et al., 
1966). In an in vitro experiment the DNA binding affinity for class 1 mutated p53 protein 
was shown to be significantly enhanced following substitution of the mutated amino acid 
(Thr284) with arginine (Wieczorek et al., 1966). Experimentally at least, it appears that it 
is possible to rescue cells from p53 mutation and in so doing restore cell cycle control 
enabling DNA repair or apoptosis to occur as appropriate and thereby reducing 
unrestrained growth. The future therapeutic possibilities of these experimental findings are 
very exciting. 
Quality of life 
A major consideration when planning and implementing a curative treatment 
protocol is that postoperative function should be as near normal as possible. However, if 
cure is the goal, the desire to restore normal functioning must never sway the surgeon into 
performing a less than ideal oncological resection for fear of leaving tumour behind. 
Nonetheless, when assessing the results of any treatment regimen, simple estimation of the 
length of survival is no longer acceptable. The quality of life experienced by patients is as 
important, if not more important than the quantity of life gained (Langdon and Henk,1995). 
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Providing a high quality of life for our patients is of pre-eminent importance when it has 
been decided that patients are beyond cure and are entered into a palliative care protocol. 
Palliation does not mean that patients are simply supported through their last days, it may 
involve tumour debulking to improve pain control and cosmesis both surgically and with 
radiotherapy or chemotherapy. 
Quality of life, is a vague, almost nebulous concept that is difficult to define and 
means different things to different people (Calman, 1984). Nonetheless, there is general 
agreement that it is not a single entity, but multifactorial and that in order to measure it 
several different but interrelated facets of a patients life need to be assessed. It has been 
suggested by Aaronson &.al. (1988), that these include: 
Physical complaints - somatic sensations, disease symptoms, side effects 
Social functioning - anxiety, depression 
Psychological distress - quality and quantity of relations with others 
Functional status - activity level, vocational activity. 
In addition to the above parameters, it is likely that quality of life is more than 
simply the sum of its component parts. Any instrument used to assess quality of life should 
be able to be completed by the patient as they are the best judge of how their disease and 
its treatment has impacted on their lives. Furthermore, it should be simple and quick to 
complete, valid and capable of reflecting changes over time (Jones et al., 199 1). 
The European Organisation for Research into the Treatment of Cancer (EORTC) 
has developed a modular questionnaire consisting of both general and disease specific 
modules (Aaronson et al., 1988). The EORTC QLQ-C30 consists of 30 general questions 
covering 5 function scales, 9 symptom scales and overall quality of life (Aaraonson et al., 
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1993). Patient responses on the questionnaires are linearly transformed into a O - 100 scale 
such that a score of 100 for the functional scales and quality of life indicates maximum 
functioning (good), while a score of 100 for the symptom scales indicates maximum 
symptoms (bad). A recently developed head and neck specific questionnaire, the H&N35 
(Bjordal et al., 1994) which covers 13 aspects of patient well being is currently being 
evaluated internationally (see Figure 26). 
A recent study used the EORTC QLQ-C30 questionnaire to compare the quality of 
life of 44 patients with oral cancer who were at least 1 year post treatment with 47 control 
patients who were attending for treatment of non-malignant oral conditions (Mellor and 
Worrall,l996). There was no significant difference in overall quality of life or any 
symptom scales between cases and controls, but cases had significantly poorer physical 
and role functioning than controls (Tables 16 & 17). 
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There was no significant difference in any of the scales with respect to stage of 
disease at presentation or treatment regimen instituted. However, patients with lower stage 
disease and those treated solely by surgery tended to have higher quality of life scores than 
those with higher stage disease and those treated with surgery plus radiotherapy. 
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1.10 Aims of the study 
It will be apparent from this brief introduction that oral squamous cell carcinoma 
has a high morbidity and mortality despite recent advances in many treatment modalities. 
One of the major obstacles to improving outcome is the difficulty in accurately predicting 
tumour behaviour and prognosis in individual cases. Numerous studies have shown that 
many diseases, including certain cancers are associated with particular phase 1 and phase 2 
detoxification enzyme polymorphisms. 
This study had 2 main aims: 
To investigate whether oral squamous cell carcinoma susceptibility is associated with 
polymorphism at the gene loci coding for the cytochrome P450 CYP2D6 and CYP1 Al 
phase 1 detoxification enzymes and the glutathione S-transferase GSTM1, GSTM3, 
GSTT1 and GSTP1 phase 2 detoxification enzymes. 
To ascertain whether the presence or absence of particular CYP and GST 
polymorphisms in patients with oral cancer can be used to improve prognosis 
prediction and augment existing patient and tumour specific factors to refine individual 
management strategies. 
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There were two interrelated tasks necessary for the setting up and conduct of this study: 
Designing, developing and implementing a computerised oral cancer database to record 
and analyse individual patients’ demographics, risk factors, tumour characteristics, 
treatment and outcome 
Determination of GSTM1, GSTM3, GSTT1, GSTP1, CYP2D6 and CYP1A1 
detoxification enzyme genotypes in peripheral blood samples of patients with oral 
squamous cell carcinoma and the correlation of the genotype with the clinical and 
pathological features of each patient as recorded in the database. 
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2.1 The Database 
The ability to assign patients with similar disease profiles into groups based on 
disease stage facilitates treatment planning and prediction of prognosis. However, TNM 
stage groupings take no account of other important data such as patient risk factors, 
treatment modality employed, complications, quality of life, recurrence and survival times 
etc. In order to ensure that patients are receiving optimum treatment, it is vital that this 
data is collected. Data analysis can then be used to audit results against national and 
international standards and targets. 
Although the treatment for oral cancer has advanced rapidly in recent years with 
the advent of new ablative and reconstructive techniques, the need to audit the results of 
treatment has only recently been generally accepted. Unfortunately, even when there is a 
desire to audit one’s own results, the information systems available may be woefully 
inadequate and the required data almost impossible to obtain. 
Furthermore, if novel diagnostic or treatment methods are to be assessed for usefulness and 
efficacy, it is mandatory that patients’ epidemiological, treatment and outcome data is 
available for analysis. 
Central to testing the hypothesis of this study was the need to correlate our oral 
cancer patients’ detoxification enzyme genotype data with their exposure to environmental 
carcinogens such as cigarette smoke and alcohol, and their clinical course and outcome. 
The lack of a suitable existing database to achieve these aims, together with the success of 
a previous project to design a computerised surgical logbook (Worrall, 1992), were the 
catalysts to designing and implementing a computer database to record and analyse data on 
patients with oral cancer. 
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The idea for the design of an oral cancer database first occurred to me during 1994. 
The first prototype database was written later that year (Worrall, 1994), and used in a pilot 
project to retrospectively analyse data on oral cancer patients over a 5 year period (Worrall 
and Corrigan, 1995). However, it was the realisation that the detoxification enzyme 
project required a comprehensive database capable of linking clinical events with research 
data that was the stimulus for further development and refinement. It also became 
apparent that as the project required a multi-centre approach, the database would also need 
to be capable of being installed in other units. 
I also wished to be able to produce a simple, user-friendly system that would 
encourage clinicians involved in the management of patients with head and neck cancer to 
record data on their patients in a standardised manner. A recent national survey of 
consultants who treat head and neck cancer in the UK has demonstrated a pressing need 
for such a system. Edwards et al (1997) found that only 4% (37/919) of consultants 
actively engaged in the management of patients with head and neck cancer used a 
standardised method of data collection. Of even greater concern was the finding that 14% 
of the consultant stated that they did not routinely record the clinical stage of the tumour in 
the patients’ hospital records! 
Widespread uptake of an agreed national head and neck cancer minimum dataset 
and the adoption of a standardised method of data collection and audit such as the database 
described below would ensure that vital data concerning risk factors, treatment and 
outcome is collected for all patients with head and neck cancer. For a rare disease like oral 
cancer, with only about 2000 new cases per year in the UK this approach is crucial if we 
are to improve the diagnosis, treatment and outcome for these patients and ensure that an 
acceptable standard of treatment is available throughout the UK. 
113 
In order to fulfil its designated role as a clinical and research tool, there were 
several requirements that were fundamental to the design of the database: 
It must be simple to use to encourage data input by non-medical staff 
It must be able to record both clinical and research data 
It must be cost effective to purchase and implement in other units. 
It was decided that the database should be written using Microsoft 43 Access 2 TM 
running under Microsoft Windows TM 3.1 or higher. It is relatively straightforward to 
design complex relational databases in Access 2 and to provide a friendly and intuitive 
user interface. A basic core database was written onto which specific modules for research 
purposes were added. These included modules for calculating body composition and 
recording detoxification enzyme genotype data. By using a mainstream database, which 
was likely to be supported by a major software manufacturer for some considerable time in 
the future, it was felt that the program would be able to be installed by the majority of 
interested clinicians at little extra cost. 
In order to improve usability and reduce typing errors, extensive use was made of 
choice boxes, selection lists, automatic field calculations and graphics. Several dozen pre- 
set queries, searches and reports were written, all of which are accessed by selecting 
choice buttons. Detoxification enzyme data were recorded alongside patients’ clinical 
details affording easy and rapid correlation between genotype and disease and enabling 
direct output into spreadsheet and statistical analysis software. 
Photographs of patients can also be stored directly in the database using new digital 
image technology and a Kodak DC20 digital camera (O Eastman Kodak Company). 
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Appreciating that the majority of computer users seldom read instruction manuals, 
a comprehensive on-line hypertext help file was written in standard Microsoft format. 
This was authored using Microsoft Word ® 2 together with the Windows’ Little Helper 
document template written by Mike Hardaker (O M Hardaker, 1991). The file was then 
compiled using the Microsoft help compiler HC3 1 .EXE from the Microsoft Windows 
Software Development Kit ® 
Figures 11-27 are screen shots of all the main data entry screens in sequential order, 
together with the main Help file screen and examples of some database reporting 
functions. Certain details have been removed from these screen shots to preserve patient 
confidentiality. Figure 17 details the detoxification enzyme data entry screen listing the 
selected patients’ detoxification enzyme genotype together with PCR details. 
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Database Main Menu. 
The top row command buttons from left to right open: System Information, 
Technical Support Information, Help and Exit the database. The bottom row command 
buttons from left to right open: Patient Details form and Reports Menu. 
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Database Help. 
There is an extensive on-line hypertext help file conforming to the Microsoft 
TM 
Help standard conventions and styles providing comprehensive details of all database 
functions and actions. By selecting the underlined words or phrases the user is instantly 
shown additional relevant information. 
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Patient Details Form. 
This is the main data entry form and is used for the recording of demographic and 
hospital data. In addition, all the other database forms and functions can be accessed from 
this single form. 
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Tumour Site Form. 
This form is for recording details of the site and pathological differentiation of the 
tumour. It is also used to access the DOSAK survival database enabling patient survival 
prediction (see Figure 15). 
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DOSAK Form. 
By incorporating the DOSAK survival data directly into the database it is possible 
to estimate an individual patients’ survival based on 5 pre-treatment parameters and the 
degree of tumour clearance following surgical and non-surgical treatments. 
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Classification and Stage Form. 
This form automatically calculates the appropriate tumour stage from TNM and 
STNMP data. It is also the entry point for accessing patient detoxification enzyme data 
(see Figure 17). 
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Detoxification Enzyme Data Form. 
This form is used to record details of the patient’s detoxification enzyme genotype 
and PCR data. 
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Lymph Node Data Form. 
In this section data is entered concerning the preoperative clinical and imaging 
findings with respect to the presence of cervical lymph nodes. From this data the program 
can analyse the false negative and false positive rates for assessing nodal status as well as 
the association between nodal disease extent and recurrence and survival data. 
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Treatment Form. 
All surgery, radiotherapy and chemotherapy data is entered on this form. The 
chemotherapy data section is not shown in this screen shot as it appears off screen at the 
bottom and is accessed by scrolling down the page. 
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Recurrence Data Form. 
The site and timing of local recurrences and metastasis to cervical lymph nodes and 
the rest of the body are recorded on this form. Event delays are automatically calculated 
from entered dates. 
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Basic Epidemiology Data Form. 
Data concerning risk factor exposure together with oral and general health is 
entered here. 
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Advanced Epidemiology Data Form. 
This form is used to augment the data entered on the Basic Epidemiology form. 
The type and amount of tobacco and alcohol consumption together with duration of 
exposure to environmental pollutants are recorded here. 
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Reports Menu. 
This screen provides access to several dozen pre-set database searches and queries. 
Each of the command buttons shown opens up a secondary menu from which the searches 
are launched. Custom searching and querying is performed using Access 2 filters and SQL 
queries. 
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Summary Form. 
The patient summary can be accessed from the Patient Details form or the Reports 
menu. It gives a single screen overview of all the important data concerning the chosen 
patient and is automatically updated as new or changed data is added. 
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Complications Form. 
Complication data is entered into this form from the Patient Details form and can 
be read from the Reports Menu. Data entered here can be used for compiling individual 
and unit morbidity statistics and as a tool for auditing treatment complications. 
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1 Year outcome Form. 
Quality of life data is assessed using the EORTC QLQ-C30 and H&N 35 
questionnaires. This form shows the EORTC data at 1 year post treatment. 
131 
TNM and STNMP Stages at Presentation. 
This is an example of one of the many pre-set database queries available. Here, the 
tumour stages and distribution of all patients at presentation is calculated. This data is 
extremely useful for comparing patient populations between different units. 
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2.2 Patients and Samples 
From January 1st 1995 and following the approval of the local research and ethics 
committee, all patients attending the head and neck oncology clinic at the North 
Staffordshire Hospital, Stoke-on-Trent, UK with a histologically proven diagnosis of oral 
squamous cell carcinoma (ICD 9 codes 140 - 141 and 143 - 145 (WHO, 1977; Johnson et 
al., 1993) were eligible for recruitment into the study. As a result of locally agreed 
management protocols all patients with oral carcinoma in North Staffordshire (population 
~ 480,000) presenting for treatment are managed via this clinic. Each patient is fully 
assessed on a joint clinic following initial histological diagnosis prior to commencing 
treatment and at frequent intervals post-treatment until disease-free for a minimum of 5 
years or death. Data including tobacco and alcohol consumption history, tumour stage at 
presentation, tumour differentiation at presentation, treatment, primary site recurrence, 
cervical lymph node metastases, systemic metastases and survival times were recorded for 
each patient and entered onto a standard proforma and subsequently onto the computer 
database. 
Non-smokers and non-drinkers had never smoked or consumed alcohol 
respectively. Tobacco consumption was assessed in number of cigarettes smoked per day 
or ounces of tobacco smoked per week and alcohol consumption was assessed as the 
number of alcohol units consumed per week. One unit = 10ml of alcohol and equates to ½ 
pint beer, one glass of wine or a single measure of spirits. Ever drinkers and smokers had 
done so for a minimum of 15 years (mean 47 years). Patients were classified as heavy 
drinkers and smokers if they consumed more than 20 units of alcohol/week and over 10 
cigarettes/day or over 4 oz tobacco/week. 
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All tumours were staged according to the TNM system (UICC,1987). Patients with 
carcinoma in situ or severe epithelial dysplasia were staged as TNM O. Local recurrence, 
nodal metastases and survival times were taken from the date of initial tumour diagnosis. 
All patients were treated according to agreed protocols. For patients undergoing 
surgery with curative intent, if microscopic resection margins were anywhere less than 
5mm postoperative external beam adjuvant radiotherapy was delivered to the primary site. 
Where more than 2 cervical lymph nodes contained deposits of metastatic squamous cell 
carcinoma or there was histological evidence of extracapsular spread of disease in a single 
cervical lymph node, the neck was treated with external beam adjuvant radiotherapy. 
Patients given external beam radiotherapy with curative intent as their primary treatment 
modality received 5500 cGy predominantly in 20 fractions over 28 days unless side effects 
forced a treatment rest. 
Between January 1st 1995 and July 1st 1997, 159 patients were eligible for study 
entry. Thirty-seven patients either declined their consent to participate or were 
inadvertently missed. Seventy-four patients were entered on initial diagnosis and 48 
patients were entered post-treatment. From January 1st 1997 patients were also recruited 
from The Leeds Dental Institute, Leeds, UK as part of a multi-centre collaboration. 
Approval for this arm of the study was obtained from the United Leeds Teaching Hospitals 
Research and Ethics Committee. The same patient proformas and computer database were 
used at both centres. An earlier version of the current database was developed and trialed in 
Leeds while I was a senior registrar to monitor patients with oral cancer attending the Leeds 
Dental Institute (Worrall and Corrigan, 1995). 
A previous study (Webster and Worrall, 1995) compared the demography, 
management, tumour stage, and outcome of patients in the two centres The male:female 
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ratios were 1.7: 1 and 2:1 with mean ages at first presentation of 64.3 years and 63.7 years 
in the Leeds and Stoke groups respectively. Further data on the two groups is shown in 
tables 18 - 21. 
135 
Comparison of the tumour sites at presentation between patients with oral squamous 
cell carcinoma in Leeds (n = 116) and Stoke (n = 63). 
Comparison of the tumour TNM stages at presentation between patients with oral 
squamous cell carcinoma in Leeds (n = 116) and Stoke (n = 63). 
Comparison of the treatments received between patients with oral squamous cell 
carcinoma in Leeds (n = 116) and Stoke (n = 63). 
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Comparison of the mean recurrence delays at the primary site and in the cervical 
lymph nodes between patients with oral squamous cell carcinoma in Leeds (n = 116) 
and Stoke (n = 63). 
Figures are days from initial diagnosis to first recurrence 
The similarity of the Leeds and Stoke cancer patients was felt to be sufficient to 
justify amalgamating them into a single study sample. Twenty-one Leeds patients all with 
newly diagnosed oral carcinomas were eligible for inclusion. Complete clinical data 
sufficient for study entry was available for 95 Stoke and 11 Leeds patients. There were 
thus 106 patients (100% white Caucasians, mean age 63 years) on whom full clinical data 
was available enabling complete data analysis. All patients were unrelated except 2 who 
were father and son. There were 65 males (mean age 61 years) and 41 females (mean age 
67 years). The median follow-up time was 1.7 years (mean 2.7 years, range 27 days - 9.3 
years). 
As a result of extensive previous work involving detoxification enzyme 
polymorphisms, Professor Strange’s laboratory at the North Staffordshire Hospital has 
recruited a large patient control group, which has been used extensively in previous 
research projects and is being continually expanded (Heagerty et al.,1994; Warwick et 
al., 1994a; Warwick et al., 1994b; Elexpuru-Camiruaga et al., 1995; Lear et al., 1996. 
Detoxification data were available for over 700 patients attending the North Staffordshire 
Hospital for the treatment of non-malignant conditions. North Staffordshire has previously 
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been noted for its stable population base and low rate of immigration and emigration into 
the area (Mackay and Cole, 1984). 
Following obtaining informed patient consent and preparation of a suitable 
venepuncture site with an alcohol-impregnated swab, 5ml of venous blood was withdrawn 
into a glass blood collection tube containing EDTA as an anticoagulant. The tubes were 
then placed in individual 50ml plastic centrifuge tubes (Falcon) and kept at -20° C until 
required. The samples from the Leeds patients were collected personally and transported 
on dry ice to the laboratory at the North Staffordshire Hospital where all subsequent 
investigations and data analysis was performed. 
After initial data analysis in July 1997, evidence emerged for a possible association 
between CYP2D6 polymorphisms and oral cancer susceptibility, implying a role for 
CYP2D6 metabolism in the oral mucosa. However, it was difficult to reconcile these 
findings with the knowledge that CYP2D6 was held to be primarily an hepatic enzyme 
(Ingleman-Sundberg,1995) and previous workers had failed to find evidence of CYP2D6 
expression in normal human gingiva (Zhou et al., 1996). Therefore, evidence of CYP2D6 
enzyme activity in specimens of normal oral mucosa was sought using 
immunohistochemistry. 
Specimens of normal oral mucosa for immunohistochemical study were obtained 
from surgical waste generated by patients undergoing surgical procedures for non- 
malignant oral conditions at the North Staffordshire Hospital. Tissue samples were fixed 
in 10% phosphate buffered formalin and processed to paraffin wax (Hilley et al., 1988). 
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Statistical analysis 
This is an exploratory project in which the genes studied were selected because of 
their presumed biological activities rather than for any statistical considerations. The 
results presented are considered therefore, as hypothesis setting and needing confirmation 
in further independent studies. Any possible multiple testing influences are thus felt to be 
negligble. 
Data were manipulated and analysed using a personal computer running Access 2 
TM (Microsoft), Stata 5 TM (Stata Corporation), Excel 7 TM (Microsoft), and Kwikstat 4 TM 
(TexaSoft). 
analysis was used to examine for detoxification enzyme allele homogeneity 
between cases and controls and between various sub-groups within the case group. Yates’ 
was used where appropriate. 
Cox proportional hazards regression analysis was used to determine which factors, 
both alone and in combination, significantly influenced oral cancer outcome (Christensen, 
1987). 
The log-rank test was used in preference to the Cox proportional hazards model 
where there were more than 2 data items within a group and the lowest coded value could 
not reliably be predicted to carry the lowest hazard. Hence, the log-rank test was used to 
analyse the GSTM1 data set because it contained 4 variables and the lowest coded item (1) 
represented the GSTM1 null allele, which could not reliably be predicted to have the 
lowest hazard. In contrast, the log-rank test was not necessary in order to analyse the TNM 
stage data set even though it contained 5 data items, because the lowest coded value (O), 
which represented TNM stage O (carcinoma in-situ) could be reasonably expected to carry 
the lowest hazard. 
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2.3 Health and Safety Considerations 
The extraction of genomic DNA from patient’s blood samples and the subsequent 
electrophoretic analysis of specific PCR products has numerous health and safety 
implications. Before undertaking any supervised or unsupervised laboratory bench work I 
received thorough instruction on the relevant Health and Safety guidelines from the Head 
of Department, Professor R Strange. There are several important issues relating to 
materials and methods used during the study: 
Organic solvents. Phenol is toxic by ingestion, inhalation and skin contact. It can cause 
burns and is carcinogenic and mutagenic. Chloroform is toxic by ingestion, inhalation 
and skin contact. It causes skin and eye irritation, drowsiness or unconsciousness and 
may be carcinogenic. Whenever Phenol or Chloroform was used they were handled in 
a class-2 safety cabinet and I always wore rubber gloves and eye protection 
Ethidium bromide is a mutagen and carcinogen. This material was always handled 
with extreme care in a class-2 safety cabinet while wearing rubber gloves and eye 
protection 
Ultraviolet (UV) radiation from the transilluminator used to observe the DNA 
fragments in agarose gels is carcinogenic and can cause skin carcinomas and blindness. 
Whenever the transilluminator was used UV safe protective face shields and eye 
protection was used. 
In addition to the above specific safety measures, standard laboratory Health & 
Safety policies such as no mouth pipetting and the wearing of protective laboratory 
coats and gloves at all times were strictly adhered to. 
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Throughout the remainder of this chapter I have given extensive details of all of the 
laboratory methodologies used in order to enable readers to repeat the procedures 
described if desired. 
2.4 DNA Extraction 
DNA was extracted from patient's whole blood sampIes by the phenol/chloroform 
method. Blood samples were transferred to a class-2 safety cabinet from storage at 
-20°C and allowed to thaw. Thawing always took place with the glass blood collecting 
tube still sealed within its original Falcon Hepatitis-risk protective tube as glass 
fracture is not an uncommon event during thawing. After complete thawing the blood 
samples were subsequently transferred to new, labelled Falcon tubes. Stock cold lysis 
buffer (0.32M sucrose, 10mM Tris-HC1 pH 7.5, 5 m M  magnesium chloride and 1% 
(wh) Triton-X100) was then added to a total volume of 35ml and the contents mixed 
by inversion. Samples were then centrifuged at 2000rpm for 10 minutes. The 
supernatant was then immediately decanted into 10% bleach and discarded, taking care 
to leave the leukocyte nuclei in the bottom of the Falcon tube. The nuclear pellet was 
then re-suspended and vortexed in cold SE buffer (0.75M sodium chloride containing 
0.024M disodiumethylene diamine tetraacetic acid pH 8.0). 0.17ml of 5% (w/v) 
sodium dodecyl sulphate (SDS) containing 2mg/ml of proteinase K were then added 
and the reaction mixture left to incubate overnight at 37° C. Using individual Pasteur 
pipettes each sample was transferred to a separate, labelled 10ml screw-top glass tube 
containing 1.5ml of phenol containing O. 1% (wh) 8-hydroxyquinolone saturated with 
20mM Tris-HC1 pH 8.0). The caps were screwed on firmly and each glass tube placed 
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in a Falcon tube with screw cap and centrifuged at 2000 rpm for 10 minutes. After 
centrifuging, the viscous aqueous top layer of the reaction mixture was carefully 
aspirated with a Pasteur pipette and transferred into a labelled 10 ml glass screw-top 
tube to which was added 1.5ml of ch1oroform:isoamyl alcohol (24:1). The tube caps 
were screwed on firmly and each glass tube placed in a Falcon tube with screw cap and 
centrifuged at 2000 rpm for 5 minutes. The viscous aqueous top layer of the reaction 
mixture was again pipetted off into a 10 ml glass screw-top tube and the 
chloroform:isoamyl alcohol extraction repeated. The viscous aqueous top layer of the 
reaction mixture was pipetted into a final labelled glass 10ml screw-top tube to which 
was added O. 15ml of 3M sodium acetate pH 5.2 and 3.3ml of ethanol. Following 
gentle mixing by inversion the DNA precipitated out and was gently removed from the 
reaction vessel using a glass hook. The DNA was transferred to a labelled 0.5ml 
plastic Eppendorf tube and re-suspended in O. 1ml of sterile water. Each individual 
patient's extracted DNA was then kept in these Eppendorf tubes in a 4°C fridge until 
required. All phenol and chloroform waste was carefully discarded into appropriate 
waste containers in a class-2 cabinet. 
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2.5 Determination of GSTM1 Genotype 
Polymorphism at the GSTM1 locus is based on 3 alleles, GSTM1 *O, GSTM1 *A and 
GSTM1 *B. GSTM1 *O is deleted resulting in individuals homozygous for this allele 
expressing no GSTM1 protein GSTM1 *A and GSTM1 *B are identical apart from a single 
base pair difference in exon 7. Although individuals who are homozygous for the 
GSTM1 *O allele (GSTM1 null genotype) can be reliably identified by PCR because of 
their failure to amplie for example, the exon 4-5 region of the GSTM1 gene, (Heagerty et 
al., 1994) because the full extent of the GSTM1 *O deletion has yet to be determined it is 
difficult to distinguish the heterozygote genotypes GSTM1 *O/GSTM1 *A and 
GSTM1 *O/GSTM1 *B from the GSTM1 *A and GSTM1 *B homozygous genotypes 
respectively (Strange and Fryer, 1997). 
In order to fully describe the GSTM1 genotype for patients in this study the 
amplification refractory mutation system (ARMS), described by Fryer et al., 1993 was 
used. The technique uses primers specific to exon 4-5, intron 6 and GSTM1 *A and 
GSTM1 *B on exon 7. ß-globin primers were used as an internal control. The normal 
GSTM1 *A and GSTM1 *B primer sequences were identical apart from an A-G substitution 
at the 3’ end of the GSTM1 *A primer which both improved primer binding specificity and 
also introduced an HaeII restriction enzyme cutting site (Fryer et al., 1993). The Exon 7 A 
and B specific primers differed only in their 3’ terminal bases (Figure 28). Thus the 
GSTM1 null individuals would amplie the control ß-globin DNA but not the target DNA 
and the GSTM1 *A/GSTM1 *A and GSTM1 *B/GSTM1 *B individuals would be 
distinguished from the GSTM1 *A/GSTM1 *B individuals. 
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Primer sequences used in the ARMS method to determine GSTMI genotype 
highlighting the differences at the 3’ ends of the normal GSTMI *A sequence, A specific 
exon 7 primer and B specific exon 7 primer. 
PCR 
For each patient, 2 new 0.5ml plastic microcentrifuge tubes were labelled “A’ and “B”. 
Two 0.5 ml microcentrifuge tubes were labelled as “Positive A” and “Positive B” and a 
further 2 0.5ml microcentrifuge tubes were labelled as “Negative A” and “Negative B” 
These 4 tubes were used for the positive and negative controls respectively. Two 1.5ml 
microcentrifuge tubes were labelled as “A stock” and “B stock”. Stock solutions were 
made up and aliquoted into the appropriate stock tubes as detailed below. 
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After mixing each stock tube by inversion of A stock were aliquoted into each of 
the 0.5ml “A’ tubes and of B stock were aliquoted into each of the 0.5ml “B” tubes. 
1.5 of sterile water were aliquoted into both of the negative control tubes and 1.5 of 
known GSTMI *A and GSTMZ *B DNA were aliquoted into the positive A control and 
positive B control tubes respectively. 1.5 of each patient’s test DNA were aliquoted into 
the “A” and “B” 0.5ml microcentrifuge tubes. Two drops of light paraffin oil were 
added to each tube to prevent evaporation, which were then centrifuged at 12,000 rpm for 
20 seconds. All tubes were then placed randomly in a thermal cycler (Omnigene, Hybaid 
Ltd) which was pre-programmed to deliver the following PCR cycle parameters: 
Agarose gel electrophoresis 
Fresh agarose gels were poured for each batch of tests and the technique described 
below was used to make gels for all of the genotype determinations performed throughout 
this study. Using an electrical balance, 1.2 g of agarose were placed into a clean, sterile 
50ml conical flask to which was added 3ml of 5x TBE buffer (54g Tris base, 27.58 Boric 
Acid, 20ml 0.5M EDTA pH 8.0 made up to a total volume of 800ml with distilled water) 
and 27 ml of sterile water. The flask neck was lightly plugged with tissue paper and 
heated in a microwave oven until the agarose was fully dissolved and a clear, precipitate 
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free solution produced. This technique required constant vigilance and patience in order to 
produce a gel of the required concentration (in this case 4% w/v). Over-heating lead to 
excessive evaporation and/or boiling over and under-heating produced a poor quality gel 
laden with precipitate resulting in a gel with poor resolving characteristics. Once a 
satisfactory solution was produced the flask was cooled to 60°C under running water and 
transferred to a class-2 safety cabinet. Using full Health and Safety precautions, of 
ethidium bromide (10mg/ml) was added and the flask contents mixed by gentle agitation. 
The agarose was then poured into a pre-prepared plastic electrophoresis tray and allowed 
to set for 30 minutes. 
While the agarose gel was setting, of loading buffer (30mg of O. 15% w/v 
bromophenol blue, 30mg of O. 15% w/v xylene cyanole, 6ml of 30% w/v glycerol, 8ml 5x 
TBE, 6ml sterile water) were added to each of the thawed PCR tubes and all tubes 
centrifuged at 12,000 rpm for 20 seconds. 
When set, the combs and blanking tape were removed from the agarose gel/tray 
which was placed in an electrophoresis tank and covered to a depth of 2mm with 0.5x TBE 
containing of ethidium bromide. of each sample (test DNA, positive and negative 
controls) were then loaded into separate wells on the gel and a note made of the orientation 
and location of each sample for future reference. The end well on each gel was loaded 
with of previously prepared molecular weight markers (1 pBR322 HaeII1 digest 
[Sigma: approx. concentration 500- 1 O. 5x TBE, loading buffer). 
The electrophoresis tank lid was replaced and the gel run at 120 volts for 40 
minutes. Slight adjustments to the running time were made on each “run” depending on 
the position of the leading blue bands. On completion of electrophoretic separation the gel 
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was carefully placed onto a UV transilluminator, and using full Health and Safety 
precautions photographed onto type 667 Polaroid film using a Wratten 23A filter at f4.7 
for ¼ of a second. A diagrammatic representation of the GSTM1 ARMS method is shown 
in Figure 29. 
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2.6 Determination of GSTM3 Genotype 
The 2 GSTM3 alleles, GSTM3*A and GSTM3*B have been identified. They differ 
by a 3 base pair deletion in intron 6 of GSTM3 *B. PCR amplification across exons 6 and 7 
followed by restriction enzyme digestion with Mnl 1 will identify individuals who are 
GSTM3 *A/ GSTM3 *A, GSTM3 *A/GSTM3 *B or GSTM3 *B/GSTM3 *B. The Mnl 1 enzyme 
digests the 273 base pair PCR product of the GSTM3*A allele into 3 fragments of 137, 125 
and 1 1 base pair fragments and the 270 base pair PCR product of the GSTM3 *B allele into 
3 fragments of 134, 125 and 11 base pairs. The GSTM3*A allele 137 base pair fragment is 
subsequently digested by Mnl 1 into 2 fragments of 86 and 51 base pairs whereas the 
GSTM3*B allele 134 base pair fragment lacks an Mnl 1 restriction site and is not cut 
further. The primer sequences used for GSTM3 determination are shown in Figure 30. 
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PCR 
New 0.5ml plastic microcentrifuge tubes were labelled for each test DNA sample. 
one new O. 5ml microcentrifuge tubes was labelled as “Positive Control” and another was 
labelled as “Negative Control”. A 1.5ml microcentrifuge tubes was labelled as “Stock7 
The stock solution was made up as detailed below: 
After mixing the stock tube by inversion of stock solution were aliquoted into 
each of the 0.5ml tubes. 1.5 of sterile water were aliquoted into the negative control 
tube and 1.5 of known GSTM3 *A/GSTM3 *A DNA were aliquoted into the positive 
control tube. 1.5 of each patient’s test DNA were aliquoted into the individually 
labelled 0.5ml microcentrifuge tubes. Two drops of light paraffin oil were added to 
each tube to prevent evaporation, which were then centrifuged at 12,000 rpm for 20 
seconds. All tubes were then placed randomly in a thermal cycler (Omnigene, Hybaid Ltd) 
which was pre-programmed to deliver the following PCR cycle parameters: 
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Mnl 1 Restriction Enzyme Digestion 
A 0.5ml microcentrifuge tube was labelled “Mnl 1 Stock” to which was added the 
following components: 
New microcentrifuge tubes were labelled for each patient and the positive 
control. Ten microlitres of the relevant PCR product and of Mnl 1 stock were 
aliquoted into each microcentrifuge tube which were then centrifuged at 12,000 rpm for 20 
seconds and subsequently incubated at 37°C for 18 hours. 
Agarose gel electrophoresis 
A 4% agarose gel was mixed and poured according to the protocol previously 
described for GSTMI electrophoresis. Two microlitres of loading buffer (30mg of O. 15% 
w/v bromophenol blue, 30mg of O. 15% w/v xylene cyanole, 6ml of 30% w/v glycerol, 8ml 
5x TBE, 6ml sterile water) were aliquoted into each of the test microcentrifuge tubes 
into the negative control) and all tubes centrifuged at 12,000 rpm for 20 seconds. 
When set, the combs and blanking tape were removed from the agarose gel/tray 
which was placed in an electrophoresis tank and covered to a depth of 2mm with 0.5x TBE 
containing of ethidium bromide. Seven microlitres of each sample (test DNA, positive 
and negative controls) were then loaded into separate wells on the gel and a note made of 
the orientation and location of each sample for future reference. The end well on each gel 
was loaded with of previously prepared molecular weight markers (1 pBR322 
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Haell1 digest [Sigma: approx. concentration 0.5x TBE, loading 
buffer). 
The electrophoresis tank lid was replaced and the gel run at 120 volts for 45 
minutes. Slight adjustments to the running time were made on each “run” depending on 
the position of the leading blue bands. On completion of electrophoretic separation the gel 
was carefully placed onto a UV transilluminator, and using full Health and Safety 
precautions photographed onto type 667 Polaroid film using a Wratten 23A filter at f4.7 
for ¼ of a second. A diagrammatic representation of the expected banding pattern for 
GSTM3 following Mnl 1 digestion is shown in Figure 3 1. 
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2.7 Determination of GSTP1 Genotype 
The GSTP1 *B allele differs from the GSTP1 *A allele as a consequence of the exon 
5 A-G transition at position 1578 in GSTP1 *B. The two alleles can be identified following 
digestion with the restriction enzyme Alw 26 1. Following PCR with exon 5 specific 
primers (Figure 32) to produce a 176 base pair DNA fragment, GSTP1 *A is resistant to 
digestion by Alw 261 whereas GSTP1 *B is digested to produce 2 DNA fragments of 91 
and 85 base pairs. 
PCR 
New 0.5ml plastic microcentrifuge tubes were labelled for each test DNA sample. 
One new 0.5ml microcentrifuge tubes was labelled as “Positive Control” and another was 
labelled as “Negative Control”. A 1.5ml microcentrifuge tubes was labelled as “Stock” 
The stock solution was made up as detailed below: 
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After mixing the stock tube by inversion of stock solution were aliquoted into 
each of the 0.5ml tubes. 1.5 of sterile water were aliquoted into the negative control 
tube and 1.5 of known GSTP1 *B/GSTP1 *B DNA were aliquoted into the positive 
control tube. 1.5 of each patient’s test DNA were aliquoted into the individually 
labelled 0.5ml microcentrifuge tubes. Two drops of light paraffin oil were added to 
each tube to prevent evaporation, which were then centrifuged at 12,000 rpm for 20 
seconds. All tubes were then placed randomly in a thermal cycler (Omnigene, Hybaid Ltd) 
which was pre-programmed to deliver the following PCR cycle parameters: 
Awl 261 restriction enzyme digestion 
A 0.5ml microcentrifuge tube was labelled “Awl 261 Stock” to which was added 
the following components: 
New microcentrifuge tubes were labelled for each patient and the positive 
control. Ten microlitres of the relevant PCR product and of Awl 261 stock were 
aliquoted into each microcentrifuge tube which were then centrifuged at 12,000 rpm for 20 
seconds and subsequently incubated at 37°C for 18 hours. 
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Agarose gel electrophoresis 
A 4% agarose gel was mixed and poured according to the protocol previously 
described for GSTMI electrophoresis. Two microlitres of loading buffer (30mg of O. 15% 
w/v bromophenol blue, 30mg of O. 15% w/v xylene cyanole, 6ml of 30% w/v glycerol, 8ml 
5x TBE, 6ml sterile water) were aliquoted into each of the test microcentrifuge tubes 
into the negative control) and all tubes centrifuged at 12,000 rpm for 20 seconds. 
When set, the combs and blanking tape were removed from the agarose gel/tray 
which was placed in an electrophoresis tank and covered to a depth of 2mm with 0.5x TBE 
containing of ethidium bromide. Seven microlitres of each sample (test DNA, positive 
and negative controls) were then loaded into separate wells on the gel and a note made of 
the orientation and location of each sample for future reference. The end well on each gel 
was loaded with of previously prepared molecular weight markers (1 pBR322 
HaeII1 digest [Sigma: approx. concentration 0.5x TBE, loading 
buffer). 
The electrophoresis tank lid was replaced and the gel run at 120 volts for 45 
minutes. Slight adjustments to the running time were made on each “run” depending on 
the position of the leading blue bands. On completion of electrophoretic separation the gel 
was carefully placed onto a UV transilluminator, and using full Health and Safety 
precautions photographed onto type 667 Polaroid film using a Wratten 23A filter at f4.7 
for ¼ of a second. A diagrammatic representation of the expected banding pattern for 
GSTM3 following Awl 261 digestion is shown in Figure 33. 
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2.8 Determination of GSTT1 Genotype 
A null polymorphism resulting from homozygosity for GSTT1 *0 has been 
identified at the GSTT1 locus (Pemble et al., 1994). PCR amplification using the specific 
primers (Figure 34) described by Pemble et al. (1994) distinguishes individuals with at 
least one copy of the wild type allele (GSTT1 *A) from those with the null polymorphism 
by the production of a 480 base pair DNA fragment in the latter but not the former. 
PCR 
New 0.5ml plastic microcentrifuge tubes were labelled for each test DNA sample. 
One new 0.5ml microcentrifuge tubes was labelled as “Positive Control” and another was 
labelled as “Negative Control”. A 1 .5ml microcentrifuge tubes was labelled as “Stock” 
The stock solution was made up as detailed below: 
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After mixing the stock tube by inversion of stock solution were aliquoted into 
each of the 0.5ml tubes. 1.5 of sterile water were aliquoted into the negative control 
tube and 1.5 of known GSTT1 *A/GSTT1 *A DNA were aliquoted into the positive 
control tube. 1.5 of each patient’s test DNA were aliquoted into the individually 
labelled 0.5ml microcentrifuge tubes. Two drops of light paraffin oil were added to 
each tube to prevent evaporation, which were then centrifuged at 12,000 rpm for 20 
seconds. All tubes were then placed randomly in a thermal cycler (Omnigene, Hybaid Ltd) 
which was pre-programmed to deliver the following PCR cycle parameters: 
Agarose gel electrophoresis 
A 2% agarose gel was mixed and poured according to the protocol previously 
described for GSTMI electrophoresis except that 0.6g agarose was used rather than 1.2g. 
Four microlitres of loading buffer (30mg of O. 15% w/v bromophenol blue, 30mg of O. 15% 
w/v xylene cyanole, 6ml of 30% w/v glycerol, 8ml 5x TBE, 6ml sterile water) were 
aliquoted into each of the test microcentrifuge tubes which were then centrifuged at 12,000 
rpm for 20 seconds. 
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When set, the combs and blanking tape were removed from the agarose gel/tray 
which was placed in an electrophoresis tank and covered to a depth of 2mm with 0.5x TBE 
containing of ethidium bromide. Five microlitres of each sample (test DNA, positive 
and negative controls) were then loaded into separate wells on the gel and a note made of 
the orientation and location of each sample for future reference. The end well on each gel 
was loaded with of previously prepared molecular weight markers ( 1 pBR322 
HaeII1 digest [Sigma: approx. concentration 0.5x TBE, loading 
buffer). 
The electrophoresis tank lid was replaced and the gel run at 120 volts for 25 
minutes. Slight adjustments to the running time were made on each “run” depending on 
the position of the leading blue bands. On completion of electrophoretic separation the gel 
was carefully placed onto a W transilluminator, and using full Health and Safety 
precautions photographed onto type 667 Polaroid film using a Wratten 23A filter at f4.7 
for ¼ of a second. A diagrammatic representation of the expected banding pattern for 
GSTM3 following Awl 261 digestion is shown in Figure 35. 
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2.9 Determination of CYP2D6 Genotype 
There are over 53 allelic variants of CYP2D6 but only 3 are common (Marez et al., 
1997). PCR methodology was used to identify the 2 commonest polymorphisms at the 
CYP2D6 locus. These are termed CYP2D6 A and CYP2D6 B. With respect to both alleles 
individuals may be classified as extensive metabolisers (homozygous wild type), poor 
metabolisers (homozygous null) or heterozygotes. These genotypes are referred to as EM, 
PM and HET respectively. Because of their mode of inheritance and the possible allele 
combinations that result from it, specific combinations of CYP2D6 A and CYP2D6 B 
polymorphisms combine to produce an overall CYP2D6 phenotype (Figure 36). 
The CYP2D6 A polymorphism results from a base pair deletion in exon 5. PCR 
across exon 5 and intron 5 using specific primers (Figure 37) yields a 270 base pair DNA 
fragment that in extensive metabolisers is cut by the restriction enzyme Hpa II into 2 
fragments of 188 and 82 base pairs. The exon 5 base pair deletion introduces a second 
Hpa II restriction site such that in CYP2D6 A PM individuals the 188 base pair fragment is 
further cut into 2 fragments of 168 and 20 base pairs. 
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The CYP2D6 B polymorphism results from a point mutation at the intron 3 exon 4 
boundary that produces a subsequent splice site defect. PCR across intron 3 and exon 4 
using specific primers (Figure 38) yields a 334 base pair DNA fragment that in extensive 
metabolisers is cut by the restriction enzyme Bstnl into 2 fragments of 229 and 105 base 
pairs. The intron 3/exon 4 mutation results in loss of the normal Bstnl restriction site. 
Consequently CYP2D6 B PM individuals will still have a single 334 base pair band 
following digestion with Bstnl . 
163 
CYP2D6 A PCR 
New 0.5ml plastic microcentrifuge tubes were labelled for each test DNA sample. One 
new 0.5ml microcentrifuge tubes was labelled as “Positive Control” and another was 
labelled as “Negative Control”. A 1 .5ml microcentrifuge tubes was labelled as “Stock” 
The stock solution was made up as detailed below: 
After mixing the stock tube by inversion of stock solution were aliquoted into 
each of the 0.5ml tubes. 1.5 of sterile water were aliquoted into the negative control 
tube and 1.5 of known CYP2D6 A PMDNA were aliquoted into the positive control 
tube. 1.5 of each patient’s test DNA were aliquoted into the individually labelled 0.5ml 
microcentrifuge tubes. Two drops of light paraffin oil were added to each tube to 
prevent evaporation, which were then centrifuged at 12,000 rpm for 20 seconds. All tubes 
were then placed randomly in a thermal cycler (Omnigene, Hybaid Ltd) which was pre- 
programmed to deliver the following PCR cycle parameters: 
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HPA II restriction enzyme digestion 
A 0.5ml microcentrifuge tube was labelled "Hpa II Stock" to which was added the 
following components: 
New microcentrifuge tubes were labelled for each patient and the positive 
control. Ten microlitres of the relevant PCR product and of Hpa II stock were 
aliquoted into each microcentrifuge tube, which were then centrifuged at 12,000 rpm for 
20 seconds and subsequently incubated at 37°C for 18 hours. 
Agarose Gel Electrophoresis 
A 4% agarose gel was mixed and poured according to the protocol previously described for 
GSTMZ electrophoresis. Eight microlitres of loading buffer (30mg of O. 15% w/v 
bromophenol blue, 30mg of O. 15% w/v xylene cyanole, 6ml of 30% w/v glycerol, 8ml 5x 
TBE, 6ml sterile water) were aliquoted into each of the test microcentrifuge tubes (20pl 
into the negative control) and all tubes centrifuged at 12,000 rpm for 20 seconds. 
When set, the combs and blanking tape were removed from the agarose gel/tray 
which was placed in an electrophoresis tank and covered to a depth of 2mm with 0.5x TBE 
containing of ethidium bromide. Seven microlitres of each sample (test DNA, positive 
and negative controls) were then loaded into separate wells on the gel and a note made of 
the orientation and location of each sample for future reference. The end well on each gel 
was loaded with of previously prepared molecular weight markers (1  pBR322 
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Haell1 digest [Sigma: approx. concentration 500-1000pg/ml], 0.5x TBE, loading 
buffer). 
The electrophoresis tank lid was replaced and the gel run at 120 volts for 90 
minutes. Slight adjustments to the running time were made on each “run” depending on 
the position of the leading blue bands. On completion of electrophoretic separation the gel 
was carefully placed onto a UV transilluminator, and using full Health and Safety 
precautions photographed onto type 667 Polaroid film using a Wratten 23A filter at f4.7 
for ¼ of a second. A diagrammatic representation of the expected banding pattern for 
CYP2D6 A following Hpa II digestion is shown in Figure 39. 
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CP2D6 B PCR 
New 0.5ml plastic microcentrifuge tubes were labelled for each test DNA sample. One 
new 0.5ml microcentrifuge tubes was labelled as “Positive Control” and another was 
labelled as “Negative Control”. A 1 .5ml microcentrifuge tubes was labelled as “Stock” 
The stock solution was made up as detailed below: 
After mixing the stock tube by inversion of stock solution were aliquoted into 
each of the 0.5ml tubes. 1.5 of sterile water were aliquoted into the negative control 
tube and 1.5 of known CYP2D6 B EMDNA were aliquoted into the positive control 
tube. 1.5 of each patient’s test DNA were aliquoted into the individually labelled 0.5ml 
microcentrifuge tubes. Two drops of light paraffin oil were added to each tube to 
prevent evaporation, which were then centrifuged at 12,000 for 20 seconds. All tubes rpm 
were then placed randomly in a thermal cycler (Omnigene, Hybaid Ltd) which was pre- 
programmed to deliver the following PCR cycle parameters: 
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Bstn I restriction enzyme digestion 
A 0.5ml microcentrifuge tube was labelled "Bstnl Stock" to which was added the 
following components: 
New microcentrifuge tubes were labelled for each patient and the positive 
control. Ten microlitres of the relevant PCR product and of Bstnl stock were 
aliquoted into each microcentrifuge tube, which were then centrifuged at 12,000 rpm for 
20 seconds and subsequently incubated at 60°C for 18 hours. 
Agarose gel electrophoresis 
A 2% agarose gel was mixed and poured according to the protocol previously described for 
GSTTZ electrophoresis. Eight microlitres of loading buffer (30mg of O. 15% w/v 
bromophenol blue, 30mg of O. 15% w/v xylene cyanole, 6ml of 30% w/v glycerol, 8ml 5x 
TBE, 6ml sterile water) were aliquoted into each of the test microcentrifuge tubes 
into the negative control) and all tubes centrifuged at 12,000 rpm for 20 seconds. 
When set, the combs and blanking tape were removed from the agarose gel/tray 
which was placed in an electrophoresis tank and covered to a depth of 2mm with 0.5x TBE 
containing of ethidium bromide. Five microlitres of each sample (test DNA, positive 
and negative controls) were then loaded into separate wells on the gel and a note made of 
the orientation and location of each sample for future reference. The end well on each gel 
was loaded with of previously prepared molecular weight markers (1 pBR322 
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HaeII1 digest [Sigma: approx. concentration 0.5x TBE, loading 
buffer). 
The electrophoresis tank lid was replaced and the gel run at 85 volts for 35 
minutes. Slight adjustments to the running time were made on each “run” depending on 
the position of the leading blue bands. On completion of electrophoretic separation the gel 
was carefully placed onto a UV transilluminator, and using full Health and Safety 
precautions photographed onto type 667 Polaroid film using a Wratten 23A filter at f4.7 
for ¼ of a second. A diagrammatic representation of the expected banding pattern for 
CYP2D6 B following Bstnl digestion is shown in Figure 40. 
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2.10 Determination of CYP1A1 Genotype 
Two variant CYP1A1 alleles (exon 7 Ile-Val and 3' flanking region Mspl mutations 
were detected using PCR and restriction enzyme digestion. 
Following PCR using exon 7 specific primers (Figure 4 1) a 322 base pair DNA 
fragment is produced. Subsequent digestion with the restriction enzyme Ncol splits the 
restriction fragment into 3 bands of 232,70 and 20 base pairs. In the mutated polymorphsm 
with the valine substitution Nco 1 digestion produces 2 restriction fragments of 252 and 70 
base pairs. The banding pattern seen in heterozygotes is a combination of the wild type and 
mutated alleles. 
Following PCR with CYP1A1 Mspl specific primers (Figure 42), individuals who have 
the 3' Mspl mutation develop an Mspl restriction site resulting in the digestion by Mspl of 
the 340 base pair PCR product into 2 restriction fragments of 200 and 140 base pairs. 
Individuals with the m1/m1 genotype do not have the Mspl restriction site and Mspl does not 
digest the 340 base pair PCR product. Heterozygotes have a combination of the m1/m1 and 
m2/m2 fragments 
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CYP1A1 Ile-Val (ClPlAl-1) PCR 
New 0.5ml plastic microcentrifuge tubes were labelled for each test DNA sample. 
One new O. 5ml microcentrifuge tubes was labelled as “Positive Control” and another was 
labelled as “Negative Control”. A 1.5ml microcentrifuge tubes was labelled as “Stock” 
The stock solution was made up as detailed below: 
After mixing the stock tube by inversion of stock solution were aliquoted into 
each of the 0.5ml tubes. 1.5 of sterile water were aliquoted into the negative control 
tube and 1.5 of known CYP1A1 m1/m2 DNA were aliquoted into the positive control 
tube. 1.5 of each patient’s test DNA were aliquoted into the individually labelled 0.5ml 
microcentrifuge tubes. Two drops of light paraffin oil were added to each tube to 
prevent evaporation, which were then centrifuged at 12,000 rpm for 20 seconds. All tubes 
were then placed randomly in a thermal cycler (Omnigene, Hybaid Ltd) which was pre- 
programmed to deliver the following PCR cycle parameters: 
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Ncol restriction enzyme digestion 
A 0.5ml microcentrifuge tube was labelled "Ncol Stock" to which was added the 
following components: 
New microcentrifuge tubes were labelled for each patient and the positive 
control. Ten microlitres of the relevant PCR product and of Ncol stock were 
aliquoted into each microcentrifuge tube which were then centrifuged at 12,000 rpm for 20 
seconds and subsequently incubated at 37°C for 18 hours. 
Agarose gel electrophoresis 
A 4% agarose gel was mixed and poured according to the protocol previously 
described for GSTMI electrophoresis. Two microlitres of loading buffer (30mg of O. 15% 
w/v bromophenol blue, 30mg of O. 15% w/v xylene cyanole, 6ml of 30% w/v glycerol, 8ml 
5x TBE, 6ml sterile water) were aliquoted into each of the test microcentrifuge tubes 
into the negative control) and all tubes centrifuged at 12,000 rpm for 20 seconds. 
When set, the combs and blanking tape were removed from the agarose gel/tray 
which was placed in an electrophoresis tank and covered to a depth of 2mm with 0.5x TBE 
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containing of ethidium bromide. Seven microlitres of each sample (test DNA, positive 
and negative controls) were then loaded into separate wells on the gel and a note made of 
the orientation and location of each sample for future reference. The end well on each gel 
was loaded with of previously prepared molecular weight markers (1 y1 pBR322 
HaeII1 digest [Sigma: approx. concentration 0.5x TBE, loading 
buffer). 
The electrophoresis tank lid was replaced and the gel run at 120 volts for 60 
minutes. Slight adjustments to the running time were made on each “run” depending on 
the position of the leading blue bands. On completion of electrophoretic separation the gel 
was carefully placed onto a UV transilluminator, and using full Health and Safety 
precautions photographed onto type 667 Polaroid film using a Wratten 23A filter at f4.7 
for ¼ of a second. A diagrammatic representation of the expected banding pattern for 
CYP1A1-1 following Ncol digestion is shown in Figure 43. 
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CYP1A1 Mspl (CYP1A1-2) PCR 
New 0.5ml plastic microcentrifuge tubes were labelled for each test DNA sample. 
One new 0.5ml microcentrifuge tubes was labelled as “Positive Control” and another was 
labelled as “Negative Control”. A 1 .5ml microcentrifuge tubes was labelled as “Stock” 
The stock solution was made up as detailed below: 
After mixing the stock tube by inversion of stock solution were aliquoted into 
each of the 0.5ml tubes. 1.5 of sterile water were aliquoted into the negative control 
tube and 1.5 of known CYP1A1 m2/m2 DNA were aliquoted into the positive control 
tube. 1.5 of each patient’s test DNA were aliquoted into the individually labelled 0.5ml 
microcentrifuge tubes. Two drops of light paraffin oil were added to each tube to 
prevent evaporation, which were then centrifuged at 12,000 rpm for 20 seconds. All tubes 
were then placed randomly in a thermal cycler (Omnigene, Hybaid Ltd) which was pre- 
programmed to deliver the following PCR cycle parameters: 
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Mspl restriction enzyme digestion 
A 0.5ml microcentrifuge tube was labelled "Mspl Stock" to which was added the 
following components: 
New O. microcentrifuge tubes were labelled for each patient and the positive 
control. Ten microlitres of the relevant PCR product and of Mspl stock were 
aliquoted into each microcentrifuge tube which were then centrifuged at 12,000 rpm for 20 
seconds and subsequently incubated at 37°C for 18 hours. 
Agarose gel electrophoresis 
A 2% agarose gel was mixed and poured according to the protocol previously 
described for GSTT1 electrophoresis. Two microlitres of loading buffer (30mg of O. 15% 
w/v bromophenol blue, 30mg of O. 15% w/v xylene cyanole, 6ml of 30% w/v glycerol, 8ml 
5x TBE, 6ml sterile water) were aliquoted into each of the test microcentrifuge tubes 
into the negative control) and all tubes centrifuged at 12,000 rpm for 20 seconds. 
When set, the combs and blanking tape were removed from the agarose gel/tray 
which was placed in an electrophoresis tank and covered to a depth of 2mm with 0.5x TBE 
containing of ethidium bromide. Five microlitres of each sample (test DNA, positive 
and negative controls) were then loaded into separate wells on the gel and a note made of 
the orientation and location of each sample for future reference. The end well on each gel 
was loaded with of previously prepared molecular weight markers pBR322 
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Haell1 digest [Sigma: approx. concentration 0.5x TBE, loading 
buffer). 
The electrophoresis tank lid was replaced and the gel run at 120 volts for 30 
minutes. Slight adjustments to the running time were made on each “run” depending on 
the position of the leading blue bands. On completion of electrophoretic separation the gel 
was carefully placed onto a UV transilluminator, and using full Health and Safety 
precautions photographed onto type 667 Polaroid film using a Wratten 23A filter at f4.7 
for ¼ of a second. A diagrammatic representation of the expected banding pattern for 
CYP1A1-1 following Ncol digestion is shown in Figure 44. 

2.11 Immunohistochemical Detection of CYP2D6 
Serial 5pm sections were cut from the normal oral mucosa specimens, mounted on 
glass microscope slides and dried overnight in a 37°C incubator and placed in a 56°C 
incubator for 30 minutes. The sections were then de-waxed in xylene for 3 minutes and 
taken up through graded alcohols to industrial methylated spirit (IMS). Endogenous 
peroxidase activity was blocked by immersion in 0.3% hydrogen peroxide 10 minutes 
followed by washing in running tap water for 20 minutes. The specimens were then 
microwaved at 10 minutes on high power followed by 10 minutes on medium power in a 
solution of 10 mM citrate buffer, pH 6.0 and allowed to cool to room temperature before 
being mounted onto cover plates and loaded into an auto-stainer (The Cadenza, Shandon 
Scientific Ltd, UK). Specimens were then incubated in normal swine serum diluted 1:5 
with TRIS-buffered saline (TBS) pH 7.6 (8g NaCl, 6g TRIS in 10 litres for 20 
minutes and washed with TBS for 5 minutes. Sections were incubated for 60 minutes at 
20°C with a rabbit polyclonal antiserum (Hand et al., 1996) specific for the human 
CYP2D6 subunit (generous gift from Professor C R Wolf, Imperial Cancer Research Fund, 
Scotland) diluted 1:75. Normal human liver and kidney sections were used as a positive 
control and an oral mucosal section not exposed to the primary antibody served as a 
negative control. All sections were then exposed to a biotinylated sheep anti-rabbit 
antiserum (Dakopatts, Denmark) diluted 1 : 1 00 for 30 minutes and washed in TBS for 5 
minutes. Streptavidin conjugated horseradish peroxidase (Binding Site, UK) diluted 1 :75 
was added and the specimens incubated for 30 minutes before washing for 5 minutes in 
TBS Peroxidase activity was developed using a 10mg tablet of diaminobenzidine- 
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tetrahydrochloride (Sigma, UK), 30 TBS and 15 0.3% for 5 minutes, 
counterstained with haematoxylin, dehydrated and assessed by standard light microscopy. 
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2.12 Problems and Errors 
With increasing experience the majority of DNA extractions, PCR’s and 
electrophoreses worked satisfactorily. However, there were several occasions, especially 
early in the study when problems were encountered with all aspects of the methodology. 
DNA extraction 
Insufficient or absent DNA harvest following Phenol/Chloroform extraction was 
most commonly due to having taken less than the desired 4ml of venous blood and/or 
allowing the blood sample to clot in the collecting bottle. These events commonly 
coincided, as it was occasionally difficult to perform adequate venepuncture on certain 
patients, especially those who were elderly, frail or dehydrated. 
PCR 
It rapidly became apparent that successful PCR requires a methodical approach 
with strict attention to detail. Any deviation from the specific protocol, either intentional 
or unintentional, usually resulted in PCR failure. This most commonly occurred while 
making up the various PCR stock mixtures due to failure to add dNTP’s, allele specific 
primers or Taq polymerase. Occasionally, despite all reagents being correctly added the 
PCR would still fail because one or more reagents had been aliquoted from stock that had 
undergone numerous freeze-thaw cycles resulting in partial or complete loss of activity. 
These errors resulted in failure of all the batched PCR reactions. Failure of individual 
PCR’s within a batch of otherwise successful reactions also occurred. It was noted that 
occasionally, blood samples had been collected in blood bottles containing Lithium 
183 
Heparin as the anticoagulant rather than EDTA. The Lithium Heparin samples produced 
good DNA harvests but the anticoagulant commonly inhibited the PCR reaction. 
Wherever possible repeat blood samples using EDTA tubes were taken. Simple, avoidable 
errors such as failing to add the PCR stock to the sample tubes also resulted in individual 
PCR failures. 
In a technique as exquisitely sensitive as PCR, contamination by, and subsequent 
amplification of “foreign” DNA is a constant danger. Both general and specific 
techniques were employed to minimise the risk of contamination. The laboratory 
containing the thermal cyclers where the PCR was actually performed was physically 
removed from those where the PCR stock solutions were made up and electrophoresis of 
final PCR product undertaken in order to reduce as far as possible the amount of 
extraneous DNA in the PCR laboratory. New sterile reaction vessels were used for each 
PCR step and new sterile pipette tips were used to aliquot reagents and samples. 
Electrophoresis 
The electrophoresis process per se was usually trouble free, although occasionally 
the gels would run faster or slower than expected. The main determinant of successful 
electrophoresis and subsequent UV visualisation and Polaroid photography was the quality 
of the agarose gel. As described previously all gels were made and poured individually, 
commercial gels were never employed. Making the 2% gels was fairly straightforward and 
the electrophoreses requiring 2% gels usually ran correctly first time and produced good 
quality Polaroid photographs on which the individual lanes were well resolved. However, 
the 4% gels were more problematical. The main difficulty was ensuring complete 
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dissolution of the agarose in the water. Not infrequently the gels would “boil-over’’ in the 
microwave oven or were subject to excessive evaporation, both scenarios resulting in a gel 
of >4% concentration. Gels with inadequate agarose dissolution or those of >4% 
concentration were of poor quality, containing collections of undissolved agarose, air 
bubbles and streaks. The subsequent Polaroid photographs were often indistinct with poor 
detail resolution. 
As experience increased the above errors were minimised and the number of 
samples requiring repeat PCR reduced. 
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3.1 Patient Demographics 
Patient age at initial tumour diagnosis was normally distributed (Figure. 45). The 
mean age was 63.3 years and the median age was 63.5 years (range. 3 1 - 90 years, SD = 
11.3). 54 patients (51%) were younger than or the same as the median age and 52 patients 
(49%) were older than the median age at initial tumour diagnosis. For the purposes of this 
study, patients aged 63 years or younger were termed “young” and patients over 63 years 
were termed “old”. 
Over one third of patients presented with late stage tumours (TNM stage 3 or 4) 
(Table. 22). There was no association between gender and tumour stage at presentation 
= 2.64,p = 0.619). 
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Over 15% of patients were non-drinkers and non-smokers and over 20% were 
heavy drinkers and heavy smokers (Table 23). Heavy drinking and heavy smoking was 
more common in males than in females = 14.57,p <0.001) and in young than in old 
patients = 12.46,p <0.001). 
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3.2 Oral Cancer Susceptibility 
100 /106 patients were fully informative for the GSTM1 genotype, 100/106 patients 
were fully informative for the GSTM3 genotype, 99/106 patients were fully informative for 
the GSTT1 genotype, 100/106 patients were fully informative for the GSTP1 genotype, 
100/106 patients were fully informative for the CYP2D6 genotype, 9 1 /106 patients were 
fully informative for the CYP1A1-1 genotype and 93/106 patients were fully informative 
for the CYP1A 1-2 genotype. 
Following analysis of the frequencies of the GSTM1, GSTM3, GSTT 1, GSTP 1, 
CYP2D6 and CYP1 Al phenotypes in the oral cancer patients and in the North 
Staffordshire controls, only the CYP2D6 phenotype was found to be significantly different 
(Tables 24 and 25). 
CYP2D6 genotype frequencies in the controls were similar to those previously 
reported in Caucasians resident in North Staffordshire (Warwick et al. , 1994a; Elexpuru- 
Camiruaga et al., 1995; Lear et al., 1996). The frequency of the wild type EM allele was 
0.79 and of the two mutant alleles combined was 0.21 (Equation 1). Assuming Hardy- 
Weinberg equilibrium (Equation 2), these frequencies gave the expected genotype 
frequencies for CYP2D6 EM, HET and PM (Equation 3). 
Equation 1. 
EM allele frequency = EM frequency + O. 5 HET frequency. 
EM allele frequency = 0.63 + O. 16 = 0.79 (corrected to 2 decimal places). 
Mutant allele frequency = PM frequency + O. 5 HET frequency. 
Mutant allele frequency = 0.05 + O. 16 = 0.21 (corrected to 2 decimal places). 
Equation 2. (Hardy-Weinberg equation). 
This equation, discovered independently in 1908 by Wilhelm Weinberg, a German 
physician, and Godfrey Harold Hardy, a British mathematician, states that in a large, 
random-mating population, the proportion of dominant and recessive genes present tends 
to remain constant from generation to generation unless outside forces act to change it 
(Internet 1). Consider an adult population having 2 allelic genes a and b of frequencies p 
and q respectively. If the population is assumed to mate randomly, then the proportion of 
the genotypes AA, ab and BB in the first generation after mating is: + 2pq + = 1 
(Internet 2). For North Staffordshire control patients p = 0.79 and q = 0.21. 
+ 2(0.79 x 0.21) + 0.0441 = 1 
Equation 3 
Expected wild type homozygous allele frequency (EM) = = 0.6241 = 62.4%. 
Observed EM frequency = 63%. 
Expected mutant homozygous allele frequency (PM) = = = 0.0441 = 4.4%. 
Observed PM frequency = 4.5%. 
Expected heterozygote allele frequency (HET) = 2(0.79x0.21) = 0.3318, = 33%. 
Observed HET frequency = 32.5%. 
The CYP2D6 PM frequency was significantly higher in the oral cancer patients 
than in the controls = = 0.0012, OR = CI = 1.55 - 6.5). 10.56,p 
Apart from the CYP2D6 polymorphisms there were no significant differences in 
phenotype frequencies between the young and old patient groups (Tables 26 and 27). The 
mean age at presentation of the patients with the CYP2D6 E M  genotype (60.4 years, SD = 
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10.9) was lower than that of the patients with the CYP2D6 PM and CYP2D6 HET 
genotypes (66.6 years, SD = 13.7 and 66.8 years, SD = 10.1 respectively). The Newman- 
Keuls test demonstrated that this difference was significant at the 5% level. 
The difference seen with the CYP2D6 genotype was mainly due to the EM 
frequency being significantly lower in the old patients = 8.67, p = 0.003). The low 
EM allele frequency in the old patient group is reflected in the observation that both the 
HET and the PM allele frequencies are correspondingly higher than in the young patient 
group = 3.78,p = 0.052 and = 2.96,p = 0.085 respectively). 
Young males accounted for 46.7% of the CYP2D6 EM genotypes and old females 
accounted for 46.1% of the CYP2D6 PM genotypes = 5.17,p = 0.023). 
No significant differences were found in any phenotype frequencies between males 
and females (Tables 28 and 29). Even though the CYP2D6 PM allele frequency in females 
was over twice that in males this difference was not significant = 1.08, p = 0.222). 
No significant differences were found in any phenotype frequencies between non- 
drinkers and non-smokers and heavy drinkers and heavy smokers (Tables 30 and 3 1). The 
much higher CYP2D6 EM frequency in the heavy smoking and drinking group compared 
to the non-smoking and non-drinking group failed to reach significance = 1.5 1 , p = 
O. 140). Similarly, the high CYP2D6 PM frequency observed in the non-drinkers and non- 
smokers was not significantly different to that in the heavy drinkers and heavy smokers 
= 1.06, p = 0.303). 
93.7% of heavy smokers and heavy drinkers were young males with the CYP2D6 
EM genotype. 67% of the CYP2D6 EM heavy drinkers and heavy smokers were GSTM1 
null and 94% were GSTM3 AA. No association was found between detoxification enzyme 
genotype and tumour differentiation or TNM stage at presentation. 
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3.3 Oral Cancer Outcome 
During the study period 13 patients (12.2%) developed a recurrence at the primary 
site, 21 patients (19.8%) developed cervical lymph node metastases and 20 patients 
(18.9%) died. In 8 patients (40%) the cause of death was either directly or indirectly 
related to their oral cancer. The mean group survival time was 25 1 1 days (Figure. 46). 
Figure 46 
Kaplan-Meier survival estimate for oral cancer group (n = 106). 
Survival is time to death in days from date of diagnosis. 
Patient age, tumour differentiation, tumour stage and the development of a local 
recurrence or cervical lymph node metastasis were all independent poor prognostic factors 
(Table 32). 

200 
Tumour stage at diagnosis and the development of cervical lymph node metastases 
were the strongest predictors of poor survival after correcting for the influence of age, 
differentiation and local recurrence (Table 33). 
Mantel-Haenszel comparison of the Kaplan-Meier survival estimates by TNM 
stage (Figure 47) confirmed the Cox regression model analysis model that tumour stage at 
diagnosis was a significant prognostic factor for survival = 10.64, p = 0.032). 
There were no significant differences in any of the detoxification enzyme 
phenotype frequencies between survivors and non-survivors (Tables 34 and 35). 
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GSTP1 was the only detoxification enzyme genotype shown to have a possible 
association with local recurrence. The GSTP 1 phenotype frequency differences between 
patients who did, and who did not develop a local recurrence, approached significance at 
the 5% level (Tables 38 and 39). This was due to the higher GSTP1 AB phenotype 
frequency in the patients developing local recurrence (Yate’s = 4.33,p = 0.038). 
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Local recurrence, poor tumour differentiation and the CYP2D6 EM and HET 
genotypes were the only independent risk factors found to be significantly associated with 
the development of cervical lymph node metastasis (Table 40). Of these 4 risk factors only 
the CYP2D6 EM genotype remained a significant prognostic factor after correcting for 
their combined effect (Table 41). Similarly, after correcting for the effects of age, sex, 
tobacco and alcohol the CYP2D6 EM genotype was a significant prognostic factor for the 
development of cervical lymph node metastasis (p = 0.006, HR = 0.24,95% CI = 0.09 - 
0.66). The CYP2D6 EM genotype conferred a significantly reduced risk for cervical node 
metastasis, i.e. the CYP2D6 genotype appears to be protective with respect to the 
development of cervical lymph node metastasis in this patient population. 
The individual contributions of each of the 3 CYP2D6 genotypes to the risk of 
developing cervical node metastasis is shown graphically in the Kaplan-Meier survival plot 
(Figure 50). Patients with the PM and HET genotypes developed nodal metastases 
significantly earlier and more frequently than those with the EM genotype. The Kaplan- 
Meier plot suggests that the PM and HET genotypes carry an almost identical risk for the 
development of cervical node metastasis, indicating that the increased risk is mediated by 
the loss of a single normal allele. 
The GSTP1BB genotype was also positively associated with the development of 
cervical node metastases, which approached significance at the 5% level (Table 40). 
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Mantel-Haenszel comparison of the Kaplan-Meier survival estimates for cervical 
node metastasis by CYP2D6 genotype (Figure 50) demonstrated a statistically significant 
difference between the 3 genotypes = 1.08, p = 0.005) confirming the results of the log 
rank test (Table 40). 
There was a significant difference between CYP2D6 phenotype frequencies in 
patients who did and did not develop a nodal metastasis during the study period (Tables 42 
and 43). This was as a result of the EM frequency in patients developing nodal metastases 
being significantly lower than in those with no nodal disease (Yates’ = 7.88,p = 
0.005). The high PM phenotype frequency (20%) in patients with nodal metastases was 
not significantly different to that seen in patients with no nodal metastases almost certainly 
due to the small numbers involved = 1.08, p = 0.30). 
An enlarged photograph of a representative CYP2D6B gel illustrating the EM, HET 
and PM bands is shown in Figure 5 1. 
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3.4 CYP2D6 Immunohistochemistry 
Strong CYP2D6 expression was demonstrated in all sections of normal oral mucosa 
examined including gingiva, tongue, buccal mucosa, lip and hard palate. The majority of 
sections examined displayed strong cytoplasmic expression in the epidermis, particularly 
in the stratum spinosum and also in minor salivary glands and striated muscle. (Figure 52). 
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4.1 Review 
All of the patients in the study group were extremely well characterised in terms of 
their demographics, risk factors, tumour, treatment and outcome affording an excellent 
opportunity to study the effects of the chosen polymorphisms on their susceptibility to oral 
cancer in comparison to a large group of oral cancer-free North Staffordshire patients. 
Although only 106 patients were recruited into the study group, oral cancer is an 
uncommon condition and very few studies of this type have reported on larger numbers of 
patients. 
The ability to record and analyse a standardised clinical data set on all patients and 
correlate the findings with their detoxification enzyme genotype by using the computerised 
cancer database greatly facilitated the conduct of the study. Without it, it is likely that 
many data items would have been missed reducing the power of the subsequent data 
analysis. 
The known risk factors for poor outcome such as poor tumour differentiation, high 
TNM stage, local recurrence and cervical lymph node metastasis were all identified as 
being statistically significant risk factors in the study population. This is good evidence 
that the clinical data recorded is reliable and that the North Staffordshire and Leeds oral 
cancer patients are typical of similar patients previously reported world-wide with oral 
cancer. 
It was never a stated aim of this study to investigate the relationship between putative 
risk factors and patient outcomes because of the problems with short follow-up times. 
Rather, the main aim was to investigate oral cancer susceptibility in a large, homogenous 
and extremely well characterised patient sample. Nonetheless, the study has generated 
interesting pilot outcome data worthy of further analysis. While it is likely that some 
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factors that to date have not been shown to be significant in this group of patients will 
emerge in due course, it is unlikely that factors already shown to be significant will cease 
to be so over the same time period. This is especially likely to be the case for those factors 
that have also been shown to be significant by other workers in previous studies. 
To a large extent I believe that the results of this study have enabled me to answer the 
3 questions which generated its’ original aims, namely: 
Is oral cancer susceptibility related to polymorphisms at loci coding for specific 
cytochrome P450 and glutathione S-transferase detoxification enzymes 
Is the CYP2D6 PM genotype a risk factor for oral cancer because of reduced 
detoxification of tobacco and/or alcohol-derived carcinogens 
Can any of these polymorphisms be used to improve prognosis prediction and hence 
improve outcome in an individual patient. 
The study has clearly shown that individuals who have the CYP2D6 PM genotype are 
at significantly increased risk of developing oral squamous cell carcinoma than those with 
the normal wild type EM genotype. None of the other CYP and GST genotypes 
investigated were shown to be significantly associated with oral cancer susceptibility. 
However, the reasons for the increased risk in the CYP2D6 PM patients are unclear 
and have not been determined by this study. The finding that CYP2D6 enzyme is strongly 
expressed in normal oral epithelium is fascinating and suggests that the enzyme may be 
important for the detoxification of xenobiotics that come into contact with the oral mucosa. 
However, my study hypothesis that increased oral cancer risk in CYP2D6 PM patients 
is mediated via reduced phase 1 metabolism of tobacco-smoke derived carcinogens such as 
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NNK is not supported by the study data. Therefore, it is likely that some other mechanism 
or an as yet unknown carcinogen is involved. 
Allele frequencies were compared between the oral cancer patients and the cancer-free 
control patients in order to derive data on susceptibility by genotype. However, clinical 
data was not available for the control patients and so it was not possible to use more 
powerful statistical models such as Cox regression to control for other variables such as 
age, sex, tobacco and alcohol consumption. While I think it unlikely that such analysis 
would have reduced the significance of the association between CYP2D6 genotype and 
oral cancer susceptibility, I do believe that it is important to achieve better clinical 
characterisation of the control patients in future studies of this type. 
Although data analysis suggests that the CYP2D6 PM genotype is associated with poor 
outcome as a result of earlier and more frequent cervical lymph node metastases I do not 
believe that the data is not strong enough at present to enable its' presence or absence to be 
used as a prognostic factor to direct patient management strategies. For example, I do not 
believe that the data is sufficiently robust to suggest that all CYP2D6 PM patients with 
T1N0M0 oral tumours should undergo elective neck dissection. However, if this data is 
confirmed in 2 years time when actuarial survival data is available I think there may well 
be a case for such treatment, particularly with lingual carcinomas. 
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4.2 The Database 
The computerised database proved invaluable for the collection, manipulation and 
analysis of both clinical and research data throughout this study. Its’ usefulness extended 
beyond the strict confines of the study protocol and it has become an integral part of the 
infrastructure of our joint head and neck cancer clinics. Every speciality involved with the 
management of head and neck cancer in our hospital now enters clinical information on 
their patients onto a computerised database developed from the program used in this study. 
The program has now been adopted by several other hospitals in the UK enabling 
them to audit their head and neck cancer practices and eventually to compare their results. 
This is an important and encouraging development in a frequently neglected area of patient 
care (Edwards et al., 1997). 
Ideas firmly based on the dataset used in this database are now at the heart of a 
national data set for head and neck cancer sponsored by the British Association of Head 
and Neck Oncologists. 
Accurate, comprehensive and standardised data collection covering not only the 
clinical findings at presentation but also management protocols, complications and 
outcomes are vital if we are to improve the standards of care, disease free survival times 
and the quality of life of our patients with oral cancer, (Tobias, 1987). 
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4.3 Oral Cancer Patients’ Characteristics 
The male:female ratio of the patient population in this investigation was 1.6: 1 
which is in good agreement with previous studies (Langdon et al. 1977; Henk and 
Langdon,1985; Worrall and Corrigan,1995). The mean population age at presentation was 
63.3 years which is also in good agreement with previous studies (Langdon et al. 1977; 
Worrall and Corrigan, 1995). On average, males were 6 years younger at diagnosis than 
females (61 years and 67 years respectively). This is in contrast to Langdon et al. (1977) 
who found virtually no difference in mean age at diagnosis (63.6 years for males and 63.7 
years for females) and Waterhouse (1974) who found that males were an average of 3 
years older than females at diagnosis (63.5 years and 60.6 years respectively), 
However, the present data are very similar to those previously reported by the 
author in a study of 116 patients (none included in the current investigation) with oral 
cancer presenting to the Leeds Dental Institute (Worrall and Corrigan,1995). 
While Binnie et al. (1972) reported that 72% of all oral cancers occurred in patients 
aged between the ages of 55 years and 75 years, the present study found that this figure had 
fallen to 62% and that 19.8% of patients were under 55 years of age at diagnosis. This may 
well be further confirmation that oral cancer is affecting a younger population than in the 
past, particularly amongst males (Hindle et al., 1996). 
The TNM stage distribution at presentation of patients in this study was remarkably 
similar to the findings from an earlier project, particularly the distribution of stage 3 and 4 
tumours (Worrall and Corrigan, 1995). Almost a quarter of all patients presented with a 
stage 4 tumour while over 12% presented with a stage 3 tumour. This is a reversal of the 
findings reported by Henk and Langdon (1985) and although extremely worrying as it may 
reflect a tendency to later patient presentation, it is likely that it also reflects an increasing 
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willingness by clinicians to “upstage” some tumours, particularly lingual carcinomas. 
Indeed, there is some evidence that the current patient group actually presented with earlier 
stage disease than in other studies. Of the 1 18 patients with oral carcinoma reported by 
Rich and Radden (1984) 45% had early (stage 1 and 2) disease and 55% had late (stage 3 
and 4 disease) at presentation. In the current study, 65% of patients presented with early 
disease. 
Less than 16% of all patients in the study stated that they had never drunk alcohol 
or used tobacco products, while over 20% admitted to being heavy consumers of tobacco 
and alcohol products. Older patients were more likely to be never smokers and never 
drinkers (25%) than younger patients (5.5%) while younger patients were more likely to be 
heavy smokers and drinkers (33.3%) than older patients (7.7%). Over 77% of heavy 
drinkers and heavy smokers were young males, while over 68% of the never drinkers and 
never smokers were old females. 
Similar findings were reported by Hodge et al. (1985) who found that of 945 
patients with carcinoma of the aero-digestive tract only 3.4% had never used tobacco 
products and that the non-smokers were significantly older than the smokers. 
The CYP2D6 enzyme was shown to be expressed in both normal oral mucosa and 
also in oral carcinomas. This is an important finding because previous work has suggested 
that CYP2D6 is primarily an hepatic enzyme which is rarely expressed outside the liver 
(Ingleman-Sundberg, 1995). Zhou et al. (1996) using both polyclonal and monoclonal 
antibodies to various CYP and GST demonstrated that CYP1A1, CYP1A2, CYP2C9, 
CYP2E1 and CYP3A4 are present in normal human gingiva but failed to demonstrate the 
presence of both CYP2D6 and CYP2B6. The reasons for the disparity in findings with the 
225 
present study are unclear but may be due to the increased specificity of the anti-CYP2D6 
antibody utilised by our laboratory. 
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4.4 Oral Cancer Susceptibility 
Oral squamous cell carcinoma has a multifactorial aetiology and is the terminal 
result of many different mutational pathways (Cox et al., 1991; Balaram et al., 1995). 
Evidence is also emerging that in some patients head and neck cancer may be familial. 
Foulkes et al. (1996) investigated 1429 first degree relatives of 242 patients with head and 
neck cancer and found their relative risk for head and neck cancer compared to controls to 
be 3.79 (95% CI = 1.11 - 13.0). The relative risk rose to 7.89 (95% CI = 1.5 - 41.6) if the 
index case had multiple primary head and neck tumours. The greatest risks were seen with 
pharyngeal and oral cancer (relative risks 4.24 and 3.82 respectively) but there was no 
demonstrable increased risk associated with a family history of cancer outside of the head 
and neck. 
It was hypothesised at the commencement of this study that certain individuals are 
at increased risk of developing oral cancer not only because of increased exposure to 
mutagenic environmental agents consequent on their lifestyle, but also because of a 
reduced ability to deal adequately with these agents due to inherited genetic defects in the 
loci coding for phase 1 and phase 2 detoxification enzymes. 
As it is highly unlikely that oral cancer risk in an individual patient could be 
predicted from a single genetic marker, several detoxification enzyme polymorphisms 
were examined in the oral cancer patient group and their effects on susceptibility and 
outcome investigated both alone and in combination. 
Detoxification enzyme polymorphisms have been shown to confer altered disease 
susceptibility in humans. Patients with the CYP2D6 PM genotype possess a 2-3 fold 
increased risk of developing Parkinson’s disease (Smith et. al., 1992) and both astrocytoma 
and meningioma have been reported to be more frequent in patients who are CYP2D6 PM 
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or GSTT1 null (Elexpuru-Camiruaga et. al., 1995). The GSTM1 null and GSTT1 null 
genotype frequencies have been reported to be significantly more common in patients with 
head and neck squamous cell carcinomas in general (Trizna et. al., 1995) and oral 
squamous cell carcinomas in particular (Hung et al., 1997). 
However, of all the phase 1 and phase 2 detoxification enzyme polymorphisms 
investigated in this study, only CYP2D6 showed a significant association with oral cancer 
susceptibility = 10.85,p = 0.005). 
In a study of 380 German patients with head and neck cancer (120 oral/pharyngeal, 
260 laryngeal) Matthias et al. (1998a) found that the GSTP1 AA genotype frequency was 
significantly lower in patients with oral/pharyngeal cancer than in 180 controls after 
correcting for the effects of age and gender (p = 0.003, OR = 0.47). It was not possible to 
perform the same statistical analysis in the present study because the control group data did 
not permit logistic regression analysis. However, it is interesting to note that the GSTP1 
AA, GSTP1 AB and GSTP1 BB allele frequencies observed in the oral cancer group in this 
study (37%, 51% and 12%) were virtually identical to those reported by Matthias et al. 
(1998a) in their oral/pharyngeal cancer group (37.5%, 50.8% and 11.7%) 
Although the GSTT1 null allele frequency was higher in the oral cancer patients 
than the control group this difference was not statistically significant = 2.18,p = O. 14). 
No association was found between the GSTM1 null genotype and oral cancer risk = 
1.06, p = 0.30). 
13% of the oral cancer patients in the current study were both GSTM1 null and 
GSTT1 null whereas 9.6% of the North Staffordshire control patients had this combined 
null genotype (Yates’ = 2.6,p = O. 105). Hung et al. (1997) reported an increased oral 
cancer risk (OR = 3.1) in Taiwanese males who had the combined GSTM1 null / GSTT1 
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null genotype (7.3%) compared to disease free controls (20.3%) after correcting for age, 
smoking, betel chewing, alcohol consumption and ethnicity. By comparing the uncorrected 
GSTM1 and GSTT1 genotype frequencies using published data between cases and controls 
in their study group (Hung et al., 1997, page 903 Table 2) I determined that they were 
similar to those found in the present study and that there was no statistical difference 
between the 2 groups (Yates’ = 2.8, p = 0.094). This finding emphasises the point that 
detoxification enzyme genotypes do not act as risk factors per se but in conjunction with 
exposure to xenobiotics. 
The GSTT1 null genotype frequency in the Taiwanese control group (52.9%) was 
significantly higher (p <0.001) than in the North Staffordshire control group (25.3%) 
highlighting the need for caution when comparing detoxification enzyme genotype 
frequencies and disease in different ethnic groups. 
The current study data and previous work from our laboratory (Deakin et al., 1996) 
do not support the observations by Trizna et al. (1995) that both the GSTM1 null and the 
GSTT1 null genotypes carry an increased risk for the development of oral cancer. There 
are a number of possible explanations for this. 
Firstly, although the authors demonstrated an increased odds ratio (2.37) in the 
GSTM1 group, which was statistically significant = 6.38,p = 0.012), the odds ratio for 
the GSTT1 group (1.47) was not statistically significant = 1.08,p = 0.30) and p 
values not originally reported but derived from the published data). 
Secondly, the authors did not distinguish between patients with oral, pharyngeal 
and laryngeal cancer. As these three cancers are known to have different aetiological 
factors, with smoking playing a larger role in laryngeal cancer and alcohol being more 
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significant in the aetiology of pharyngeal cancer (Elwood et al., 1984), confounding 
factors may well have been present in the case group. 
Thirdly, the racial composition of the case and the control groups (which also 
contained relatives of the cases) was not defined. Thus the known significant racial 
variation in allele frequencies may have lead to errors in interpretation of the study data. 
The CYP2D6 PM genotype was observed significantly more frequently in the oral 
cancer patients than it was in the control group. Together with the immunohistochemical 
demonstration of CYP2D6 enzyme activity in samples of normal oral mucosa, these data 
initially suggest that reduction or absence of normal CYP2D6 activity leads to a local 
perturbation of xenobiotic detoxification resulting in an increased risk of oral squamous 
cell carcinoma in some patients. 
However, of the 22 oral cancer patients who were heavy drinkers and heavy 
smokers 18 (81.8%) had the CYP2D6 EM genotype compared to only 1 (4.5%) with the 
CYP2D6 PM genotype. The CYP2D6 EM genotype was also more common in the younger 
patient group. The 89% CYP2D6 EM allele frequency in young heavy smokers and heavy 
drinkers was significantly higher than in the North Staffordshire controls = 5.05, p = 
0.025). While the CYP2D6 EM allele frequency was higher in heavy drinkers and heavy 
smokers (8 1.8%) than in non-drinkers and non-smokers (57.1%) the difference was not 
statistically significant = 2.59,p = O. 1 1), probably due to the small number of patients 
in each group (22 and 14 respectively). 
These data are similar to the findings in lung cancer patients reported by Caporaso 
et al. (1990) who, in a case-control study of 188 patients (96 with lung cancer and 92 with 
non-malignant pulmonary diseases) found that patients with the CYP2D6 extensive 
metaboliser phenotype (EM) were at significantly greater risk of developing lung cancer 
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than those who were intermediate (HET) or poor metabolisers (PM) (OR = 6.1,95% CI = 
2.1 - 17.1). The authors speculated on the importance of this finding as a potential marker 
for lung cancer risk “. . . if a compound that undergoes an oxidation by the CYP2D6 enzyme 
could be identified in tobacco smoke, a completely new strategy for prevention could be 
devised” (Caporaso et al., 1990). 
The following year their colleagues at the National Cancer Institute in Bethesda, 
USA reported the discovery that the tobacco-smoke derived nitrosamine, 4- 
(methylnitrosamino)- 1 -(3 pyridy1)- 1 -butanone (NNK), the most potent of all tobacco- 
smoke derived carcinogens, is metabolically activated by CYP2D6 resulting in increased 
mutagenicity and reduced cell survival time (Crespi et al., 1991 ). 
One possible explanation for the preponderance of CYP2D6 EM individuals in the 
heavy smoking and heavy drinking group is that they represent a subgroup of oral cancer 
patients whose risk factor profile is different from the CYP2D6 PM oral cancer patients. 
Thus, it is not that CYP2D6 PM is a risk factor because of reduced detoxification of 
carcinogens present in tobacco and alcohol, rather CYP2D6 EM is a risk factor in some 
individuals who consume large quantities of tobacco and alcohol because they are capable 
of activating procarcinogens in these products. It is interesting to speculate whether within 
this sub-group of patients there are individuals who are “ultra-rapid metabolisers” (Smith 
et al., 1995) and as such capable of enhanced carcinogen activation. 
The CYP2D6 PM genotype was observed more frequently in the older oral cancer 
patients. A similar finding was reported by Caporaso et al. (1990) who found that the PM 
frequency was more prevalent in their ageing control patient group (non-malignant 
pulmonary disease) but not their lung cancer group. The authors speculated that this 
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phenomenon might be a result of the more susceptible EM individuals succumbing to lung 
cancer at an earlier age. 
Such an explanation may also apply to the oral cancer patients but I believe it is 
unlikely in view of the longer survival experienced by these patients compared to those 
with lung cancer. A more plausible explanation is that CYP2D6 EM individuals who 
smoke and drink heavily develop their oral cancer early because of phase 1 carcinogen 
activation. Whereas, in the absence of heavy tobacco and alcohol consumption, oral cancer 
presents later in life when the CYP2D6 PM genotype becomes a distinct and separate risk 
factor. This explanation is consistent with the finding by this study that the CYP2D6 PM 
allele frequencies observed in both the heavy drinking and heavy smoking group (4.5%) 
and the young patient group (7.5%) were not significantly different to the CYP2D6 PM 
allele frequency observed in the control group (4.5%). 
It is interesting to speculate that if some of the CYP2D6 EM patients had not 
consumed the large quantities of tobacco and alcohol products that they did at an early age 
whether they would still have developed oral cancer. The provisional conclusions of this 
study suggest that many of them would not have. 
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4.5 Oral Cancer Outcome 
It is extremely important to appreciate that although the median follow-up time for 
patients in this study was 1.7 years, less than 85% of patients had been followed up for 
more than 6 months and only 44% for more than 2 years at the time of data analysis. Henk 
and Langdon (1985) have demonstrated that for patients destined to develop a local 
recurrence, over 69% will do so within the first 6 months following diagnosis and 
treatment and a further 2 1 % will do so within the following 18 months. A similar temporal 
relationship exists for lymph mode metastases and survival. For example, patients with 
carcinoma of the mandibular alveolus have been shown to continue to die of their disease 
up to 10 years following diagnosis and treatment (Langdon et al., 1977). Accepted clinical 
practice is to follow-up patients with oral squamous cell carcinoma regularly until they 
have been disease-free for a minimum of 5 years or death. 
Survival 
Perhaps not surprisingly, survival was worse in the older patients. Previous reports 
have shown that patients younger than 60 years at presentation had a 5-year survival rate of 
59.5% compared to 22% for those over 60 years old (Henk and Langdon, 1985). 
Comparable figures in this study were 8.7% and 24.8% respectively, underlining the need 
for caution when interpreting outcome data derived from this study. 
No association was found between gender and length of survival. While Henk and 
Langdon (1 985) reported that females had better survival times than males, Binnie et al 
(1 972) were unconvinced that a real gender difference exists for survival in oral cancer 
patients. 
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The finding that patients with poorly differentiated tumours had significantly 
shorter survival times than those with well differentiated tumours is in agreement with 
previous reports (Langdon et al. 1977; Lighthelm et al. 1989). It does not support the 
assertion of Nason et al. (1990) that the association between the degree of tumour 
differentiation and prognosis is of little significance. 
Also in keeping with previous reports (Langdon et al. 1977; Henk and 
Langdon, 1985; Rich and Radden, 1984; Worrall and Corrigan, 1995), prognosis worsened 
with increasing TNM stage. The reversal of stages 2 and 3 with respect to survival may 
well reflect the clinical uncertainty associated with the diagnosis of metastatic deposits in 
cervical lymph nodes (Shah et al., 1990; Woolgar et al., 1994). 
Numerous authors have attested to the adverse prognostic significance of cervical 
lymph node metastases in patients with oral cancer (Hibbert et al., 1983; Henk and 
Langdon, 1985; Phillips,1989; Zatterstrom et al.,1991). In the present study the 
development of cervical node metastases following treatment of the primary oral tumour 
resulted in significantly shorter survival times, as did a recurrence at the primary site. 
Even allowing for the short follow-up times, the results of this study with respect to 
patient survival are in very good agreement with previous reports in showing that patient 
age, degree of tumour differentiation, tumour stage, local recurrence and cervical lymph 
node metastases are all independently associated with poor prognosis. Of these 5 
independent risk factors, a high TNM stage at presentation and the subsequent 
development of cervical lymph node metastases carried the worst prognosis. 
No statistically significant associations were found between survival and any of the 
detoxification enzyme genotypes investigated. 
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Local recurrence 
Poorly differentiated tumours were more likely to recur than well differentiated 
tumours and patients with stage 4 disease at presentation developed local recurrences 
earlier and more frequently than patients with earlier stage disease. The development of 
cervical lymph node metastases following initial therapy was significantly associated with 
recurrent disease at the primary site. 
Alcohol was a strong independent predictor for local recurrence although no 
association was found between tobacco and recurrence. Similar findings were reported by 
Elwood et al. (1984) who, in a case control study of 374 patients with head and neck 
cancer found that while alcohol and tobacco were both significant independent risk factors 
for the development of oral cavity cancer, only alcohol remained a risk factor after 
controlling for other variables such as socio-economic status and dental care. Interestingly, 
Hindle et al. (1996) commented on the fact that oral cancer incidence in the UK has been 
increasing during a period of falling tobacco consumption. However, while the population 
consumption of tobacco products has been falling there has been a substantial increase in 
the consumption of alcohol, particularly amongst young males which many authors feel 
partly explains the recent changes in oral cancer incidence and age distribution (Hindle and 
Nally, 199 1 ; Macfarlane et al., 1992). The results from this study also suggest that alcohol 
is an important risk factor for local recurrence. 
GSTP1 AB was the only detoxification enzyme allele shown to have any 
statistically significant association with local recurrence = 4.33,p = 0.038). The 
GSTP1AA allele frequency in patients who did not develop a local recurrence (39.8%) was 
over twice as high as in those that did (16.7%) although this difference was not statistically 
significant =2.42,p = O. 121). These findings are similar to those reported by Matthias 
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et al (1998a) who demonstrated significantly lower (p = 0.003) levels of the GSTP1 AA 
genotype in patients with orallpharyngeal cancer compared to controls. Their data suggests 
that individuals with the GSTP1 AA genotype have a lower risk of developing 
oral/pharyngeal cancer, perhaps as a result of enhanced detoxification of environmental 
carcinogens. 
A possible explanation for the protective effect of the GSTP1 AA genotype in 
comparison to the GSTP1 BB genotype is that the substitution of Valine for Isoleucine at 
amino acid number 104 in the latter results in a reduced affinity for electrophilic substrates 
consequent on changes to the geometry of the hydrophobic substrate-binding site 
(Zimniak. et al., 1994). 
The low numbers of patients with local recurrence in the present study may account 
for the lack of a statistically significant difference between the case and control groups 
being found. 
Cervical lymph node metastasis 
Unlike the findings for local recurrence and survival, overall TNM stage at 
presentation was not significantly associated with nodal metastasis. However, as shown 
graphically in Figure 57 the time to first nodal metastasis was a function of TNM stage at 
presentation, although the relationships were different to those seen for local recurrence 
and survival. Patients with stage 2 and 3 tumours developed new nodal metastases earlier 
and more frequently than those with stage 1 and 4 tumours. This is, of course, exactly what 
one would predict from knowledge of tumour behaviour and current clinical management. 
The majority of patients with stage 4 disease will have had clinically palpable 
cervical lymph nodes at presentation. These will have been treated by either a neck 
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dissection or in a minority of cases by radiotherapy. All patients with stage 2 disease will 
have had no clinically detectable cervical nodes at presentation but subsequently developed 
nodal metastases following treatment for their primary tumour. 
The likeliest explanations for nodal metastases in the stage 3 and 4 patients are the 
development of nodal metastases in patients who were clinically NO at presentation but 
staged 3 or 4 because of their large tumour size and failure of primary modality treatment 
in the neck with subsequent nodal recurrence in patients who had nodal disease at 
presentation. 
The strongest predictors for the development of cervical node metastasis were local 
recurrence, poor tumour differentiation and the CYP2D6 genotype. The CYP2D6 HET and 
PM genotypes were both associated with an increased risk of nodal metastasis (Figure 58) 
indicating that the loss of a single CYP2D6 allele is associated with earlier and more 
frequent nodal metastases in oral cancer. However, the CYP2D6 EM genotype was 
associated with a much lower risk of nodal spread as shown by both the Cox hazards 
model and the significantly lower EM allele frequency in patients with nodal disease (30%) 
in comparison to those without nodal disease (67.5%) = 9.37,p = 0.002). 
Individuals with the GSTP1 BB genotype were at increased risk for the 
development of cervical lymph node metastases (p = 0.057, HR = 2.69,95% CI = 0.97 - 
7.49). Taken together with the findings for local recurrence, these data suggest that the 
GSTP1 BB genotype may be a risk factor for disease progression and poor outcome in oral 
squamous cell carcinoma. 
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4.6 The CYP2D6 PM and HET Genotypes and Oral Cancer 
In sections 4.3 and 4.4 I have summarised the data available from this study, which 
support the hypothesis that CYP2D6 polymorphisms are associated with both an increased 
risk for, as well as a poorer prognosis of, oral squamous cell carcinoma. 
The CYP2D6 PM genotype was found at a significantly higher frequency in 
patients with oral cancer compared to a large group of oral cancer-free control patients. 
Furthermore, both the CYP2D6 PM and HET genotypes were associated with the 
development of earlier and more frequent cervical lymph node metastases. 
However, oral cancer patients with the CYP2D6 EM genotype were the heaviest 
consumers of tobacco and alcohol products rather than those with the PM or HET 
genotypes. There was also a definite predilection for the PM and HET genotypes to occur 
in patients who were older at initial presentation than those with the EM genotype. It is 
thus difficult to reconcile these data with the study hypothesis that reduced detoxification 
of tobacco smoke-derived carcinogens in individuals with the PM genotype results in an 
increased oral cancer risk. 
In his extensive review of the literature and current knowledge on the cytochrome 
P450’s, Ingleman-Sundberg (1 995) concludes that CYP2D is essentially a functionless 
gene and that data purporting to show an association between CYP2D6 pheno- and/or 
genotypes are controversial. It has also been suggested that the CYP2D6 protein serves no 
useful function (Rannug et al., 1995). Nonetheless, data from this study and others 
previously cited, clearly shows that patients with the CYP2D6 PM genotype are at 
Significantly increased risk from certain diseases including oral squamous cell carcinoma. 
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Perhaps the comment that these observations represent “some kind of functional 
association” Ingleman-Sundberg (1995) is the key to this puzzle and that any association 
between the CYP2D6 genotype is casual not causal. 
There is extensive evidence that the CYP2D locus at 22q 13.1 is intimately 
associated with several putative tumour suppressor genes. Bryan et al. (1996) have 
identified 2 candidate tumour suppressor genes for ovarian carcinoma that flank the 
CYP2D locus. LOH at these loci was observed in 53% of 110 ovarian carcinomas. The 
authors found that the frequency of LOH at 22q 12 in ovarian cancers increased with 
increasing tumour stage and concluded that 22q 12 LOH is more relevant to tumour 
progression than initiation. 
Ewing’s sarcoma is associated with the specific chromosomal translocation t( 11; 
22) (q24; q12) resulting in the substitution of a putative RNA-binding domain (EWSR1) 
for Hum-FLI-1, the DNA-binding domain of the human homologue of the mouse FLI-1 
retroviral integration site associated with murine erythroleukaemia (Ben-David et al., 
199 1 ; Delattre et al. , 1992). The translocation results in a novel gene sequence that codes 
for a 656 amino acid protein termed EWS, which appears to be essential for tumorigenesis. 
Also, because Hum-FLI-1 is now subject to control by the EWS promoter region and not its 
normal promoter, the translocation results in both deregulation and aberrant activation of 
the Hum-FLI-1 target genes (Delattre et al., 1992). 
EWS is located in the same 22q 12 region as the gene defect causing 
neurofibromatosis type 2 (NF2) (Delattre et al., 1992). NF2 and a subset of sporadic 
meninigiomas are associated with inactivation of the tumour suppressor gene NF2 located 
at 22q 12 (Trofatter et al., 1993; De Vitis et al., 1996). The NF2 gene codes for a 587 
amino acid moesin (membrane-organising extension spike protein)-ezrin-radixin protein 
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named merlin (Trofatter et al., 1993). The moesin-ezrin-radixin proteins are involved with 
linking certain cell membrane proteins to the cytoskeleton (De Vitis et al., 1996). 
The cytoskeleton plays a major role in many normal cell functions including 
changes in cell shape, cell motility, mitosis and anchorage-dependent growth. These 
functions are also critically involved in neoplastic cell invasion and metastasis (Bernal and 
Stahel, 1985). Inactivation of NF2 and aberrant expression or merlin could thus be 
expected to interfere with many of these functions with a consequent effect on cell growth 
control and migration (Bernal and Stahel, 1985; Trofatter et al., 1993). 
These data are compatible with the findings of the present study in which the 
CYP2D6 PM allele frequency was higher in cases than controls, the CYP2D6 HET allele 
frequency was higher in non-survivors than survivors, and both the PM and HET 
genotypes were associated with more frequent and earlier cervical lymph node metastases 
than the EM genotype. 
It is thus possible that the CYP2D6 PM and HET genotypes are linkage markers for 
mutations at 22q 12, and that it is actually the loss of a tumour suppressor gene at or close 
to the NF2 locus that mediates the increased oral cancer susceptibility and early nodal 
metastases seen with these genotypes. 
An extensive literature search (Medline and the Internet) has failed to identify any 
published work that demonstrates LOH at 22q 12 in oral squamous cell carcinoma. 
Indeed, in their comprehensive study of LOH on 39 chromosome arms in 52 head and neck 
squamous cell carcinomas, Field et al. (1995) failed to identify LOH on 22q perhaps 
because the micro-satellite markers used were directed against the wrong region. 
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An alternative explanation for these findings is that individuals with the CYP2D6 
PM genotype fail to effectively detoxify an as yet unknown substrate involved in oral 
cavity carcinogenesis. The data on tobacco and alcohol consumption in the CYP2D6 PM 
group in this study would tend to suggest that this putative carcinogen is unlikely to be 
contained in these products. 
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4.7 Conclusions 
The study has shown that not only is the CYP2D6 PM genotype associated with an 
increased risk for the development of oral squamous cell carcinoma but also, together with 
the CYP2D6 HET genotype, with an increased risk for the development of cervical lymph 
node metastases. Although it was not possible to show any association between the 
CYP2D6 PM genotype and survival, it is interesting to speculate that as this group of 
patients gets older whether an association with poor survival will become apparent. In my 
opinion, the extremely strong association between cervical lymph node metastasis and poor 
survival shown by this and other studies makes such an association likely. 
Contrary to expectations implicit in my initial working hypothesis, the study 
demonstrated that it was the oral cancer patients with the CYP2D6 EM and not the PM 
genotype who were the heaviest consumers of tobacco and alcohol products. This finding 
casts severe doubt on the idea that oral cancer risk is increased in patients with the poor 
metaboliser phenotype because of their reduced ability to detoxify carcinogens present in 
tobacco smoke. 
Data analysis suggests that this study has identified 2 distinct sub-groups of oral 
cancer patients, each with different risk factors for susceptibility and outcome. It appears 
likely that in one group of patients, inactivation of a tumour suppressor gene at or close to 
the NF2 gene on 22q 12 leads to increased susceptibility to, and poor outcome from, oral 
squamous cell carcinoma. Data analysis suggests that the CYP2D6 PM and HET genotypes 
are linkage markers for this putative tumour suppressor gene. 
The CYP2D6 EM genotype appears to be a risk factor for oral cancer susceptibility 
in patients who smoke and consume alcohol heavily, possibly via phase 1 activation of 
tobacco smoke- and/or alcohol-derived carcinogens. These patients appear to develop their 
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tumours at an earlier age than individuals with the PM genotype. CYP2D6 EM activation 
of nitrosamines such as 4-(methylnitrosamino)-1-(3 pyridyl)-1 -butanone present in tobacco 
smoke with the subsequent production of mutagenic compounds is an attractive oral 
tumorigenesis model in these patients and is compatible with the association between 
smoking, CYP2D6 EM genotype and lung cancer risk previously reported (Caporaso et al., 
1990; Crespi et al., 1991). The demonstration by this study that CYP2D6 is expressed 
locally in the oral mucosa is further support for this hypothesis. 
Of all the detoxification enzyme genotypes investigated in this study, CYP2D6 was 
the only one to have been shown to be significantly associated with both oral cancer 
susceptibility and outcome. Furthermore, no significant interactions between the 
detoxification enzymes studied and either oral cancer susceptibility or outcome were 
observed. 
However, the study has also shown that the GSTP1 genotype appears to play a role 
in oral cancer tumorigenesis and progression confirming the findings of Matthias et al. 
(1998a). GSTP1 AA appears to be protective while GSTP1 BB appears to enhance the risk 
for the development of local recurrence and cervical node metastasis in oral squamous cell 
carcinoma. Although the study was unable to show a statistically significant association 
between the GSTP1 AA genotype and oral cancer susceptibility, the very strong correlation 
of GSTP1 allele frequencies observed in oral cancer patients in this study with those 
reported by Matthias et al. (1998a) suggests that an association is likely. 
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4.8 Study Critique and Suggestions for Future Research 
Although I am happy with the study results and I have learned an enormous amount 
about research methodologies in general and detoxification enzyme polymorphisms in 
particular, there are several areas where the study could have been improved. 
Firstly, the number of patients recruited is less than ideal. While this is a function 
of the rarity of the disease under investigation this fact should not be allowed to dictate 
future study protocols. The logical approach is to ensure that all future studies of this type 
are truly multicentre so that as far as possible, all newly diagnosed patients in the UK are 
recruited and their data made available for study and audit. The availability of a 
standardised database and a nationally agreed head and neck cancer minimum dataset 
greatly facilitates such multicentre collaboration. If study populations become 
multinational due regard will need to be given concerning the variation in allele 
frequencies with the racial mix of the population. 
Mention has already been made of the need to improve the characterisation of the 
control patients used in studies of this type. In future I would wish to collect the same 
demographic and risk factor data on control and study patients. This would allow me to 
repeat previous studies in which the recruitment of age, sex, ethnicity and risk factor 
matched control subjects enabled the demonstration of a significant association between 
the GSTM1 null and GSTT1 null genotypes both alone (Trizna et al., 1995) and in 
combination (Hung et al., 1997) and oral cancer risk after allowing for the effect of known 
risk factors. 
Smoking and alcohol data were not available on the control patients in this study 
and the numbers of oral cancer patients in the non-drinking non-smoking group and heavy 
drinking heavy smoking group were too small to show any significant differences in allele 
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frequencies between them. In order to substantiate the hypothesised link between the 
CYP2D6 EM genotype, phase 1 nitrosamine activation, smoking and earlier tumorigenesis 
a prospective case-control study is required in which the tobacco and alcohol consumption 
in controls as well as cases is recorded. 
Further research is needed to unravel the mechanism by which the CYP2D6 PM 
genotype exerts its’ influence on oral cancer susceptibility and perhaps, outcome. 
To this end, investigation of LOH around 22q 12 is urgently required in this patient 
group to ascertain whether the PM and HET polymorphisms are acting as genetic markers 
for tumour suppressor genes or other detoxification enzyme polymorphisms which are 
present close to this locus. One arm of such an investigation is currently underway in our 
laboratory using matched tumour and blood sample pairs taken from patients reported on 
in this study. 
The newly described GSTZ (Board et al., 1997) and GSTT2 (Strange RC, personal 
communication) polymorphisms are candidate susceptibility genes for oral cancer. The 
fact that their coding genes are located close to the CYP2D6 locus makes them of special 
interest as they may display linkage disequilibrium with CYP2D6 polymorphisms and as 
such may offer an explanation for the increased incidence of oral cancer seen in patients 
with the CYP2D6 PM genotype. 
After establishing reliable and repeatable PCR methodology for detecting GSTZ 
and GSTT2 polymorphisms they will be looked for in the DNA of the current study 
population and any association with oral cancer susceptibility and outcome both alone and 
in combination with CYP2D6 PM polymorphisms will be investigated. 
Of critical importance for outcome data verification is the absolute requirement to 
follow-up the oral cancer patient group until death or for a minimum of 2 years (preferably 
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5 years) from diagnosis. Only then can the effects of any detoxification polymorphisms on 
actuarial outcome be fully assessed and verified. With this in mind, I intend to re-analyse 
the current 106 patients in 2 years and 5 years time. Recruitment into this study is still on- 
going and so as well as being able to produce actuarial 2 and 5-year local recurrence, nodal 
metastasis and survival data for the current group of patients, susceptibility data will be 
available on approximately a further 200. 
This study has provided interesting data suggesting that the GSTP1 BB genotype is 
associated with a poor outcome in patients with oral cancer and possibly also with an 
increased susceptibility to the disease. With better characterisation of the oral cancer 
control group, and increased recruitment into the oral cancer case group in the future it will 
be possible to investigate the association between GSTP1 polymorphisms and oral cancer 
susceptibility and outcome more completely than was possible in the current study. 
Finally, it would be extremely interesting to ascertain the CYP and GST 
polymorphisms in first-degree relatives of patients with oral cancer, particularly those 
relatives who have a history of malignant disease themselves. Our laboratory has had 
success in extracting DNA from buccal epithelial squames collected using a simple 5ml 
0.9% saline mouthwash. Living first-degree relatives will be asked to supply a mouthwash 
sample from which their DNA will be extracted and their CYP and GST genotype 
ascertained. The results will be analysed particularly looking for genotypes that display a 
high frequency of correlation between generations of patients with oral cancer. If pilot 
data is encouraging this study will need to be organised on a multi-centre collaborative 
basis in order to recruit sufficient numbers of affected first-degree relatives to enable 
reliable statistical analysis of the study data to be performed. 



































